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The application of induced pluripotent stem cell (iPSC)-derived cells in clinical trials is 
in its infancy but the potential is vast. A key asset of iPSCs is the ability to derive 
autologous cell therapies, but to date most current or approved clinical trials are using 
fully characterized allogeneic or non-allogeneic cell banks alongside 
immunosuppressive drugs. Until now, all current or approved clinical trials utilize iPSC 
generated using EBNA1 expressing plasmids containing the OriP sequence to 
maintain a self-replicating episome. These vectors are amplified in bacterial hosts and 
contain bacterial DNA motifs recognized by the transfected cells innate and intrinsic 
interferon host defense responses. Moreover, the continued forced expression of the 
Epstein-Barr virus EBNA1 protein is known to cause widespread alterations in gene 
expression as well as elevated oxidative stress and DNA damage occurrence. 
Additionally, this method of iPSC derivation incorporates a short-hairpin RNA (shRNA) 
for the p53 protein; often referred to as the guardian of the genome. The shRNA 
functions to transiently silence the expression of p53 protein and has been 
demonstrated to result in an increased persistence of DNA damage in iPSC produced 
this way. All of these factors have significant implications for the safe clinical use of 
iPSC generated using oriP/EBNA1 plasmid episomes. 
The aim of my project was to investigate the function of a novel system in 
reprogramming and iPSC development. Doggybone DNA (dbDNA) vectors are free of 
oriP/EBNA1 sequences, bacterial motifs and are produced in a chemically defined, 
low endotoxin, cGMP compliant manufacture. My results describe efficient iPSC 
reprogramming by applying equivalent gene sequences transiently expressed from 
dbDNA vectors in protocols employing both animal-derived and animal-free 
constituents when using weight equivalents of both systems and not molecular 
equivalents. In direct comparator experiments with the current state-of-the-art gold 
standard oriP/EBNA1 episomes, dbDNA vectors produced iPSC colonies with the 
same efficiency but dbDNA-iPSC displayed evidence of greater stability in terms of 
maintenance of pluripotency. Differential transcriptomic evaluations by microarray 
showed that the persistence of oriP/EBNA1 episomes resulted in an elevated 
interaction with immune system processes and IFN signalling in iPSC when compared 
to dbDNA generated iPSC. Moreover, an increased susceptibility for DNA damage 
incitement alongside unwanted spontaneous differentiation in iPSCs incorporating the 
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oriP-EBNA1 were all demonstrated and showed to be intrinsically linked to one-and-
other. We propose a potential that utilizing dbDNA vectors presents a safer and more 
stable approach to iPSC production and development and that this could, with further 
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1.0 - Introduction:  
 
1.1. Classification of stemness: 
 
The term meristem was coined by botanist Karl Nägeli in 1858. It is still used to 
describe populations of self-renewing cells within plants that retain a capacity to divide, 
and are responsible for plant growth and organ production (Kastin, 2013). With a clear 
functional likeness, it has been suggested that the term ‘stem cell’ was derived from 
its botanic counterpart (Ramalho-Santos and Willenbring, 2007; Monti et al., 2012). 
Stem cells are unspecialized cells of the human body that are able to perpetually self-
renew in this state, whilst also retaining an ability to differentiate into all somatic cell 
types when exposed to appropriate stimuli.  
A stem cells ability to form a spectrum of different somatic cell types is referred to as 
its ‘potency’. Consequently, stem cells are grouped based on their relative potent 
properties. Potency can be viewed hierarchically, with totipotency at the apex of the 
hierarchy and unipotency at the base - Figure 1. Derived from the Latin word 
totipotentia meaning an ‘ability for all things’, human totipotent stem cells are capable 
of forming all embryonic and extra-embryonic cell types (Mahla, 2016). Pluripotent 
stem cells (PSCs), derived from pluripotential a term meaning an ‘ability for many 
things’, are a step below totipotent stem cells in terms of their potency. PSCs can form 
all cells of the three somatic germ lineages (mesoderm, endoderm & ectoderm), and 
so are accountable for the formation of all cell types within the human body. However, 
unlike totipotent stem cells, PSCs cannot develop extra-embryonic structures such as 
the placenta. As stem cells commit to becoming more specialised, their differentiation 
capacity and relative potency becomes more limited. Multipotent stem cells can form 
a number of different cell types but are confined to a specific lineage - such as a 
haematopoietic stem cell which can only specify to form blood cells. The most 
restricted stem cell class in terms of its potency are unipotent stem cells. This cell type 
has an ability to self-renew and maintain a stem-like state, however is only capable of 







1.1.1. Stemness in early embryogenesis: 
 
During early human embryogenesis, potency stages can be mapped onto different 
phases of the developing embryo (Figure 2). A post fertilization zygote (E0-5) is the 
only human totipotent stem cell source. The zygote is capable of forming all cell types 
relating to whole organism development, including extra-embryonic structures. Then, 
at approximately E6, the zygote develops into a blastocyst. The blastocyst consists of 
the discernible trophectoderm (TE) and inner cell mass (ICM). The TE is responsible 
for the development of extra-embryonic support structures such as the placenta, 
umbilical cord and chorion (Niakan et al., 2012). The ICM retains an unspecialised 
state, consisting of a pluripotent cell type often termed embryonic stem cells (ESCs/ES 
cells). As embryogenesis progresses beyond approximately E8, ES cells from the ICM 
become more specialised reaching the multipotent stage and are therefore limited in 
terms of their potency to a single germ lineage. Much later in the developmental 
process, the cells will then ultimately reach unipotency before coming to a terminally 
differentiated state (Zakrzewski et al., 2019). This timeline provides a key insight into 
the transient and short-lived nature of totipotent and pluripotent stem cells in 
embryogenesis. Totipotent stem cells exist only within the first 5 days post-fertilisation, 
Figure 1. Hierarchy of potency and their associated somatic cell types.  
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whilst ESCs exist only within a ~48-hour timeframe, both pertaining to an incredibly 
transitory state.  
 
 
1.1.2. ESCs – derivation, roadblocks & recovery:  
 
The National Institute of Health (NIH) define human ESCs as “cells that are derived 
from the inner cell mass of blastocyst stage human embryos, that are capable of 
dividing without differentiating for a long period in culture and are known to develop 
into cells and tissues of the three primary germ layers” (Glossary | stemcells.nih.gov, 
n.d.). ES cells, and their unique pluripotent characteristics, have clear research and 
clinical promise. It was believed that the derivation of this cell type would herald a new 
modern era for science, the era of regenerative medicine. In 1981, the first successful 
derivation of a mouse embryonic stem cell line was carried out (Martin, 1981). This 
pioneering work effort, alongside exponential improvements in culturing techniques, 
eventually led to the isolation of the first stable human ES cell line (Thomson et al., 
1998). The isolated cells were demonstrated to express key pluripotent markers 
(Alkaline phosphatase+, SSEA3+ Tra-160+ & Tra-181+) and possess a capacity to form 
teratomas expressing all three somatic germ layers in immunodeficient mice. All this 
to say, the successful derivation of ESCs resulted in a multitude of new prospects, 
ranging from cell replacement therapy for a plethora of disorders, ‘off the shelf’ ex-vivo 
organ development, disease modelling and novel drug screening mechanisms (Vazin 
and Freed, 2010).  
Figure 2. Early embryogenesis up to blastocyst formation.  
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Despite steps being taken to develop the methodology of the derivation and culturing 
of ESCs, there was critical opprobrium generated by the field of stem cell research vis-
à-vis the inviolability of life. Early methods of ESC isolation obligated the destruction 
of an embryo. As such, moral and ethical complications soon became entangled within 
stem cell research. The most vociferous of arguments arose from religious 
communities in relation to the disregard for the sanctity of life that is central to providing 
the starting material to effectuate this line of research. The ethical volatility surrounding 
ESC derivation soon engendered global political engagement (Figure 3). The Dickey-
Wicker amendment and the subsequent prohibition of federal funds by President Bush 
stymied any research with embryonic stem cells across the U.S.A. During this hiatus, 
new players entered the stage of pluripotency. Yet, embryo destruction, the raison 
d’etre for stymying stem cell research, was soon negated with the isolation of ESCs 
from a single blastomere (Chung et al., 2008). This, alongside a reversal of funding 
prohibitions has exponentially increased ESCs therapeutic potential. Over 20 clinical 
trials using ESC-derived cells are ongoing, targeting conditions such as macular 
degeneration (NCT01344993), type 1 diabetes (NCT03162926) and Parkinson’s 
disease (NCT03119636) (Eguizabal et al., 2019).  
 
 
Figure 3 - Progression of embryonic stem cell research in parallel with American research sanctions. 
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1.2. Induced pluripotent stem cells:  
 
1.2.1. History of iPSC development:  
 
August Weismann devised a genetic theory of heredity at the end of the 19th century 
commonly known as the Weismann barrier. He postulated that for cells to become 
committed to a specific, differentiated state, any unnecessary genetic code must be 
removed or terminally inactivated (Weismann, A. 1893). In the 20th century, Conrad 
Waddington developed the, now widely renowned, Waddington’s landscape theory. 
This, of a similar ilk to Weismann’s theory, suggests that cell fate and differentiation is 
a perpetual and irreversible state. Waddington’s landscape depicts cellular 
differentiation as a ball at the top of a hill (Figure 4). As the ball descends and begins 
rolling down the hill, this metaphorically represents the cell transitioning from its 
pluripotent/precursor state to a differentiated state, with the cell ultimately reaching its 
terminal fate at the bottom of the hill (Waddington, 1957). Both theories, although 
originating from different lines of research both represent the idea that cellular 
differentiation is an irreversible, unidirectional process. 
 
 
Figure 4 - Waddington's landscape:  image depicting a ball at the top of a hill to represent 
embryonic cell differentiation as the ball progresses down the hill to its terminally differentiated 
state. The crevices in the hill represent different potential fate outcomes for the cell dependent on 
its path (Source: Waddington, 1957).  
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Somatic cell nuclear transfer (SCNT) is the process of isolating a nuclei from one cell 
type and transplanting it into a second enucleated cell (Briggs and King, 1952). The 
derivation of this technique was the basis for the innovative work carried out by Sir 
John Gurdon. Gurdon utilised SCNT to transfer the nucleus from a differentiated 
intestinal tadpole cell to an enucleated recipient oocyte. The oocyte, containing the 
transplanted nucleus, was able to develop into a healthy feeding tadpole. Thus, 
Gurdon demonstrated that a nucleus, which can promote the formation of a 
differentiated cell, can simultaneously retain the genetic information necessary for the 
formation of all other cell types too (Gurdon, 1962). This seminal work permitted an 
important and novel insight; development and differentiation are not irrevocable 
changes (Stadtfeld and Hochedlinger, 2010). The birthing of a number of different 
mammals, most notably Dolly the sheep, adopting the use of SCNT and nuclei from 
terminally differentiated cell types, again corroborated the theory initially developed by 
Gurdon (Wilmut et al., 1997; Takahashi and Yamanaka, 2016).  
It was first demonstrated in the 1980’s that the ectopic overexpression of lineage 
associated transcription factors can differentiate one cell fate directly to another, a 
process termed transdifferentiation. The overexpression of MyoD, a transcription 
factor associated with myogenesis and muscle development, was found to convert 
terminally differentiated fibroblast cells into myoblasts (Davis et al., 1987). This 
premise was then adopted by several labs alluding to the transdifferentiation of a broad 
range of different cell types. The body of work carried out provided unequivocal 
evidence that mature cells can differentiate across and within germ lineages to 
different mature cell types; without reverting to a stem cell state (Stadtfeld and 
Hochedlinger, 2010).  
In 2001, work from Takashi Tada’s lab in Japan focused on the production of a fusion 
cell type, with the foundations of the process being outlined for over a decade (Blau et 
al., 1983). The lab fused T-cell progenitors, thymocytes, with ES cells mediated by 
electric fusion. The resulting cell type demonstrated functional and transcriptional 
characteristics of the reactivation of inactive X chromosomes, and were part 
epigenetically reset to the point of endogenous pluripotency gene expression (Tada et 
al., 2001). The derivation of cell fusion models demonstrated a possibility of resetting 
somatic cell types to a pluripotent status, and, what’s more, that transcription factors 
exist that may help to mediate this process (Takahashi and Yamanaka, 2016). 
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In the early 2000s, research with ESCs, as aforementioned, became restricted in some 
areas as a result of ethical and moral complications. Scientists working within the field 
looked to bypass the complications of ESC use, whilst still retaining cells with a 
pluripotent capacity and vast research potential. These seminal, yet seemingly 
separate pieces of work would ultimately provide the basis for a break in the PSC 
research stalemate. A search for transcriptional regulators of pluripotency, that if 
identified and over-expressed, could potentially convert a terminally differentiated cell 
type to a pluripotent phenotype was underway.  
It was long established that a transcriptional hierarchy exists which is critical to the 
specification of ES cell identity as well as the cells unique functional properties. OCT4 
(POU5F1) has been identified as a protein critical to the maintenance of pluripotency, 
as its loss of function in ES cells results in their unwanted differentiation (Nichols et 
al., 1998). OCT4 is a member of the POU class of homeodomain proteins, a heavily 
conserved set of proteins with functional attributes within cell fate specification (Boyer 
et al., 2005). Along with OCT4, NANOG and SOX2 are also central to the 
transcriptional hierarchy necessary for pluripotency maintenance. It is now clear that 
these three factors function in-conjunction with one and other to control a large 
population of downstream regulatory genes. This is achieved by the protein’s co-
occupancy of promoters for other developmentally important homeodomain 
transcription factors, permitting the maintenance of the specialised ESC regulatory 
network. With a developed understanding of the main transcriptional regulators of 
pluripotency, this would be key in narrowing the search for factors critical to the de-




In an initial search for Oct3/4 target genes, work by the Shinya Yamanaka lab isolated 
F-box containing protein (Fbx15) as a novel target of Oct3/4. It was well established 
that the expression of Oct3/4 in ES cells was critical for self-renewal (Nichols et al., 
1998). The Yamanaka lab was subsequently able to correlate a direct relationship 
between Oct3/4 inactivation and the extinction of Fbx15 expression too. However, 
despite this specific relationship, the loss of Fbx15 did not promote any developmental 
defects in homozygous mutant mice and thus was concluded to be dispensable in 
terms of the maintenance of ES cell self-renewal (Tokuzawa et al., 2003). The 
Yamanaka lab subsequently wanted to elucidate if a panel of 24 candidate genes 
would be able to induce a pluripotent phenotype in terminally differentiated cells and 
if so, which transcription factors would be critical to this process. This involved the 
development of an assay in which the induction of pluripotency, if achieved, would be 
detected as a resistance to G418 (Geneticin). The genes responsible for this antibiotic 
resistance were inserted into the prior mentioned Fbx15 gene via homologous 
recombination. This would provide an ideal marker as the Fbx15 gene is upregulated 
specifically in murine ES cells and early development but as mentioned is dispensable 
in relation to the maintenance of pluripotency. The retroviral transduction of all 24 
candidate genes into mouse embryonic and adult fibroblasts gave rise to G418 drug-
resistant colonies, with morphologies similar to that of ES cells. The cells produced 
were termed induced pluripotent stem cells (iPSCs/iPS cells). Subsequently, each of 
the 24 factors were removed individually from the remaining 23 and the effect on 
 Figure 5 - Pluripotency network: transcription factors necessary for the maintenance of 
pluripotency. OCT4 (POU5F1), SOX2 and NANOG are critical to this process and regulate the 
transcription of several different genes permitting the maintenance of pluripotency. 
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colony formation after 10 and 16 days was noted. This allowed the lab to isolate 10 
factors which they continued to compare in the same manner before a final 4 factors 
were isolated as being important in the generation of induced pluripotent stem cells – 
Oct3/4, Sox2, Klf4 & c-Myc (OSKM). Figure 6 summarises the idea that development 
and differentiation is not a linear and irreversible process, using a modified version of 
Waddington’s landscape.  
 
The development of human iPSCs followed within a year of producing the murine 
counterparts. Adult human skin fibroblasts were successfully reprogrammed back to a 
pluripotent state using human equivalents of the same OSKM transcripts that 
successfully produced the first mouse iPSC line (Takahashi et al., 2007). Concurrently, 
a lab led by James Thompson also successfully produced human fibroblast-derived 
iPSCs (Yu et al., 2007). The Thompson lab however, did use a different combination 
of human transcription factors – maintaining OCT3/4 and SOX2 while replacing KLF4 
and c-Myc with NANOG & LIN28. A multitude of subsequent papers and laboratories 
were able to reproduce this same process and procure iPSCs using both OSKM and 
OSNL factors with similar efficiencies. In both the Yamanaka and Thompson lab, viral 
transduction was utilised as the vehicle or vector to deliver the pluripotency factors to 






Figure 6 – Waddington’s landscape re-examined: adopted version of Waddington’s landscape to 
include the updated ideals of transdifferentiation and reprogramming. 
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Thompson, a lentiviral system, both with the aim of having prolonged ectopic 
transgenic expression of pluripotency transcripts. The prolonged expression would 
ensure complete induction of endogenous pluripotency gene expression and 
ultimately, the development of bona-fide iPSCs. Both iPSC types were demonstrated 
to have typical ESC-like structure (round morphology, scant cytoplasm and large 
nucleoli) and express key endogenous pluripotency markers (SSEA3, SSEA4, TRA-
1-60, TRA-1-81, NANOG). Likewise, the cells were demonstrated to maintain a 












Figure 7 - Process of reprogramming somatic cells to iPSCs. Depiction of prolonged transgene 
expression which ultimately drives endogenous pluripotency gene expression. 
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1.2.2. Reprogramming:  
 
1.2.2.1. Phases of reprogramming  
 
The process of reverting a terminally differentiated cell back to a pluripotent state is 
termed induced pluripotent stem cell reprogramming. The reprogramming of 
differentiated fibroblasts back to iPSCs offers, as the use of ESCs does, a platform to 
continue to develop the potential for regenerative medicine as well as studying the 
mechanisms of early development. However, with the possibility of deriving the 
somatic cellular material (dermal fibroblasts) necessary to produce iPSCs in an 
autologous fashion, this mitigates any immunological complications previously 
identified with ESC use. Moreover, being derived from adult somatic cells, this may 
help to assuage previous ethical and moral complications surrounding the isolation 
and use of ES cells. 
The reversal of development and epigenetic erasure that ensues when reprogramming 
terminally differentiated somatic cells is a complex process. Sustained transgene 
expression is necessary to facilitate chromatin re-arrangement on both a global and 
local scale – ultimately mediating the silencing of lineage specific genes and an 
activation of pluripotency-related ones (Biran and Meshorer, 2012). The exogenous 
over-expression of key pluripotency transgenes has also been demonstrated to result 
in the ordered progression of X-chromosome reactivation (Xa) in both murine and 
human iPS cells (Cantone and Fisher, 2017). In humans cells, the reactivation of the 
X-chromosome is however unstable. The reprogramming process, despite facilitating 
Xa, doesn’t yield wholly reactivated iPSC colonies - with culturing conditions being 
implicated in such variability (Kim et al., 2014). The process of reprogramming 
remains, on the whole, elusive and specifically in its early stages, largely stochastic in 
nature (Buganim et al., 2012).  
Upon the successful derivation of iPSCs from both murine and human cells, work had 
been undertaken to elucidate the mechanism behind the global cellular resetting back 
to pluripotency. Extensive time course transcriptomic analysis permitted great insight 
into the process of reprogramming and its subsequent grouping into 3 main phases: 
initiation, maturation and stabilization (Samavarchi-Tehrani et al., 2010).  
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There are a number of different fates which may be exhibited by cells in the initiation 
phase of pluripotency onset, such as apoptosis, senescence, transdifferentiation and 
reprogramming (Buganim et al., 2012). Of cells that undergo faithful reprogramming, 
it has been elucidated that all of these cells must acquire a number of mesenchymal 
to epithelial transition (MET) related modifications. This ubiquitous nature of MET-
onset during reprogramming was demonstrated by backtracking Oct4/Nanog positive 
iPS cells using single cell time lapse microscopy (Smith et al., 2010). The initiation 
phase is therefore characterised largely by the cells undergoing MET. The process of 
MET instigates changes to the cellular transcriptome, with a loss of somatic cell 
signatures and an upregulation of epithelial related genes. Moreover, MET also 
initiates changes to cellular morphology, with this morphological re-construction alone, 
being demonstrated to hold the capacity to initiate epigenetic changes associated with 
pluripotency regulation (Downing et al., 2013). Subsequently, reprogramming cells 
undergoing MET also develop ESC-like features, including an increased proliferation 
alongside an increased resistance to apoptosis and senescence (Hong et al., 2009). 
It has become apparent that despite the probabilistic nature of the initiation process, it 
occurs with a degree of systematism, with the requirement being that cells hit well-
defined MET checkpoints as opposed to the synchronicity in which they do so 
(Buganim et al., 2013; David and Polo, 2014).   
Predominantly, the changes associated with the maturation phase of reprogramming 
are, on the whole, well-established. This phase, and its transitioning cells, are largely 
defined by major transcriptional changes, specifically the onset of pluripotency-related 
genes (Buganim et al., 2013; David and Polo, 2014). However, the initial period of the 
maturation phase has been determined to be largely random in nature. Exogenous 
expression of the Yamanaka factors (OSKM), ultimately gives rise to a somewhat 
stochastic upregulation of pluripotency transcriptional regulators whose specific order 
remains mostly unknown. Yet, beyond the stochastic activation of said genes, in the 
latter maturation phase, the transcriptional activation becomes more deterministic. 
The core pluripotency genes such as OCT4, SOX2 and NANOG will all be readily 
upregulated during this period, along with their downstream targets. This suggests 
that, despite the stochastic nature of transcriptional onset during the early maturation 
phase, that a hierarchy of pluripotency gene activation exists towards its latter end and 
is critical to the development of fully-fledged iPSC formation. 
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The final stage of iPSC development is the stabilisation phase. At this point the cells 
have become iPSCs – expressing key pluripotent markers and having typical 
morphological characteristics. The stabilisation phase encompasses an assessment 
of the newly-developed iPSCs pluripotent signature via their ability to maintain the 
expression of pluripotency-related genes independent from ectopic transgene 
expression. At this point the cells will be passaged, expanded and subsequently tested 
for transgene independent endogenous pluripotency gene expression. Despite the 
seemingly fully-fledged, committed nature of these cells at the stabilisation phase, 
epigenetic alterations will continually occur during this phase and for a number of 
passages beyond this point too.  
1.2.2.2. Transgene modifications:  
 
Despite an incomplete understanding of the reprogramming process, many steps have 
been taken to attempt to increase its efficiency, as well as increasing the number of 
different somatic cell types that can be manipulated back to pluripotency. One area of 
reprogramming susceptible to manipulation has been the use of different pluripotency 
transgenes. Since its initial description in humans in 2007, the OCT4, SOX2, KLF4, c-
MYC transcription factor cocktail described by the Yamanaka lab has been a mainstay 
of the reprogramming protocol, being more readily employed than other published 
counterparts. Since then, a number of different transgenes have been tried and tested 
in synergistic combinations, but none seemingly long-standing enough to challenge 
the status quo. 
Yet, published in 2011, the Yamanaka lab outlined how the inclusion of a short-hairpin 
RNA for p53 (p53-shRNA) and replacing c-Myc for L-Myc helped improve the quality 
of the iPSCs produced (Okita et al., 2011). L-Myc is, like c-Myc, a member of the myc 
oncoprotein family. Yet, L-Myc is reported to be much less oncogenic, being far less 
associated with cancer development in comparison to the more volatile c-Myc (Nesbit 
et al., 1999). The Okita lab reported that the addition of these two factors increased 
reprogramming on average by approximately 3-fold in comparison to the highest 
efficiency achieved by a combination of any other reprogramming factors. It is a well-
established line of thought that p53 is an inhibitor of successful reprogramming. Often 
referred to as the guardian of the genome, p53 is responsible for a number of 
processes such as senescence, apoptosis and DNA damage response (Horikawa et 
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al., 2017). The functional properties asserted by p53, do therefore make its function 
incompatible with the self-renewing properties of iPSCs, further perpetuating the role 
of p53 as a barrier to iPSC production (Zhao and Xu, 2010). The inhibition of p53 
expression, by blocking mRNA translation, has been demonstrated to dramatically 
increase the efficiency of reprogramming and murine iPSC development for over a 
decade (Hong et al., 2009). That said, the inclusion of further genetic modifications 
permits more implications for the downstream use of iPS cells in the clinic and beyond. 
Loss of wild-type p53 function is a prerequisite to the onset of the majority of human 
cancers. With p53 being responsible for the suppression of genomic instability, its 
transcriptomic inactivation and subsequent reduced functionality increases the 
possibility of genomic aneuploidy amongst other chromosomal aberrations (Zhao and 
Xu, 2010). The inhibition of p53 function during reprogramming therefore poses 
considerable concerns about the tumorgenicity and genomic integrity of the iPSCs, 
with identifiable chromosomal aberrations being commonly reported (Chin et al., 2009; 
Hong et al., 2009). Moreover, an extensive study characterising 140 independent ESC 
lines was carried out using whole exome sequencing (WES) which isolated a number 
of previously undetected mutations to the TP53 gene. Such affected residues in the 
ESCs were likewise commonly mutated in human tumours. The mutational abundance 
on each allele was then quantified using droplet digital PCR (ddPCR). Such cells were 
therefore demonstrated to naturally acquire p53-related mutations as commonly seen 
in human cancers and moreover, that such mutated allelic fractions increased in 
proportion to the cells passage number. This suggests that the p53 mutation confers 
a selective bias which may go unnoticed in most applications of such cells, with the 
paper highlighting the necessity of careful genetic analysis of any prospective clinical 
application of such cells (Merkle et al., 2017). Despite the suggestion of its rate-limiting 
functionality on the reprogramming process, the suppression of p53 expression is not 
a necessity for the success of somatic cell reprogramming to iPSCs. However, 
suppression of its function is well-characterised to result in cancerous transformation 
of cells which render then clinically redundant. Therefore, a clear rationale exists to 
actually allow the natural persistence of p53 during the reprogramming process. 
Moreover, work from the Ichida lab demonstrated how an inherent antagonism 
between transcription and proliferation is a limiting factor in cellular reprogramming. 
Transcription factor overexpression during reprogramming within hyperproliferative 
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cells is critical to lineage conversion. However, sustenance of transgene expression 
throughout the reprogramming process impedes cell proliferation and DNA replication 
– processes necessary for its completion (Babos et al., 2019). However, natural 
populations of simultaneously hypertranscribing, hyperproliferative cells (HHCs) 
exists. Furthermore, it has been suggested that the expression of wild-type p53 
increases the population of the privileged HHC cell types in comparison to p53 knock-
down cells during reprogramming. WT-p53 is suggested to interact with 
topoisomerase related genes and that a loss of p53 function reduces nuclear 
expression of these genes and results in a reduction in HHC levels. This newfound 
data suggests the role of p53 is more nuanced than first thought in the context of 
cellular reprogramming (Babos et al., 2019).  
Duly, the process of increasing the number of transgenes to improve the efficiency of 
reprogramming may or may not improve the clinical applicability of iPSCs. As prior 
mentioned, the mechanism of reprogramming remains incompletely understood, 
therefore the true implications of added transgenic material cannot be unequivocally 
elucidated. However, in terms of the applicability of iPSCs into the clinic, an argument 
exists that the more simplistic route with minimal genetic modification, may in turn 




Another area that has received considerable research effort and is a critical factor to 
the reprogramming process, is the type of transgene delivery system used. The 
transgene delivery vehicle is referred to as the vector. The choice of vector when 
reprogramming somatic cells is a pivotal decision affecting both the efficiency (number 
of iPSC colonies produced in respect to the number of fibroblasts subjected to 
reprogramming) and quality of iPSC developed, which in turn is also determinative of 
the cells prospective downstream use.  
When first derived from human fibroblasts in seminal studies in 2007, iPSCs were 
generated using genome integrating viral vectors in both the Yamanaka & Thompson 
labs (Takahashi et al., 2007; Yu et al., 2007). The Yamanaka lab utilised a γ-retroviral 
vector to develop human iPSCs in a proof-of-principle study. This method of iPSC 
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production is robust and pertinent in this respect. However, permanent modifications 
to the genome of the transduced somatic cell makes the subsequent iPSCs unsuitable 
for clinical use. Takahashi reported that each clonal iPSC line generated had between 
three and six retroviral integrations per reprogramming factor. This meant that every 
clone therefore had more than 20 retroviral integration sites in total (Takahashi et al., 
2007). The permanent and semi-random nature of such integrations of transgenic 
DNA into a somatic cell genome can increase the risk of tumorigenesis via insertional 
mutagenesis. The retroviral vector will, by nature, integrate within the host cell 
genome. Preferences of such semi-random insertions lie between actively transcribed 
genes and cis-regulatory elements (CpG motifs) (Baum, 2007). Dependent upon the 
site of the insertion, such transduced cells may develop an induced, serial replication 
capacity providing them with a clonal bias. Such clonal imbalance and subsequent 
clinical transfer of these cells into a patient has, in previous studies using transduced 
haematopoietic cell types, resulted in the onset of Leukaemia or sarcoma (Hacein-
Bey-Abina et al., 2003). Hence, there is a clear prospect that utilising an integrating 
vector can result in a secondary morbidity. This was re-iterated in murine studies 
where approximately 20% of mice derived from iPSCs reprogrammed using the γ-
retroviral vector developed tumours. The aetiology of the tumours were, in part, 
determined to be associated with the reactivation of c-Myc retroviral DNA (Okita et al., 
2007).  
It was recognised that for iPS cell therapies to progress into the clinic, that alternative 
reprogramming methods had to be developed that negated any integration into the 
manipulated somatic cell genome. As such, considerable research efforts have been 
applied to the area of non-integrating vectorology in an attempt to diversify and 
improve safe methods of pluripotency protein upregulation to aid in iPSC clinical 
development. Now, a myriad of different non-integrating vectors have been identified 
and demonstrated, with varying levels of success, to be able to induce pluripotency 
onset and iPSC development. More recently, a multitude of small molecules and the 
CRISPR-cas9 technology has been demonstrated to be capable of iPSC production 
(Weltner et al., 2018). However, virus, plasmid DNA, mRNA and recombinant proteins 
are more commonly manipulated and utilised for iPSC development. These vector 
types have long-been identified and as such, much progress has been made to 
develop their place within the iPSC research field.  
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1.2.2.3.1. Sendai virus (SeV) 
 
Belonging to the Paramyxoviridae family of viruses, SeV is an enveloped virus having 
a non-segmented, negative-sense, single-stranded RNA genome. SeV is non-
pathogenic in humans and will typically complete its cell cycle in the infected host cells 
cytoplasm, with its viral genome encoding a total of six critical proteins (Nakanishi and 
Otsu, 2012). The Hasegawa lab was first to report the production of iPSCs using a 
SeV vector (Fusaki et al., 2009). The report details the use of a fusion protein-deficient 
SeV vector to reprogram and produce bona-fide iPSCs. The vector reprogrammed 
human dermal fibroblasts at efficiencies from 0.001-1%, in a non-integrative manner. 
Transgene expression is reduced proportionately with cell division, and this loss was 
reported to be accelerated by the addition of antibodies to the haemagglutinin (HN) 
surface envelope protein, small interfering RNAs to RNA-dependant RNA 
polymerases (RdRp) or by modifying the SeV to be temperature sensitive (Seki et al., 
2010; Ban et al., 2011). The production of SeV vectors ultimately apexes with the 
generation of the replication-deficient, auto-erasable SeV (Nishimura et al., 2017). The 
vector is designed to self-regulate its expression in relation to the presence of specific 
micro-RNAs/miRNAs. It has long been recognised that with the inclusion of miRNA 
target sequences in the 3’UTR (untranslated region) of a gene,  that its expression will 
be downregulated in the presence of its targeted miRNA (Brown et al., 2007). 
Subsequently, a SeV vector was produced with target sequences to miR-302 within 
the 3’UTR of the large protein (L) gene within the SeV genome. The expression of 
miR-302 is ubiquitously upregulated in pluripotent cell types, with diminished 
expression in terminally differentiated cells. Subsequently, within a differentiated cell, 
the SeV will persist and express its exogenous pluripotent transgenes. As the 
differentiated cells reprogram and develop a pluripotent state, expression levels of 
miR-302 will increase which will inversely promote a decrease in SeV levels. This 
process should therefore result in integration-free, SeV-free iPSCs with minimal effort 
(Nishimura et al., 2017; Borgohain et al., 2019) 
Duly, there are clear advantages to employing the SeV system within the process of 
reprogramming and iPSC production. The virus, by nature, binds to the ubiquitously 
expressed, membranous, sialic acid receptor and as such proffers the virus with a 
wide-ranging tropism (Nakanishi and Otsu, 2012). The vectors tropism is reflected 
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within its ability to efficiently infect and reprogram a broad range of differentiated cell 
types, including: peripheral blood, fibroblasts, urine-derived cells and keratinocytes 
(Yang, 2014; Cristo et al., 2017; Boonkaew et al., 2018). The viral vectors transgenic 
requirements can be easily manipulated to ensure competitive reprogramming rates, 
and its lack of a DNA phase reduces the SeVs susceptibility to any silencing or 
modifications engendered by the infected host cell (Borgohain et al., 2019).  
That said, drawbacks exist with regards to the use of the SeV system and how this 
can negatively impact iPS cells and their path to the clinic. Firstly, the process of SeV 
production is laborious and technically challenging in comparison to the production of 
other viral delivery systems (Rao and Malik, 2012). There are commercially available 
kits to combat this issue. Yet, these kits are extremely costly, this therefore limits the 
prospect of a homogeneous, replicable global method of iPSC production. This makes 
the SeV system unsustainable in terms of developing iPSCs for clinical appliances 
and also deters the potential for autologous cell therapies. That said, concerns also 
exist over the SeV vectors cytotoxic and immunogenic side-effects too. The Chen lab 
demonstrated that Sendai potentiates severe cytotoxic side-effects on cells 
undergoing transduction. The virus therefore had to be batch tested and an MOI 
titration carried out to perpetually analyse and minimise the vectors potential negative 
cellular impact (Beers et al., 2015). Moreover, despite newer modified SeV vector 
types being deficient of fusion, matrix and hemagglutinin-neuraminidase proteins, both 
fusogenic and immunogenic concerns still persist with the vectors use. Likewise, 
despite the vector also being non-integrative, it is common practise that all iPSCs 
produced by SeV undergo thorough screening protocols for integrations and the 
presence of viral genes - adding more complication and cost to the process (Borgohain 
et al., 2019).  
 
1.2.3.3.2. mRNA:  
 
The transfection of reprogramming factors in the form of messenger RNA (mRNA), 
offers a transient and simplistic method for iPSC production. Despite descriptions of 
synthetic mRNA synthesis originating from the 1980s, it was not a widely utilised 
scientific tool, as virus, plasmid and small interfering RNAs (siRNAs) were. In the early 
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2000s, reports of long-lived and efficiently expressed mRNAs were published with the 
transcripts aiming to mimic natural mRNA features and structure (Karikó et al., 1999, 
2008; Jemielity et al., 2003; Mockey et al., 2006). Typically, these mRNAs, contained 
5’ cap, polyA tails and untranslated regions (UTRs) as natural mRNA would, and could 
moreover be mass produced and delivered to different cultured cell types. The first 
publication surrounding the use of mRNA transfection for the reprogramming of 
fibroblasts and production of iPSCs came in 2010 (Yakubov et al., 2010). Despite 
providing evidence supporting pluripotency transgene and protein expression during 
the reprogramming process (OCT4, SOX2, NANOG, SSEA4), and iPSC colonies 
produced staining positive again for pluripotency markers (AP & NANOG), there was 
a degree of uncertainty surrounding the fully-fledged nature of these iPSCs (Warren 
and Lin, 2019). This, and subsequent attempts made to produce iPSCs using mRNA 
did highlight some of the key issues associated with this method of pluripotency 
activation. mRNA expression is extremely transient, with even the long-lived mRNAs 
expressing in the host cytoplasm for only 12-24 hours before undergoing degradation. 
Such minimal transgenic expression ultimately led to the curtailment of pluripotency 
protein expression and subsequently restricted the capacity for pluripotency induction 
and complete reprogramming within differentiated cell types. To overcome this, 
repeated daily transfections were undertaken to help maintain transgenic and 
ultimately the expression of pluripotency-related proteins. Yet, the continued, daily 
transfection of mRNA into cells is not only labour-intensive and time-consuming for the 
lab user, but repeatedly subjecting cells to transfection reagents can also pose a 
degree of cellular toxicity. Moreover, it has been documented that the transfection of 
synthetic mRNA into a host cell, activates somatic innate immune responses. 
Transfection of the single-stranded mRNAs activates host anti-viral responses, 
subsequently upregulating type-1 interferon expression (Angel and Yanik, 2010). This 
likewise, makes the repeated, daily transfections unsustainable again, due to an 
increased cytotoxicity. Continued endeavour and optimisation of this process, 
however, has led to the successful derivation of iPSCs from fibroblasts using both 
feeder and feeder-free approaches. Methods to combat innate stimulation have been 
adopted, such as the inclusion of B18R, a decoy receptor for type 1 interferons, which 
can be included as a media additive to slow the onset of the host cell inflammatory 
response (Warren et al., 2010). Moreover, continual adaptations of the synthesised 
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mRNAs has shown that the replacement of canonical DNA bases with non-normal, 
pseudo-nucleosides permits a greater evasion of the cell’s immune response (Karikó 
et al., 2008). These changes have helped to permit the daily transfections of the mRNA 
pluripotency transgenes with less-severe repercussions. This has ultimately led to the 
production of iPSCs, which display a high efficiency, alongside low aneuploidy rates 
and limited major alterations to copy number variants (CNVs) in comparison to other 
reprogramming vector types (Boonkaew et al., 2018). However, the time-consuming 
nature of the protocol, as aforementioned, does prevent the mRNA vector from being 
more frequently adopted as standard practise in labs globally. 
 
1.2.2.3.2. miRNAs:  
 
MicroRNAs (miRNAs) are short, non-coding RNAs that are approximately 22 
nucleotides in length. They function in the post-transcriptional regulation of gene 
expression by interacting with transcribed mRNA structures based upon 
complimentary ‘seed sequences’, usually present in the mRNA’s UTR. The miRNA 
can then promote mRNA degradation or an inhibition of the mRNAs translation to limit 
gene expression and protein production. Thus through the repression of lineage-
specific genes, miRNAs have been demonstrated to be able to reprogram 
differentiated cells back to pluripotency (Anokye-Danso et al., 2012). miRNA clusters 
have been isolated and identified to be able to produce iPSCs, such as miR 290-295 
and miR 302-367. The latter cluster has also been demonstrated to reprogram and 
produce iPSCs independently, being able to replace the traditional OSKM transgenes. 
Integrative miRs are capable of complete reprogramming, being delivered using 
lentiviral vectors, but this is counter-intuitive in terms of progressing iPSCs to the clinic. 
Transient transfection of miRNAs has also been demonstrated to produce iPSCs, but 
as with the mRNA system, miRs are extremely transient and as such multiple 
transfections are required, which dramatically increases the workload of the protocol. 
Moreover, the system, although functional in producing iPSCs, does so at a low 
efficiency (~0.01%), making it a less-attractive option for widespread iPSC production 




1.2.2.3.3. Recombinant proteins:  
 
The isolation of pure bioactive forms of reprogramming proteins represents a novel, 
safe and transgene-free approach to iPSC generation. The proteins can be produced 
in large quantities, by manipulating prokaryotic or eukaryotic systems, and fused with 
cell-penetrating peptides to help facilitate its passage into the host cell. This system 
was first successfully utilised in murine iPSC production in 2009 (Zhou et al., 2009). 
The OSKM proteins produced were fused with poly-arginine PTD (11-R) at the protein 
C-terminus to aid cellular penetration, before being amplified in bacteria. During 
reprogramming, the cell medium was also supplemented with 1mM Valproic Acid 
(VPA), a histone deacetylase inhibitor, to attempt to increase the reprogramming 
efficiency (Rao and Malik, 2012). The protein was transduced into mouse embryonic 
fibroblasts (MEFs) containing an Oct4-GFP reporter. The kinetics and efficiency of the 
reprogramming was, however, considerably poorer in comparison to other vector-
types. The system functioned at an overall efficiency of ~0.006%, with colonies 
appearing between 30-35 days after transfection. The biggest issue however, was that 
the transient transfection of protein alone was not sufficient to reprogram and produce 
iPS cells, VPA was required for the induction of OCT4 positive colonies. This far-
reduced efficiency was largely in relation to the endosomal entrapment of 
reprogramming proteins within the host cell, rendering them useless (Zhou et al., 
2009). That said, in the same year, a team in Harvard medical school were the first 
lab to successfully recapitulate this process in human cells, producing human iPSCs 
mediated by the delivery of OSKM proteins to neonatal fibroblasts. The four 
reprogramming proteins were fused with poly-arginine PTD (9R), again to facilitate the 
proteins crossing of the fibroblast cell membrane. HEK293 lines were then generated 
expressing the modified versions of the OSKM proteins before fibroblasts were 
subjected to the HEK293 protein lysates. The process, overall, was successful, 
leading to the derivation of iPSCs expressing endogenous pluripotency markers whilst 
also retaining a tri-lineage differentiation potential. That said, the protocol was also 
fairly arduous, with 6 rounds of protein transductions only peaking at a maximal 
efficiency of 0.032%, inferred by AP staining. Moreover, the six rounds of 
transductions take place over an 8-week protocol, with primary colonies being picked 
approximately 56 days following the initial transduction (Kim et al., 2009). This low 
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efficiency, again, was said to be in relation to the proteins’ continual endosomal 
entrapment. A number of studies have been carried out since these seminal pieces of 
work, yet only one publication has reported a reprogramming efficiency over 0.05% in 
humans (Lee et al., 2012). In theory, the process of reprogramming using purified 
proteins is ideal in terms of the progression of iPSCs to the clinic. Transient protein 
transduction is a significantly safer method of iPS cell production as opposed to 
exogenous pluripotency transgene expression. Its ease of manipulability permits the 
editing of pluripotency factors for transduction. Likewise, its protocol for iPSC 
production allows precise control of both protein dosage and timeframe of 
reprogramming factor expression. Yet, the power of complete control held within this 
method  is outweighed by a number of bottlenecks. Protein reprogramming functions 
at a much lower efficiency than other widely accepted vectors and reprogramming 
methods. In addition, the proteins demonstrate manufacturing variability, poor in-vitro 
solubility/stability and perpetual endosomal entrapment, all of which are confounding 
factors to the vectors minimal uptake within the reprogramming field (Borgohain et al., 
2019).  
 
1.2.2.3.4. Transposon Vectors (PiggyBac & Sleeping beauty):  
 
Transposons are non-viral, DNA vectors which typically consist of a transposition DNA 
sequence of interest and an additional transposase expression cassette. 
Transposons, in comparison to other DNA vectors, have been demonstrated to 
possess a high transfection efficiency, a reduced immunogenic response and a 
versatility in terms of its genetic payload or cargo (~10kb). That said, the transposon 
system relies on the integration of its expression cassettes into the host cell genome 
to permit prolonged gene expression (Rao and Malik, 2012). However, the virtue with 
transposon vectors is that once the required expression period is complete, transient 
re-introduction of the transposase enzyme permits the excision of the integrating 
vector leaving the cells genome intact. On the whole, transposons provide a system 
which is inexpensive, easy to purify, demonstrates a high transfection efficiency and 
can stably express a gene of interest without leaving any permanent modifications - 
providing a good candidate for iPSC production and clinical progression. 
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As such, two main transposon vectors have been utilised in iPSC research, PiggyBac 
(PB) and Sleeping beauty (SB). Both of these transposon systems consist of a donor 
plasmid – containing the gene(s) of interest to be introduced into the host cell genome. 
These donor plasmids are flanked by inverted terminal repeats (ITRs) that are critical 
to its transposition. Finally, as mentioned, a helper transposase-expressing plasmid is 
also co-transfected alongside the donor plasmid. The transposase enzyme functions 
by catalysing the ITR sequence to isolate the gene/sequence of interest before 
integrating it into the genome of the host cell via a ‘cut and paste’ mechanism 
(Haridhasapavalan et al., 2019). Few differences exist between the PB and SB 
transposon vectors. The PB transposon donor integrates in a semi-random fashion, 
being more inclined to integrate within transcription units in the host cell genome (Hu, 
2014b). Meanwhile, the SB system integrates randomly within the hosts genome, 
displaying no propensity for specific genes/gene regulatory elements. However, both 
systems have, from a single transfection, been demonstrated to be able to develop, 
and ultimately be excised from, murine and human iPSCs (Kaji et al., 2009; Woltjen et 
al., 2009; Muenthaisong et al., 2012; Davis et al., 2013). This, however, is a far from 
perfect method of iPSC production. Firstly, both the PB and SB systems reprogram 
with low efficiencies – with the PB method being reported to reprogram at efficiencies 
of 0.02-0.05% and the SB system at ~0.02-0.03% (Haridhasapavalan et al., 2019). 
Moreover, the transposon system functions on the fundamental basis of integrating 
foreign DNA into the somatic cell genome. Ultimately, this may increase the risk of 
insertional mutagenesis and chromosomal rearrangements. Despite the fact that the 
DNA can be excised with the transposase enzyme at the end of the protocol, thorough 
screening of cells produced using this vector is still a necessity. In addition, reports 
also suggest that with both transposon systems, that the transposase excision reaction 
occurs with a 95% success rate, an important caveat, reiterating the necessity of 
screening protocols post iPSC production (Wang et al., 2008). As aforementioned, the 
extra-step adds further time and labour to the protocol, making it longer than 
procedures carried out for other non-integrating vectors (Igawa et al., 2014).  That 
said, both of these systems have been demonstrated to produce integration-free 




1.2.2.3.5. Plasmid DNA: 
  
One of the most rudimentary methods to manipulate gene expression is with the use 
of plasmid DNA derived from bacteria. Plasmids have the capacity to replicate 
autonomously within the bacterium and can be both linear and circularised. However, 
the linear form is more susceptible to exonuclease digestion and so the circular 
plasmid is most often utilised (McLenachan et al., 2007). Plasmids have long been 
manipulated to over-express a gene of interest in a host cell and this method has been 
recognised as having clear potential for exploitation in the field of iPSC development. 
The Yamanaka lab was first to publish the successful derivation of iPSCs using 
transient plasmid transfections in murine fibroblasts (MEFs), with no signs of 
integration (Okita et al., 2008). The Yamanaka lab have recognised since their 
pioneering work first producing both mouse and human iPSCs, that for iPSC 
technology to have a clinical applicability, that a non-integrating vector must be utilised 
to minimise the risk of tumorgenicity. The lab utilised two plasmids, one expressing 
Oct3/4, Sox2 and Klf4 and the other plasmid expressing c-myc, all under a 
constitutively active CAG promoter. The plasmids likewise contained an ampicillin 
resistance gene. MEFs, modified to contain a Nanog-GFP reporter were subjected to 
multiple rounds of plasmid transfections. Four transfections were carried out in total, 
the OSK plasmid was transfected on days 1 and 3, while the c-myc plasmid on days 
2 and 4. The plasmid was found to successfully produce iPSCs in 70% of 
reprogramming experiments with efficiencies ranging from 0.0001-0.0029% (Okita et 
al., 2008). It was clear from this initial experiment that the plasmid-based 
reprogramming system offered a much more clinically viable method of iPSC 
production, as opposed to integrating viral vectors. Yet, with multiple transfections 
required, increasing workload and cellular toxicity, and an extremely low 
reprogramming efficiency, it was clear that further work on plasmid-based iPSC 
production was required. Alterations to the stoichiometry of the plasmids utilised within 
the reaction were soon undertaken. Experiments were carried out utilising the key 
Yamanaka factors, each in separate plasmids, successfully producing human iPSCs, 
albeit again, at a considerably lower efficiency than other reprogramming 
methodologies (Si-Tayeb et al., 2010). It was recognised that polycistronic vectors, 
expressing multiple reprogramming factors could potentially increase the plasmid 
systems reprogramming efficiency. This would, in theory, increase the propensity of 
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transfected cells receiving the complete reprogramming transcription factor ‘cocktail 
mix’ and therefore increase the cells chances of undergoing complete pluripotency-
recapture. Despite this, the use of polycistronic vectors was also viewed as a ‘double-
edged sword’. The dogma central to successful reprogramming is having continual 
and balanced pluripotency transgene expression, sanctioning a cells progression 
through the three reprogramming phases. A polycistronic vector holds the potential to 
create an imbalance within the transgene stoichiometry which may result in non-
beneficial effects on a cell’s reprogramming potential.  Moreover, having an all-
encompassing reprogramming plasmid, would increase the size of the vector 
dramatically, which in-turn, would inversely decrease the transfection efficiency of the 
plasmid. This again would not hold any benefits in terms of increasing the 
reprogramming efficiency of the vector (Haridhasapavalan et al., 2019). However, the 
introduction of the picornaviral 2A system, brought about a ‘happy medium’ in terms 
of altering the plasmid systems stoichiometry. The 2A system, in brief, permits the 
joining and simultaneous transcription of several transgenes producing a single 
transcript containing all said transgenes. The system is then however, self-cleaving, 
permitting no subsequent changes to the reprogramming factors eventual translation 
(Osborn et al., 2005). That said, the issues associated with stoichiometry are not the 
only sticking point in relation to the lack of success achieved using transfected 
plasmids. Plasmids are not self-replicating in eukaryotic cells, and as such the 
transient nature of the system is insufficient to induce a complete reversal of the 
differentiation process and onset of pluripotency. It is reported that a minimum of 12 
days of continual pluripotency gene expression is necessary to reprogram and 
produce iPSCs, and that ultimately expression is likely also required for a period 
beyond this too, to ensure completion of the maturation-stabilisation phase transition 
(Brambrink et al., 2008; Si-Tayeb et al., 2010). Therefore, the transient nature of this 
vector is likely to owe to its reduced functionality. The presence of immunogenic 
plasmid backbone prokaryotic DNA sequences such as antibiotic resistance genes 
and unmethylated CpG dinucleotides will potentiate an upregulation of pro-
inflammatory cytokines (including IFN-γ) from the host cells. This, in turn, will increase 
levels of plasmid removal and transgene silencing – contributing to the plasmids 
aforementioned transiency (Yew et al., 2000). It was clear that for plasmid to become 
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a more effective system within reprogramming, that changes to alter its transiency, 
and the aetiology of that transiency, were required.  
 
1.2.2.3.6. Minicircle:  
 
Being first described in the Crouzet lab, minicircle vectors were generated and found 
to transcend traditional expression plasmids by negating many issues associated with 
their use (Darquet et al., 1998). Conventional plasmids, through bacterial-associated 
DNA sequences, carry a risk of cytotoxicity, immunogenicity and uncontrolled 
therapeutic gene dissemination. Minicircles, however, are episomal, supercoiled 
circular DNA sequences which are devoid of almost all bacterial-associated DNA 
sequences including: the origin of replication sequence and antibiotic resistance genes 
(Hu, 2014b). Additionally, the minicircle system is reported to produce vectors which 
are smaller in size to traditional plasmids (~4kb in comparison to sizes as high as 15kb 
with plasmid) and seemingly have a greater transgene expression capacity both in-
vitro and in-vivo too (Chen et al., 2003; Maucksch et al., 2009). Moreover, being 
smaller in size the vector demonstrates a greater transfection efficiency and likewise 
being devoid of pro-inflammatory bacterial sequences, possesses a much greater 
longevity of expression within its host cell in comparison to conventional plasmids 
(Darquet et al., 1998; Chen et al., 2003; Narsinh et al., 2011; Haridhasapavalan et al., 
2019). It is clear from the above work, that the physical and functional properties 
associated with minicircle, make it a much more attractive candidate for the delivery 
of pluripotency transgenes in somatic cell reprogramming. Initially, successful 
reprogramming was carried out utilising a polycistronic, ‘reprogramming minicircle’ in 
adipose stem cells (Jia et al., 2010; Narsinh et al., 2011). The minicircle system 
however, still functioned at a low reprogramming efficiency, ~0.005%. This was 
disappointing, as not only did the vector fail to reprogram and produce iPSCs in an 
efficient manner, it did so on a cell type that is considered to have a greater plasticity 
and ease of reprogramming than fibroblasts (González et al., 2011). Moreover, upon 
reprogramming fibroblasts with the same vector, Jia et al, 2010, were able to produce 
bona-fide iPSCs but with a 10-fold drop in efficiency again. Additionally, the protocol 
undertaken in these experiments was laborious and potentially cytotoxic with a 
nucleofection of the minicircles on day 0, subsequent FACs sorting of successfully 
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transfected cells before a second and third transfection on days 4 and 6 following 
nucleofection (Jia et al., 2010). Despite this, the vector was able to produce transgene-
free iPSCs which could express key pluripotency markers whilst also demonstrating 
an ability to also differentiate into cells of each of the three germ lineages. In the years 
and research efforts undertaken with minicircle since its first description in iPSC 
production, little improvement has been made in terms of improving its efficiency within 
the reprogramming process. This is despite changes being made to the delivery 
system, and its subsequent transgenes too. A report was published, however, using a 
4 in 1 codon-optimized minicircle vector which was demonstrated to be able to 
reprogram and produce integration-free iPSCs in feeder-free and chemically defined 
conditions with a single transfection (Diecke et al., 2014). Duly, being able to 
reprogram and produce integration free iPSCs in this manner brings a high-level 
clinical relevance to this reprogramming method which should be considered 
seriously. Yet, with the efficiency of the process being so low, this is a big confounding 
factor which needs to be addressed in order to propel this method further into the 
clinical setting.  
 
1.2.2.3.7. Episomal plasmid – oriP-EBNA1 system:  
 
As previously discussed, plasmid expression vectors are cheap, easy to produce, 
store and have a much longer shelf-life in comparison to other delivery vehicles utilised 
within the remit of reprogramming. Accordingly, oriP-EBNA1 episomal plasmids are 
an attractive candidate for the clinical production of iPSCs. Standard plasmid-based 
vectors are limited in their ability to reprogram somatic cells. This is often because the 
vector is highly transient, providing a transgene expression period that is insufficient 
to induce complete somatic cell reprogramming and subsequent iPSC production (Rao 
and Malik, 2012). To overcome this, episomal plasmids have been modified to contain 
both oriP (Origin of replication), and EBNA1 (Epstein-Barr nucleic antigen 1) and have 
since been demonstrated to reliably produce iPSCs from fibroblasts amongst a myriad 
of other cell types (Yu et al., 2009; Okita et al., 2013; Wang et al., 2013).  The functional 
success of this system relates to the oriP-EBNA1 plasmid being capable of correcting 
transiency issues associated with standard plasmid-based vectors. Such corrections 
are conveyed by the modified vectors ability to tether to its host-cells somatic 
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chromosomes – a function conveyed by the Epstein-Barr virus (EBV)-derived EBNA1 
protein. Moreover, the modified vector is able to replicate concurrently with somatic 
chromosomes during mitosis, again reducing any previous transiency-associated 
issues and thus permitting prolonged transgenic expression (Frappier, 2012). 
Modifications to the systems persistence and expression period have been critical to 
the success of the oriP-EBNA1 system.  
Episomal tethering is, as mentioned, largely dependent on the viral EBNA1 protein 
which functions to temporarily unify chromosomal DNA and episomal plasmid DNA. 
The EBNA1 protein interacts at the bipartite locus oriP of the plasmid to maintain 
continual persistence and to also aid in plasmid replication within transfected cells 
(Hodin et al., 2013). The oriP locus consists of two main cis elements - as 
demonstrated in Figure 8 – the Family of repeats (FR) and Dyad symmetry (DS) 
(Lindner and Sugden, 2007). Both of these elements are, respectively, pivotal for the 
maintenance and replication of the plasmid and its subsequent transgene. As above-
stated, the EBNA1 protein has binding properties, allowing it to interact with both the 
expression plasmid and the hosts chromosomal DNA. The binding of the EBNA1 
protein to the expression plasmid is mediated by the FR region of the oriP locus. The 
FR, consisting of 20 tandem repeats of a 30bp sequence, contains around 20 high-
affinity EBNA1 binding sites which mediates the binding of the viral protein to the 
plasmid (Hodin et al., 2013). The EBNA1 protein is likewise also capable of attachment 
to host cell genomic DNA via its protein N-terminal hook motifs, LR1 and LR2, that 
bind to AT-rich somatic cell chromosomal regions (Hodin et al., 2013). Both of these 
interactions create a semi-permanent unification between the plasmid and host cell 
chromosomes (Sears et al., 2004). This interaction alone would permit greater vector 
persistence and subsequently, a prolonged transgenic expression. However, without 
an ability to replicate alongside the host cell, the plasmid, and its expression, would 
ultimately become diluted resulting in a far reduced reprogramming efficiency. Duly, 
the DS unit of the oriP bipartite locus, functions as an origin of plasmid replication and 
has been demonstrated to be essential to this function (Yates et al., 2000). Within its 
65bp sequence, DS consists of 4 EBNA1 binding sites, alongside 3, 9bp sequences 
referred to as ‘nonamers’ (Frappier, 2012). The binding affinity of these sequences for 
EBNA1 is relatively weak. Despite this, it has been suggested that both of these 
sequences are essential for DS function as a DNA replicator. There is, however, a 
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degree of ambiguity surrounding the exact function and necessity of the EBNA1 
sequence within the initiation of this process, with conflicting reports being published. 
However, it is suggested that the EBNA1 protein is important in the recruitment of the 
origin recognition complex (ORC), which binds to the DS element of oriP, initiating 
host cell/plasmid DNA replication (Frappier, 2012). Moreover, reports have also 
demonstrated that the EBNA1 protein has direct interactions with proteins associated 
with ORC recruitment and DNA replication such as Cdc6 in murine models and 
Trf2/TRF2 likewise (Deng et al., 2002; Moriyama et al., 2012). It is therefore proposed 
that the DS unit of the oriP locus and the EBNA1 protein function with a dual-synergy 
and co-dependency in initiating the replication of the episomal plasmid within the host 
cell. Such co-dependency is further substantiated by reports demonstrating that 
EBNA1 bound to the FR region of oriP displays an inability to recruit ORC and initiate 
DNA replication – establishing the decisive role that the EBNA1-DS interaction has 
within this process (Schepers et al., 2001; Frappier, 2012). The confirmation of the DS 
locus is suggested to be the decisive factor to its function as a replicator – with the 
locus having a 21bp centre-to-centre spacing (Hodin et al., 2013). Duly, despite the 
exact mechanism remaining to be completely elucidated, it is experimentally clear that 
the addition of both oriP & EBNA1 to the expression plasmid system provide it with a 
prolonged capacity to divide and express its desired transgene.  
 
                  
 
Figure 8 - Features of both the oriP bipartite locus & the EBNA1 protein – source: Hodin 
et al, (2012). 
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The attribute of having an increased transgene persistence but still being a non-
integrating vector provides key functional properties to the oriP-EBNA1 system, that 
are desirable to the process of reprogramming and iPSC development. As such, the 
oriP-EBNA1 system has become a staple in the development of iPSC technology and 
has been successfully utilised within labs globally. The system currently relies on a 
single nucleofection of a 6-factor formula – OCT4, SOX2, KLF4, LIN28, L-myc & 
shp53. These six factors are split across three plasmid backbones. Nucleofection of 
an extra plasmid expressing the EBNA1 is also included to improve reprogramming 
efficiency by means of increasing the propensity of plasmid tethering and replication 
(Yu et al., 2009). The oriP-EBNA1 system utilises a CAG promoter to initiate and drive 
strong transgene expression. The CAG system is synthetically derived, utilising an 
early enhancer element from cytomegalovirus, the first exon and intron of the chicken 
β-actin gene alongside the splice acceptor of the rabbit β-globin gene (Wang et al., 
2017). Each vector likewise also contains two of the six pluripotency factors separated 
by a 2A sequence. Derived from Picornavirus, the 2A sequence permits the co-
expression of multiple genes (SOX2 & KLF4 in one vector (hSK) and L-myc & LIN28 
(hUL) in another) by the well-characterised “stop-go” translational stuttering 
mechanism. The two transgenes, SOX2 & KLF4 for instance, are transcribed as a 
single unit, then, during translation the 2As “self-cleaving” properties come into fruition. 
At the ribosome, cleavage occurs between glycine and proline codons at the 2A C-
Terminus upon translation (Wang et al., 2015). A proline codon directly after the 2A 
sequence permits the synthesis of two non-overlapping proteins. This is accomplished 
as the glycine codon promotes subsequent termination of translation before the “stop-
go” system allows continued translation with proline permitting N-terminal formation of 
the next protein (Atkins et al., 2007). This subsequently allows the transcription and 




 The oriP-EBNA1 plasmid-based system has, duly, been uptaken in the 
reprogramming process as it displays a number of functional advantages which may 
favourably translate iPSC-technology into a clinical setting. The vectors prolonged 
expression alongside its reliability in producing iPSCs from a number of different cell 
types are clear incentives for the vectors proposed use. Moreover, the protocol 
outlined to employ the oriP-EBNA1 system into is extremely simplistic, and, although 
time-consuming, is relatively less labour intensive in comparison to some of the prior 
mentioned methods of iPSC production (Yu et al., 2009). Owing only to a single 
transfection, the oriP-EBNA1 operates with a relatively good efficiency as a non-
integrating vector. The reprogramming efficiency of the system in xeno-free, 
chemically-defined conditions is however lower, with a report optimising this process 
finding that 9µg of vector being nucleofected into 1.0x105 cells being optimal for colony 
formation. The lab was, with these conditions able to reach peak efficiencies of around 
0.017% (Bang et al., 2018). However, this was only 14 days from the initial 
nucleofection as opposed to a standard protocol reaching up to 30 days. Despite this, 
it is possible to reprogram using chemically-defined, xeno-free products and gain 
iPSCs which are transgene and integration free on a regular basis (Yu et al., 2009; 
Lee et al., 2014; Schlaeger et al., 2015). This is obviously hugely beneficial in terms 
of progressing the highly anticipated but largely underused iPSC technology into the 
clinic and beyond.  
Figure 9 - Mechanism of cleaving of the 2A system with an upstream and downstream gene to be 
expressed. The cleavage at glycine forms the C-Terminal of the upstream gene to be expressed. 
Whilst, the subsequent praline forms the N-Terminal of the downstream gene to be expressed 




Yet, the process of iPSC production with the oriP-EBNA1 system is not without 
potential pitfalls. Crucially, some of these issues associated with the vector could be 
limiting factors to the number of clinical grade lines produced in this manner. First, 
some of the transgenes expressed which permit the induction of pluripotency within 
somatic cells using the oriP-EBNA1 system can likewise infer the induction of gene 
networks associated with cancer development. MYC transcription networks contribute 
to the maintenance of iPSC self-renewal and iPSC multiplication, likewise, shp53 is 
reported to increase reprogramming efficiency, however both also harbour a potential 
for an increased tumorigenicity (Chin et al., 2009; Hong et al., 2009).  
Secondly, the chromosomal binding nature of oriP-EBNA1 system which permits the 
production of iPSCs contributes, for the same reason, to the prolonged retention of the 
vector subsequent to iPSC production. Considerable ambiguity surrounds the theory 
and actuality of when iPSCs become plasmid deficient. Ultimately, prolonged retention 
of the vector reduces the clinical applicability of said iPSCs (Drozd et al., 2015; 
Schlaeger et al., 2015; Churko et al., 2017). Additionally, although rare, a chance 
exists that the oriP-EBNA1 system may integrate into the hosts somatic genome, 
increasing the work capacity of the reprogramming process as any iPSCs produced 
using this system must be screened for any vector-derived integrations (Churko et al., 
2017; Haridhasapavalan et al., 2019). Despite the possibility of isolating transgene 
free iPS cells, the persistence of the plasmid limits which iPS cells can be used 
clinically, since cells with persisting vector and transgene expression or potentially 
containing integrations could have adverse downstream inflammatory/innate immune 
responses and tumorigenic implications (Yoshinda & Dowdy, 2017). 
The EBNA1 protein, as previously mentioned, is critical to the improved functionality 
and applicability of expression plasmids within the realm of reprogramming and 
pluripotency induction within somatic cells. The system is robust and can produce 
iPSCs that meet cGMP requirements (Baghbaderani et al., 2015). Yet, the inclusion 
of the volatile viral protein, EBNA1, within the vector is both a blessing and a curse, 
as expression plasmid retention is dependent on the protein’s functionality, yet it has 
been clearly identified to potentiate a myriad unwanted effects within transfected cells 
(Kennedy et al., 2003; Hong et al., 2006; Gruhne et al., 2009; Valentine et al., 2010; 
Pannone et al., 2014). As such, a fine balance exists with the use of this vector with 
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regards to honing its ability to produce iPSCs whilst also turning a blind eye to its 
unequivocally detrimental side effects.  
Despite this, clinical trials that are currently ongoing and receiving approval using 
iPSCs have almost always been reprogrammed using the oriP-EBNA1 vector. 
Currently, as of mid-2019, there are nine clinical trials utilising iPSC-derived cell 
therapies (Vanneaux, 2019). The first was approved in 2014, using autologous iPSC-
derived retinal pigment epithelium (RPE) cells which were transplanted as a sheet, 
with the aim to reconstitute sight in age-related macular degeneration (AMD) patients 
(Mandai et al., 2017). Since then, trials using iPSC-derived cell therapies for treating 
a number of disorders, from Parkinson’s disease, spinal cord injury and 
thrombocytopenia, as well as producing iPSC-NK cells (FT500) for immunotherapeutic 
purposes, have arisen (Kikuchi et al., 2017; Akabayashi et al., 2018; Crow, 2019; 
Nagoshi et al., 2019). There are however, more than double the amount of trials 
utilising ESCs than iPSCs, which when considering the issues surrounding their 
derivation and increased susceptibility of rejection in comparison to iPSCs, can seem 
surprising. A number of issues have stunted the clinical delivery of iPSC-cell therapies 
such as tumorgenicity in relation to both transgenes and integrations, alongside the 
scalability of clinically relevant iPSCs to meet therapeutic demand (Vanneaux, 2019). 
It is clear that there are still a number of limiting factors with regards to iPSC 
exploitation that can be related to the choice of vector to reprogram and produce iPSC 
lines with.  
Ultimately, it is clear that the choice of vector is critical, not just in determining the 
process and efficiency of iPSC development, but also their quality, which in turn has 
huge implications on the cells prospective use. The oriP-EBNA1 system is a robust, 
efficient and practical system in terms of iPSC development, but is by no means 
perfect. The ideal modality for generating iPSCs would be a robust, efficient method, 
based on a non-viral, non-integrating, transient vector. Such vector would have 
minimal augmenting elements, lack any pro-inflammatory additional sequences and 
non-specific modulatory effects. Indeed, the discussion offered thus far has 
demonstrated why the oriP-EBNA1 system has become the main preference amongst 
a plethora of other reprogramming systems. The vector has helped to progress iPSC-
related therapies and is subsequently providing the foundations for potentially life-
changing treatments. That said, the vector does have its downfalls and so, despite the 
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systems successes, these issues should not be ignored and if possible, be corrected 
for with a vector type that can match the oriP-EBNA1 systems functionality, whilst also 
negating some of the above-mentioned issues. 
Table 2 - Overview of reprogramming methods. 
Vector Advantages of use within stem 
cell research 






o Efficient and 
widespread infection in 
target cells. 
o Stability & longevity in 
expression. 
 
o Genomic integration.  
o insertional mutagenesis.  
o Re-activation of silenced transgenes. 
o  increased propensity tumorigenesis.  
o Viral proteins increase the propensity 
for inflammatory/innate immune 
response. 
o Transduction limited to dividing cells.   
 
(Takahashi 
et al., 2007; 









o Efficient and stable 
transduction.  
o Dividing and non-
dividing cells 
transduced.  
o Potential for integrase 
deficiency 
o  limited genomic 
integration.  
 
o Genomic integration. 
o Insertional mutagenesis.  
o Inflammatory response associated with 
viral transduction. 












o Stable exogenous 
expression within target 
cells.  
o Low-level genomic 
integration.  
 
o Altered reprogramming kinetics.  
o Highly inefficient in relation to other 
viral derived vectors.  
o Development of Tetraploid iPSC lines.  














o Relatively high 
reprogramming 
efficiency.  
o Reliable colony 
production.  
 
o The vector is slow in clearing – high 
passage cells still contain the viral 
vector.  
o Reduced ability to manipulate 









o Non-integrating RNA 
vector. 
o Single transduction 
required. 
o Little workload for iPS 
cell production.  
o Presence of viral proteins undesirable 
for clinical translation.  
o Single clinical vendor thereby 
increasing expense. 








o No genomic integration.  
o Vector transiency 
improves clinical 
applicability.  
o Shorter reprogramming 
duration.  
o Relatively efficient 
within colony 
production.  
o Low donor cell level 
required.  
o Relatively low 
aneuploidy rate.  
 
 
o Increased workload. 
o mRNA extremely transient so multiple 
transfections required (up to 17 
transfections).  
o Difficulties within reprogramming 
primary fibroblasts.  
o Difficulties in the reproducibility and 
implementation within laboratories.  
o No validation or reported iPSC 

















o Transient system  
o Demonstrated to 
reprogram fibroblasts to 
bona-fide iPSCs 
o Can completely replace 
the OSKM system  
 
 
o Transient system which requires 
multiple transfections making the 
protocol laborious.  
o Reprograms with a low efficiency 
(~0.01%) 
o Can function with a higher efficiency 
but requires permeant integration into 













o Extremely safe system 
of iPSC development 
o Transient. 




o Protein expression is transient – often 
being trapped in host cell endosomes 
reducing functionality.  
o Protocol requires multiple transfections 
and is also a long process – laborious 
for lab users.  
 
 
(Zhou et al., 






o Protocol allows 
complete control of 
protein dosage and 
timeframe of dosage. 
o Great variability in success levels 






o Easily excisable system 
despite being 
integrative. 
o Single transfection 
reducing labour of 
protocol.  
o Can transport large 
cargo in excess of 
10kb.   
 
o Risk associated with re-integration of 
the system and subsequent 
downstream insertional mutagenesis-
related issues.  
o Low reprogramming efficiency 
(~0.05%).  
o Time consuming iPSC analysis to 
ensure integrity is imperative.  













o Easy to produce and 
manipulate  
o Easy to store  
 
o Reprograms with an extremely low 
efficiency (~0.0029%).  
o Transient system requiring multiple 
transfections. 
o Pro-inflammatory bacterial sequences 
increase propensity of transgene 
silencing and plasmid removal.  
o DNA-based system carries rare chance 
of integration.  
 
(McLenacha
n et al., 
2007; Si-
Tayeb et al., 
2010; 
Haridhasapa











o Minimal bacterial 
sequences within 
vector limiting 
transgene silencing.  
o Transient by nature 
minimising vector 
persistence. 
o Very low efficiency in adipose stem 
cells (0.005%). 
o Ten times lower efficiency in neonatal 
fibroblasts.  
o Little disparity between Minicircle and 
conventional plasmid efficiencies.  
o No confirmed reprogramming in adult 
hDFs.  
o Minimised efficiency increases need for 
multiple transfections.  
o Vector is bacterially amplified 
increasing propensity for retention of 


















o No genomic integration.  
o Can be transient to 
produce “footprint free” 
iPSCs.  
o Easily produced and 
cheap.  
o Simplistic protocol and 
limited reprogramming 
workload promoting 





o Inefficient (0.01% efficiency in 
fibroblasts).  
o Relatively high rates of aneuploidy 
(~11.5% of iPSCs produced).  
o Slow removal of vector – more than a 
1/3 of iPSCs produced still contain 
reprogramming vector beyond P11.  
o Increased propensity for transgene 
silencing with bacterial sequences 
being present.  
o Persistence of bacterial sequences and 
viral proteins disadvantageous for 
clinical progression.  






Churko et al., 
2017; Mora 
et al., 2017; 
Haridhasapa
valan et al., 
2019) 
 
1.3. Doggybone (dbDNA) clinical grade vector:  
 
Produced by Touchlight Genetics and patented since 2008, Doggybone DNA (dbDNA) 
is a novel vector. The dbDNA system utilises clinical grade DNA, producing a double-
stranded closed linear construct with a flexible transgenic cassette. dbDNA vectors 
are subsequently free from bacterial CpG islands/sequences as well as antibiotic 
resistance genes, thereby minimising any potentially immunostimulatory effects of the 
vector within its host cell. A premise therefore exists to test the dbDNA system within 
reprogramming and iPSC production and to note how it performs in comparison to 
other reprogramming methods to elucidate any benefits and disadvantages this new 
system may have. 
 
1.3.1. Manufacture:  
 
Doggybone DNA vectors are produced enzymatically via rolling circle amplification 
(RCA) (Figure 10) with no need for bacterial augmentation. The core method utilises 
the activity of two main enzymes; a Phi29 DNA polymerase and a protelomerase or 
telomere resolvase. Phi29 DNA polymerase is adopted within this process due to its 
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high fidelity (error rate of 1x106 – 1x107) as well as its high processivity (~70kbp). 
These features pertain to a high-suitability of the polymerase for the large-scale 
production of good manufacturing practise (GMP) DNA. The process of dbDNA 
manufacture, in brief, begins with a circular double-stranded DNA molecule (e.g., a 
plasmid) which is utilised as a starting template. The sequence of interest within the 
DNA template should be flanked by a 56bp palindromic protelomerase recognition 
sequence on either side. Once the starting template is denatured, the addition of the 
Phi29 DNA polymerase will then initiate RCA, resulting in double-stranded 
concatemeric repeats of the original template. A protelomerase/telomere resolvase is 
then added, the enzyme will subsequently bind to its recognition sites which flank the 
templates sequence of interest. The protelomerase after recognising inverted 
palindromic DNA sequences will catalyse strand breakage, strand exchange and 
ultimately DNA ligation. This results in multiple monomeric double-stranded, linear, 
covalently closed DNA constructs. The successful formation of dbDNA closed-ended 
structures makes the vector resistant to exonuclease activity. The DNA outside the 
gene of interest (e.g., the original vector backbone) will likewise be concomitantly 
processed by the protelomerase enzyme. However, these regions are removed by the 
sequential action of restriction enzymes cutting at restriction sites unique to the vector 
backbone before exonuclease digestion of the released fragments, leaving only the 
covalently closed linear DNA containing the target sequence intact. dbDNA is then 
purified from small fragments and reaction components using size separation to leave 
only the dbDNA sequence of interest. The resulting dbDNA™ constructs can be used 
as a starting material for further amplification reactions if required. Ultimately, the final 
dbDNA constructs are minimal, containing only the sequence of interest. They are also 
therefore free from bacterial CpG motifs and the requirement for antibiotic resistance 
genes necessary for bacterial amplification. The dbDNA product will then undergo a 
number of quality control (QC) checks to ensure the purity and quality of the product. 
The vector undergoes Sanger sequencing to ensure sequence homology. The DNA 
quality will be determined from running the vector on an agarose gel ensuring 
uniformity, before a western blot is carried out to check for the removal of any 
processing enzymes. Endotoxin testing is likewise carried out to ensure a negligible 
or null presence. The vector purity is then likewise determined using readings from a 
spectrophotometer. The manufacturing process of dbDNA is rapid, taking only up to 2 
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weeks to produce clinical grade, cGMP compliant DNA that has undergone rigorous 
quality control checks. Production is also easily scaled-up with the possibility of 
producing grams (g) of a final product. Crucially, the process of vector production and 
quality control is cost effective, providing no limitations for its research or clinical use 




1.3.2. dbDNA reprogramming systems: 
 
The dbDNA reprogramming system utilises three separate vector constructs, similar 
in principle to the oriP-EBNA1 system. The oriP-EBNA1 approach permits the 
expression of 6 transgenes across 3 different vectors - hSK (SOX2 & KLF4), hUL (L-
myc & LIN28) and hOCT4-shp53 (OCT4 & Short hairpin for p53). The dbDNA 
constructs utilise the same number of vectors, yet with the expression of only 5 
Figure 10 - dbDNA manufacturing process from amplification and strand displacement to creating 
the closed end double-stranded product (Source: Karbowniczek et al, (2017) online) 
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transgenes, as the shp53 is not present within this system. The Doggybone system, 
alike to the oriP-EBNA1 system utilises three individual vectors (Figure 11) as oppose 
to one large polycistronic construct. (Hornstein et al, 2016). 
 
 
All of this is to say that, the use of dbDNA – insofar as it offers the possibility of a 
clinical grade, non-bacterial vector to deliver and initiate the de-differentiation of 










Figure 11 - dbDNA vector contents for OCT3/4-shp53, hSK & hUL respectively. 
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2.0. Results:  
 
2.1. dbDNA vector functionality, reprogramming potential and transcriptomic 
analysis:  
 
Previous literature provides a key insight into the importance of vector longevity and 
persistence of transgene expression in the process of cellular reprogramming. It is 
apparent that in order to achieve the re-constitution of an undifferentiated phenotype 
from a differentiated cell, that prolonged expression of pluripotency-related genes is 
critical in initiating and maintaining this process. Duly, from this point onward, the cell 
should then endogenously maintain pluripotent gene expression independent of 
transgenic expression. Any shortcomings within this process, in relation to the 
timeframe of transgene expression, will ultimately inhibit the formation of a true 
pluripotent phenotype, most likely resulting in an in-between or partially reprogrammed 
phenotype. As previously mentioned, modifications to standard expression plasmids 
had to be undertaken, adding oriP & EBNA1. This was in order to improve the longevity 
of the plasmid vector within host cells, to persist and express its pluripotency 
transgenes for long-enough periods to induce the reprogramming of differentiated cells 
back to pluripotency. Therefore, it is apparent that the timeframe of transgene 
expression by a vector is critical, not just to its success within the reprogramming 
niche, but to its eventual downstream translation progression likewise. Therefore, the 
analysis of vector kinetics, in relation to transgenic expression intensity and longevity 
can be insightful into vector functionality and its propensity for success within the 
reprogramming process. Moreover, the intensity of transgene expression, being able 
to significantly upregulate pluripotency gene transcription and ultimately protein 
expression, is likewise critical to the over-haul of a somatic cell’s genetic ‘machinery’, 
permitting the onset of pluripotency. It is important that any vector kinetics analysis 
therefore details the longevity of transgene expression, but also the intensity of such 
expression too.  
Yet, the true value of the novel dbDNA system will be when applied to the process of 
reprogramming and incorporated into the publicised McKay lab protocol (Hawkins et 
al., 2016). The efficacy and efficiency of the vector to reprogram and produce iPSCs 
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will be determined within such experiments. Likewise, any cells produced should 
function to perpetually maintain an undifferentiated pluripotent phenotype but, also 
maintain an ability to differentiate into cells of the 3 germ layers following specific cues. 
The functional potential of iPSCs lies largely within the clinic, therefore, being able to 
produce iPSCs from differentiated somatic cells in xenofree conditions is likewise 
pivotal to the translational potential of this novel system too.  
A transcriptomic microarray analysis would provide invaluable insights into global gene 
expression, permitting an understanding of more pronounced transitions, as well as 
more subtle changes to a cell’s transcriptome. Alongside the development of the 
dbDNA vector to produce iPS cells, another core aim of the project was to determine 
any changes that the reprogramming delivery vector may have on its host cells internal 
environment. This was in relation to any benefit being incurred by the cell when 
reprogramming using the bacterial DNA-free clinical grade dbDNA system as opposed 
to the oriP-EBNA1 system which incorporated both bacterial and viral DNA 
sequences. Therefore, an evaluation of this type and scale would provide an extensive 
insight into key differences between these two vector types. Moreover, such analysis 
will help to guide further experiments to provide more substantial and supporting 
evidence for any identifiable changes.  
Aims:  
• Determine the vectors degradation kinetics in relation to transgene expression 
longevity and intensity for both the dbDNA and a plasmid system.  
• Validate dbDNA reprogramming vectors structurally using restriction digests 
and functionally by determining the vectors ability to upregulate pluripotency 
proteins.  
• Successfully carry-out the standard McKay lab reprogramming protocol using 
oriP-EBNA1 system.  
• Carry out concurrent reprogramming experiments using both the dbDNA & oriP-
EBNA1 expression systems on more than 3 different primary human dermal 
fibroblast cultures.  
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• Characterize any iPSCs produced for the expression of key endogenous 
pluripotency marker expression alongside the cells ability to differentiate into 
cells of all 3 germ lineages. 
• Carry out reprogramming using an animal product or Xenofree protocol to 
determine the dbDNA systems robustness in terms of changing the conditions 
of the reprogramming process and denoting how this effects vector functionality 
in relation to iPSC development. 
• Carry out reprogramming using the dbDNA system in a number of different 
somatic cell sources (Peripheral blood, urine-derived cells).  Perform a 
microarray on iPSCs produced using the dbDNA & oriP-EBNA1 systems. 
Moreover, the inclusion of ESCs as a pluripotent gold standard control 
alongside the fibroblasts from which such iPSCs were derived was likewise 
important.   
• Analyse the normalised microarray data to determine any global transcriptomic 
changes between both iPSC-types (dbDNA/oriP-EBNA1). This will help to 
deduce differences within the host cells reception of both reprogramming 
vectors. 
• Begin to substantiate a mechanism behind any changes denoted between 











2.1.1. Comparison of vector degradation kinetics by quantifying transgene 
expression:  
To examine dbDNA transgene expression intensity and the longevity of its expression, 
we aimed to transfect a constitutively active GFP-expressing dbDNA vector into cells 
and quantify its expression level over a time-period. This was initially carried out in a 
Human embryonic kidney cell line, HEK293T, using a polyethylenimine (PEI) 
transfection-based system. In order to maximise the level of successful DNA 
transfection, a titration of different ratios of PEI to DNA (w/w) was undertaken. 1µg of 
DNA was transfected alongside varying ratios of PEI to determine the most optimal 
experimental conditions. GFP quantification was carried out to determine the lowest 
level of PEI accountable for the highest transfection and GFP expression levels, 





Figure 12 - Fluorescent microscopy of GFP expressing cells at different PEI ratios. 
HEK293T cells were transfected with a consistent 1µg of dbDNA vector with different ratios of 
PEI. PEI:DNA ratios graduating from 0.25:1 up to 8:1 were incorporated and analyzed. 
Representative images of each PEI:DNA ratio (w/w) were taken at using a fluorescent microscope 





Figure 12 & Figure 13 demonstrated on a qualitative and quantitative level respectively 
that a ratio of 2:1 (PEI: DNA (w/w)) resulted in the highest level of GFP expression. 
Following this, I then decided to then titrate the concentration (µg) of dbDNA, whilst 
maintaining the PEI ratio at a constant. This was carried out in HEK293T cells with 
care being taken again to isolate a concentration that provided maximal DNA uptake 
and GFP expression whilst again limiting cellular toxicity. The GFP expression within 
each DNA concentration was qualified and quantified in order to determine the most 







Figure 13 – Quantification of positive particles per representative image using ImageJ. 
The representative images from the fluorescent microscope were analyzed using ImageJ to determine the 
number of positive particles (GFP expressing cells) per image. The number of positive particles was 
proportionate to the transfection efficiency. The analysis was carried out for each PEI ratio. The data 








Figure 14 – Fluorescent microscopy imaging of cells transfected with differing dbDNA 
concentrations. 
Concentrations of DNA from 0.3µg to 4µg were transfected into HEK293T cells in a 2:1 PEI to DNA 
ratio (w/w). Images of each DNA concentration were taken using a fluorescent microscope 24 hours 
post-transfection. Scale bar represents 100µm. Images represent a single experiment. 
Figure 15 - Quantification of positive particles per representative image using imageJ. 
The representative images from the fluorescent microscope were analyzed using imageJ to 
determine the number of positive particles (GFP expressing cells) per image. The number of 
positive particles was proportionate to the transfection efficiency. This analysis was carried out 
for each DNA concentration. Graphical representation of a single experiment. 
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Both 1µg and 2µg of DNA resulted in very similar levels of GFP expression within our 
predetermined PEI ratio (Figure 14 & Figure 15). However, 1µg of DNA was preferred, 
as it limited the total concentration of DNA being transfected; as DNA can likewise 
pose a threat of toxicity within host cells too. We clearly evidenced that a 2:1 PEI to 
DNA ratio (w/w) could be applied with 1µg of dbDNA for the most optimal vector 
transfection in HEK293T cells.  
These initial experiments provided foundations which would permit further analysis 
into the vectors changes in longevity within the same cell type over time. An initial 
experiment was carried out incorporating molar eqivalent quantites of both the dbDNA 
and plasmid vector expressing a GFP transgene. The dbDNA system had a 
significantly reduced transfection efficiency in comparison to the plasmid system. 
Subsequently, net weight equivalent quantities were instead transfected, meaning that 
as the dbDNA system was often smaller than most plasmids, that more copies of 
dbDNA were transfected per cell. Only adopting this method were we able to acquire 
similar levels of transfection efficiency to the plasmid vector. It was decided that 
concurrent experiments employing the transfection of 1µg of both an eGFP-dbDNA 
vector and an eGFP-plasmid into HEK293T cells was to be carried out. The dbDNA 
vector being ~2.6kb in size and the plasmid ~4.7kb in size meant that according to 
Avogadro’s number that there would be 1.79 copies of the dbDNA system per 1 
plasmid copy (1.53x1035 total copies of dbDNA per 1µg and 8.5x1034 total copies of 
plasmid per 1µg). Subsequently, the transfected cells were then analysed using flow 
cytometry to quantify the transfection efficiency of both vectors 24 hours post-
transfection (Day 1). The degradation of expression could then be monitored, again, 




The result demonstrated, over the 6-day analysis, that the dbDNA system was able to 
match the transfection efficiency of the plasmid-based system, and that its GFP 
expression declined at a slower rate in comparison to the plasmid vector too (Figure 
16). This was an exciting result which could have profound implications with regards 
to the dbDNA systems downstream functionality within reprogramming and iPSC 
production. 
In order to add more relevance to this first result, the same experimental conditions 
were applied over a longer time-period and to human dermal fibroblasts (hDFs) 
instead of HEK293T cells. Fibroblasts are the cell type most commonly utilised as the 
starting material for iPSC procurement. In order to mimic the reprogramming 
procedure carried out in the McKay lab, a total of 8µg of both eGFP-dbDNA & eGFP-
plasmid was introduced into fibroblasts by Amaxa nucleofection. The fibroblasts were 
then analysed using flow cytometry to determine the transfection efficiency and 
monitor the longevity of GFP expression. As well as this, the intensity of such GFP 
expression was also determined by quantifying the Median Fluorescence Intensity 
Figure 16 -Analysis of GFP-expressing cells using flow cytometry. 
HEK293T cells were transfected with 1µg dbDNA-eGFP and 1µg eGFP expressing plasmid using PEI at 
a PEI:DNA ratio of 2:1. The cells were then analyzed for GFP expression using flow cytometry. This 
provided quantifiable data on the proportion of GFP expressing cells in a population. This was carried 
out 1, 3 and 6 days after the initial transfection. The data represents the transfection of a single well 
with error bars representing the SEM of the technical replicates.  
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(MFI) of each GFP-expressing cell too. The same vectors were utilised as per the prior 
experiment, meaning that again there would be around 1.79 copies of dbDNA per 1 




Figure 17 - Representative images of eGFP-dbDNA transfected hDFs. 
Images represent the nucleofection of 8µg of dbDNA-eGFP into human dermal fibroblast cells. 
The images depict both phase and fluorescence for the dbDNA transfected hDFs from Day 1 to 




Representative images from this experiment provided qualitative evidence 
demonstrating a more persistent GFP expression in dbDNA transfected fibroblasts 
over time (Figure 17 & Figure 18). Such images helped to corroborate further data 
achieved when analysing the same cells, at the same timepoints, using flow cytometry 
to quantify GFP expression and MFI.  
Figure 18 - Representative images of eGFP-plasmid transfected hDFs. 
Images represent the nucleofection of 8µg of plasmid-eGFP into human dermal fibroblast cells. The 
images depict both phase and fluorescence for the plasmid transfected hDFs from Day 1 to Day 21 




On day 1 post-transfection, it was clear that both the dbDNA and plasmid system 
nucleofected with equivalent efficiencies. The subsequent timepoints demonstrated 
that the dbDNA system maintained its GFP expression at a greater rate and for longer 
a period of time. This was most apparent at Day 10 when the dbDNA system had a 3-
fold higher GFP expression in comparison to its plasmid counterpart (Figure 19). This 
dataset substantiated the previously found data in HEK293Ts and corroborated the 
representative images taken prior to flow cytometry analysis. It was clear that the 
dbDNA system can persist and express its transgene for longer time periods in 
comparison to standard plasmid systems. However, the intensity of transgenic 
expression was still to be elucidated between the two vector systems.  
Figure 19 -A flow cytometry analysis of GFP expressing populations following nucleofection with 
either dbDNA-eGFP or Plasmid-eGFP. 
8µg of both dbDNA and plasmid GFP-expressing vectors were nucleofected into human dermal 
fibroblast cells. The cells were taken for analysis over a time-period from 1 day to 21 days following 
initial nucleofection. The cells were analyzed using flow cytometry to quantify the proportion of GFP 
expressing cells within a complete population for each vector type. This population was then 
represented as a % proportion of the entire cell population. The data represents an n=1 with 3 




As with GFP degradation, the MFI expression demonstrated a similar trend, with GFP 
being expressed at a greater intensity and for a longer timeframe in dbDNA transfected 
cells as opposed to the plasmid system (Figure 20). Taken in its entirety, the 
experiment evidenced that the dbDNA system nucleofected with similar efficiencies, 
maintain its transgenic expression for a longer time period and expressed its 
transgene with a greater intensity over a longer timeframe too. Such facets are key to 






Figure 20 - MFI of GFP expression from both dbDNA & plasmid vectors following flow cytometry 
analysis. 
Fibroblasts transfected with 8µg of either dbDNA or plasmid were analyzed using flow cytometry. 
Once the GFP expressing population of cells was determined, the median fluorescence intensity (MFI) 
could then be quantified and was proportionate to the brightness of such GFP expression. The data 
represents an n=1 with 3 technical repeats of the biological replicate. Error bars represent the SEM for 
the technical replicates 
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2.1.2. Functionality and structure of dbDNA reprogramming vectors: 
 
The results pertaining to the degradation kinetics study provided clear experimental 
evidence that the dbDNA system expressed its transgenic cassette with a greater 
longevity in comparison to a traditional plasmid. This was an exciting result which 
demonstrated key aspects of the dbDNA systems functionality which would favourably 
benefit its potential application to the process of reprogramming and iPSC 
development. Subsequently, Touchlight Genetics worked arduously, manipulated their 
methodology of dbDNA production and incorporated key pluripotency transcripts 
necessary for the reprogramming of somatic cells. This resulted in the production of 3 
novel vectors for the purpose of this project (Figure 11). The dbDNA vectors contained 
transgenes for key pluripotency markers: OCT4, SOX2, KLF4, LIN28 & L-MYC. 
Importantly, however, the dbDNA system omitted the inclusion of the shp53 transgene 
that was expressed in the oriP-EBNA1 vector. Moreover, the dbDNA system also 
contained no bacterial DNA backbone which was likewise present in the oriP-EBNA1 
system. This left us with 3 dbDNA vectors, all of which expressed the dbDNA telomeric 
cap sequence (necessary to make the vector a closed system) as well as our 
pluripotency transgene of interest. The stoichiometry of each vector was the same as 
the EBNA1 system; the dbDNA vectors expressed the same pluripotent transgenes 
on each cassette (SOX2 & KLF4 / LIN28 & L-MYC) besides from the OCT4 vector 
which was null of the shp53 sequence. Upon receiving the novel dbDNA 
reprogramming vectors, our initial experiments focused around making sure the 
vectors were structurally sound. A restriction digest was carried out using the ApaI 
enzyme and determined if the number of digests/DNA bands was as expected from 










The digest evidenced that the vectors were structurally as expected and digest 
providing the right number of bands from the sequence of each vector provided by 
Touchlight Genetics (Figure 21). This provided us with confidence that the dbDNA 
vectors we received were structurally intact, however, before incorporating them into 
the reprogramming process it was pivotal that we first tested the vectors functionality. 
Each dbDNA reprogramming vector was transiently transfected into HEK293T cells 
using PEI. The cells were then harvested for protein before a western blot was 
undertaken probing for key pluripotency markers that spanned all 3 vectors: OCT4, 
SOX2 & LIN28. Both SOX2 and LIN28 were chosen over KLF4 and L-MYC 





Figure 21 - Restriction digest of the three reprogramming dbDNA vectors using the ApaI restriction 
enzyme. 
Image depicts an agarose gel following the digestion of dbDNA reprogramming vectors with the ApaI 
restriction enzyme. Lane 1 depicts a DNA ladder, Lane 2 dbDNA-hUL vector, Lane 3 dbDNA-hSK vector 
and Lane 4 dbDNA-OCT3/4. The table in the image demonstrates the number of fragments and their 











The resulting blots demonstrated that the newly-produced dbDNA vectors were 
capable of upregulating the expression of key pluripotency genes to the level of that 
of ESCs; a pluripotent gold standard (Figure 22). This reassured us that the vectors 
we would begin working with were structurally and functionally apt and as such could 
begin to be incorporated into iPSC reprogramming protocols for functional analysis.  
 
2.1.3. Concurrent IPSC reprogramming experiments & vector efficiency:  
 
Having demonstrated that the dbDNA system was ready to be incorporated into the 
McKay Lab protocol for iPSC development, it was important to therefore be proficient 
with this process and protocol. Initial experiments incorporated 8µg total of the oriP-
EBNA1 plasmid system into 4.5x105 primary human fibroblast cells using 
nucleofection.   
Figure 22- Depiction of western blotting results from protein isolated from dbDNA transfected 
HEK293T cells for key pluripotency markers alongside their respective densitometry analysis.  
The result depicts the blot and bands for each cell type (dbDNA, un-transfected HEK293T & ESC) and 
for each pluripotency gene probed (‘A)’) alongside the respective densitometry analysis to quantify 
the level of protein upregulation (‘B)’). From ‘I’ to ‘III’ to right the genes probed include LIN28, SOX2 
and OCT4 all of which are expressed from different vectors and transgene cassettes. Result depicts 







The McKay Lab protocol was reproducibly successful when employing the oriP-
EBNA1 system, resulting in the successful reprogramming of 2 different primary 
fibroblast cultures (Figure 23). Therefore, having successfully carried out the iPSC 
reprogramming process using the ‘gold standard’ oriP-EBNA1 plasmid system and 
become accustomed with the protocol alongside the cellular changes associated with 
the process, I then wanted to apply the dbDNA reprogramming vectors to the same 
reprogramming protocol and conditions. The oriP-EBNA1 system incorporated the use 
of 4 different vectors which were 10,180bp (hSK/hUL/hOCT-shp53) and 5078bp 
(EBNA1) in size. A total of 2µg of each reprogramming vector was used in each 
reprogramming experiment (8µg sum total). Therefore, a  total of ~3.91x1035 copies of 
the oriP-EBNA1 plasmid was used in each reprogramming experiment.  The dbDNA 
Figure 23 - Successful preliminary reprogramming experiments carried out using the oriP-EBNA1 
system. 
Images depict 2 different reprogramming experiments of 2 different primary fibroblast cultures using the 
oriP-EBNA1 system. The images detail the cells and their respective survival Day 1 post Amaxa 




system incorporated the use of 3 different vectors: dbDNA-hSK (5515bp), dbDNA-hUL 
(4873bp), dbDNA-OCT4 (4110bp). A total of 2333ng of each vector was applied to a 
reprogramming experiment (8µg sum total) meaning a total of ~5.84x1035 copies of 
dbDNA reprogramming vectors were used in the same protocol. Therefore, there were 
1.49 copies of the dbDNA system per 1 copy of the oriP-EBNA1 plasmid when carrying 
out their respective experiments.  
 
The first reprogramming experiment yielded what phenotypically resembled primary 
iPSC colonies in both the oriP-EBNA1 and dbDNA nucleofected fibroblasts (Figure 
24). Primary iPSC colonies differ phenotypically from the surrounding fibroblasts, often 
growing in a compact circular organization with the cells looking much smaller with a 
scant cytoplasm and large nucleolus. However, even within this there was great levels 
of variation, often because of the rapid cell growth and division associated with this 
pluripotent cell type it may be hard to exactly distinguish a primary colony with 
complete accuracy. Therefore, what resembled primary iPSC colonies were excised 
and re-plated onto a fresh iMEF feeder layer for continued outgrowth and analysis.  
Figure 24 - Reprogramming timeline of CLN3-hDFs using both dbDNA and oriP-EBNA1 vector systems 
until primary iPSC colony formation. 
Concurrent reprogramming of the same CLN3 mutated primary fibroblasts using both the dbDNA and 
oriP-EBNA1 reprogramming vectors. Images depict a single experiment across several timepoints; from 




The re-plated primary colonies for both vector types continued to grow on fresh iMEF 
feeder layers and demonstrated a more typical iPSC phenotype as previously 
described (Figure 25). The iPSCs produced by the dbDNA system were routinely 
passaged, displaying a stable phenotype persisting above and beyond p10. The 
iPSCs produced by the oriP-EBNA1 system were likewise concurrently passaged and 
maintained but however, did not stabilise and had undergone unwanted spontaneous 
differentiation and loss of pluripotency by passage 5. This was a surprising result, it 
was established by other lab members that these fibroblasts were able to be 
reprogrammed by the oriP-EBNA1 system but that the iPSCs produced were likewise 
never stable. For the dbDNA vector to not only successfully produce iPSCs, but to 
produce more stable iPSCs this was a remarkable result. Duly, we aimed to then 
reprogram and produce iPSC lines from as many different fibroblast samples as 
possible, with the intention of gaining a greater insight into the true functionality and 
reproducibility of the dbDNA system in the context of iPSC development.  
Figure 25 – iPSCs developed from primary colonies which were isolated from reprogramming 
experiments incorporating both dbDNA and oriP-EBNA1 vectors in CLN3 mutated fibroblasts.  
Images depict subsequent iPSC colony growth following the isolation of primary colonies. The iPSCs for 
both vector types display a more typical iPSC phenotype and are shown up to passage 3.  
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Table 3 - Table depicting fibroblasts lines reprogrammed using the dbDNA system. 
 
The dbDNA system successfully reprogrammed and produced iPSC lines from a total 
of 11 different fibroblast samples from both control and Batten disease origin (Table 
3). The dbDNA system displayed a clear robustness within its functionality in respect 
to its ability to reliably reprogram and produce iPSCs from fibroblasts isolated from 
individuals of different ages and expressing different genetic mutations. Such iPSCs 
were moreover able to persist and maintain their stability with stocks being 
cryopreserved. Additionally, the dbDNA system also successfully produced iPSCs 
from fibroblasts that were previously refractory to reprogramming with the oriP-EBNA1 
system. The oriP-EBNA1 system could produce primary/early passage colonies, 
however, the cells would spontaneously differentiate leaving nothing of a pluripotent 
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phenotype behind. While the dbDNA system was able to reliably produce much later 
passage iPSCs from the same fibroblast samples.  
 
In its entirety, the dbDNA system displayed a great success in terms of its functionality 
in relation to the production of iPSCs and a robustness in terms of the fibroblasts it 
has successfully produced stabilised iPSC lines from (Figure 26). This was an 
interesting and successful result in terms of the dbDNA systems reliability and success 
where the oriP-EBNA1 vector had clearly fallen short. Such reproducible success led 
us to begin experiments with the aim of quantifying the dbDNA systems functional 
capacity in relation to the oriP-EBNA1 system in terms of its efficiency of iPSC colony 
production. An alkaline phosphatase stain (AP stain) was commonly utilised and 
critical to the quantification of the systems relative functionality. An AP stain can be 
used to determine the presence of bona-fide primary iPSC colonies, this number can 
then be calculated in proportion to the number of fibroblasts initially seeded onto the 
iMEF feeder layer to provide a percentage reprogramming efficiency. 





The dbDNA reprogramming system was demonstrated to function with a 
reprogramming efficiency that was not significantly different to that of the oriP-EBNA1 
system (Figure 27). This was an interesting insight for two distinct reasons. Firstly, the 
Figure 27 - Alkaline Phosphatase (AP) stain for reprogramming experiments carried out using 
the dbDNA and oriP-EBNA1 systems.  
Image depicts typical result following an AP stain which specifically interacts with pluripotent 
colonies. The efficiency was calculated as the number of colonies formed per the total number of 
fibroblasts seeded. The bar chart represents the reprogramming efficiency as a percentage of 
colonies formed per fibroblasts seeded. The efficiency was derived from n=4 experiments. Error 
bars represent SEM of each vectors biological replicate. The data was subjected to a Kolmogorov-
Smirnov test for normality with the p-value being >0.05 suggesting non-normal distribution. As 
such, a Mann-Whitney U-test was carried out per timepoint. A p-value of 0.78 was determined. 
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dbDNA system was a transient system with no scaffolding functionality as the oriP-
EBNA1 system does. This, in theory, provides the dbDNA system with a much greater 
transiency in terms of its expression longevity than the oriP-EBNA1 system. In theory, 
this should result in the far reduced functionality of the dbDNA system in terms of iPSC 
development in relation to its scaffolding counterpart, but it doesn’t. Secondly, the 
shp53 transgene was incorporated within the oriP-EBNA1 system with the aim to 
improve the functional efficiency of the reprogramming process using the vector. This 
was in relation to p53 and its function in the maintenance of cell cycle integrity. Cells 
exhibiting DNA damage would hit cell cycle checkpoints where p53, in synergy with 
other factors, could initiate apoptosis within cells that are too unstable to progress 
through such checkpoints. This means that potential cells that would have been 
reprogrammed instead, potentially, are not. Therefore, the short-hairpin RNA (shRNA) 
for the guardian of the genome was incorporated to improve the reprogramming 
efficiency. The dbDNA system as previously mentioned, does not incorporate this p53 
shRNA. Yet, clearly, the system still not only has a very similar functional capacity to 
that of the oriP-EBNA1 system in terms or reprogramming but, can also reprogram 
iPSCs with a greater level of success than its counterpart too (Figure 28).  
 
This greater level of success in reprogramming was due to the ability of the dbDNA 
system to reprogram and produce stabilised iPSC lines from fibroblasts that the oriP-
Figure 28 – Success rate of reprogramming for both oriP-EBNA1 and dbDNA vectors in 
fibroblasts. 
The graph depicts the successful rate of reprogramming experiments carried out using both 
vector types. Successful primary colony production persisting beyond p5 was deemed 
successful. Bar chart representative of n=12 experiments. Error bars representative of SEM of 
reprogramming experiments for both vector types. 
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EBNA1 system did not have the same level of success with (Figure 29). The results 
evidenced that the dbDNA system, despite its transient design, had a functional 
equivalence as well as a robustness which surpassed that of the oriP-EBNA1 system.  
 
In so far, the data has evidenced that the dbDNA vector  has produced stable iPSC 
lines from a number of fibroblast sources. This was unique in the sense that the dbDNA 
system was designed as a transient system. Transient systems, such as plasmid, have 
previously displayed minimal functional success in terms of reprogramming and iPSC 
development. In turn, they have had to be modified to contain the oriP-EBNA1 
sequence to improve the vectors longevity and ultimately its functionality within this 
process. It is, therefore, within reason to consider the results obtained using the 
dbDNA system as being extraordinary. In order to demonstrate the unique nature of 
the ability of the dbDNA system to produce iPSCs from fibroblasts, a large-scale 
reprogramming experiment was carried out. This employed the oriP-EBNA1 plasmid, 
the dbDNA system and a plasmid devoid of the oriP-EBNA1 system. The aim would 
be to demonstrate that the oriP-EBNA1 system was a necessary requirement to 
produce iPSCs when using plasmid. But, that the dbDNA system can be demonstrated 
to function independent of any scaffolding or tethering capacity.  
Figure 29 - Representative images of the successful reprogramming of CLN3 (417PA) using the 
dbDNA system.  
Images depicting the stabilized iPSC line produced from the reprogramming of previously 




As Figure 30 demonstrated, plasmid alone, that is without the oriP-EBNA1 system, 
was incapable of inducing a pluripotent phenotype within fibroblasts resulting in no 
positive alkaline phosphatase staining. This highlights even within our own 
reprogramming protocol, owing to a single transfection, that plasmid devoid of the oriP-
EBNA1 system was incompatible with the reprogramming process and for plasmid to 
achieve any success in the induction of pluripotency in somatic cells that the accessory 
Figure 30 – A reprogramming experiment to determine the novely of oriP-EBNA1-free iPSC 
production using the dbDNA system. 
A reprogramming experiment including a negative control (fibroblasts nucleofected with a GFP 
expressing plasmid), reprogramming plasmid (without oriP-EBNA1), oriP-EBNA1 reprogramming 
plasmid and dbDNA reprogramming vectors. All reprogramming experiments were carried out 
concurrently until on Day 28, the cells underwent AP staining to demonstrate the presence of any 
primary iPSC colonies. The negative control and the plasmid displayed no AP positive colonies. While 
the oriP-EBNA1 and dbDNA reprogrammed cells did display AP positive colonies. Images depict an 
n=1 for the experiment. 
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EBNA1 system has to be included. This helped to substantiate the novel nature of the 
efficient and reproducible functionality of the dbDNA system within this same process.  
 
2.1.4. Pluripotency characterization of dbDNA/oriP-EBNA1 produced iPSCs: 
 
The dbDNA system has been able to produce what phenotypically resemble primary 
iPSC colonies, which when isolated and continually cultured resembled the iPSCs 
produced using the oriP-EBNA1 system. Having been able to produce such cells using 
the dbDNA system, we felt it important to ensure they had fully developed pluripotent 
properties. This means that the cells are expressing genes which are critical to the 
maintenance of the cells perpetual self-renewing phenotype, and that the cells can 
also differentiate to form phenotypes of all three germ lineages. The first experiment 
we aimed to carry out was to probe the cells for pluripotent markers using 
immunocytochemistry (ICC). Both transgene-specific (OCT4/SOX2) and endogenous 
(NANOG, TRA-1-60, TRA-1-81) protein markers were analysed. This was to ensure 
that not just pluripotent proteins which were present on the vector transgene were 
being upregulated, but that the cells have undergone complete reprogramming and 
were also constitutively expressing key pluripotent markers in an endogenous fashion. 
The ICC staining was also carried out using ESCs, a pluripotent gold standard, as a 




The ICC provided clear positive staining for key transgene-specific and endogenous 
pluripotency markers in both oriP-EBNA1 and ES cells alike (Figure 31). The cells 
produced by the dbDNA system also provided clear positive staining for all 
pluripotency markers. This clearly evidenced that the cells produced by the dbDNA 
system have developed a capacity to endogenously translate pluripotent mRNA into 
protein and were therefore pluripotent by nature. This was a great result and the first 
step to demonstrating that the cells produced by the dbDNA system were in fact bona-
fide iPSCs. To further consolidate the results of the ICC, we wanted to carry out a 
Reverse Transcriptase-PCR (RT-PCR). The aim of this would be to demonstrate that 
the cells were actively transcribing pluripotent genes, thereby in combination with the 
ICC, the dataset would track such pluripotent genes through the central dogma (DNA 
Figure 31 - Immunocytochemical staining for key pluripotency markers in dbDNA-iPSCs and ESCs. 
Markers that are transgene specific (OCT4/SOX2) were probed alongside non-transgenic pluripotency 
factors (NANOG, TRA-1-81, TRA-1-60). The first row depicts dbDNA-iPSCs and the second oriP-EBNA1 
iPSCs. Embryonic stem cells were stained as a positive control. Non-specific same species negative 
control igG antibodies were also employed. Images depict iPSCs produced all from the same fibroblast 
source in concurrent experiments between the two vectors. Scale bar represents 100um. 
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– RNA – Protein) of protein/gene expression. Moreover, the primers utilised within the 
experiments were designed only to amplify endogenously expressed genes by 
including part of the 3’UTR within the amplicon. This meant that we could now 
determine if the cells being analysed were endogenously transcribing pluripotent 
genes or if they were reliant on the expression of the transgene to maintain their 
pluripotent nature. 
 
The RT-PCR consolidated the previous ICC data, demonstrating clear positive results 
for all probed endogenous pluripotency transcripts for both the dbDNA and the oriP-
EBNA1 system alike (Figure 32). This evidenced that the cells produced using the 
dbDNA system resemble a pluripotent cell type both phenotypically and genotypically. 
The cells were actively transcribing key pluripotent markers endogenously and were 
also expressing pluripotent proteins. However, another key facet of iPSCs was that 
despite being able to maintain a pluripotent phenotype, the cells can also, following 
Figure 32 - Reverse-transcription-PCR analyzing the transcription levels of key endogenous 
pluripotency markers. 
dbDNA and oriP-EBNA1-derived iPSCs alongside a positive control of ESCs were analyzed for 
pluripotent gene transcription. A housekeeper gene of RN18S1 was also employed for all 3 cell 
types too. The experiment represents a single iPSC line from the same fibroblast source for 
both dbDNA and oriP-EBNA1. 
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external cues, differentiate to form cells of all 3 germ lineages (Mesoderm, Endoderm 
and Ectoderm). Thus far, we have been able to evidence that the cells produced by 
the dbDNA system demonstrated a perpetual pluripotent capacity. However, the next 
steps to confirming that the cells were truly iPSCs was to demonstrate that they can 
also form cells of the 3 germ lineages. 
 
The dbDNA system was able to generate embryoid bodies (EBs). EBs are a three-
dimensional aggregation of pluripotent stem cells. Their formation is dependent upon 
homophilic binding between the cells mediated by E-Cadherin. The EBs were then re-
plated and the outgrowth stained positively for markers of all 3 germ lineages using 
ICC (Figure 33). 
Figure 33 – Embryoid body (EB) formation and subsequent ICC staining of the outgrowth for 
markers of all 3 germ lineages. 
iPSCs produced by the dbDNA system alongside the pluripotent gold standard ESC were analysed for 
their trilineage differentiation capacity. A) represents the phase contrast images depict different 
time-points from the experiment using dbDNA iPSCs. The first image, day 1, depicts EB formation 
using dbDNA iPSCs. While day 16 demonstrates the subsequent outgrowth from the same EBs 
which would ultimately undergo ICC analysis. The ICC stain depicted by B) demonstrates two rows 
of staining, ESC on the top row and dbDNA-iPSC on the bottom row. Then from left to right an 
ectodermal marker (B-III-tubulin), an endodermal marker (SOX17) and a mesodermal marker (alpha-
smooth muscle actin).  
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The pluripotency ICC and RT-PCR experiments alongside the EB outgrowth and 3 
germ layer staining demonstrated that the cells produced by the dbDNA system were 
bona-fide iPSCs. This was because they had been evidenced to exhibit the two most 
important features of iPSCs:  
1. To perpetually self-renew and maintain an undifferentiated or pluripotent state.  
2. To, on cue, differentiate to form cells of all 3 germ lineages.  
Having clearly evidenced that our cells met such criteria, it was clear that the dbDNA 
system could generate iPSCs.  
 
2.1.5. Reprogramming experiment using Xenofree, cGMP compliant protocol:  
 
The results described so far provided proof-of-principle that dbDNA vectors can 
successfully be employed in iPSC production. The methodology employed so far 
however, utilised experimental constituents of animal origin. This can result in 
complications and inhibit the iPSCs potential downstream clinical use due to the 
possibility for the transmission of zoonotic disease to the cells. To reduce the likelihood 
of this and to aid the progression of this cellular technology into the clinic, xenofree 
methods of reprogramming have since been developed. These protocols employed 
experimental constituents which were completely animal free, thereby negating the 
use of specific medium constituents like Foetal bovine serum (FBS) and the iMEF 
feeder layer which was derived from mouse embryo. The rationale of the whole project 
was to incorporate the use of the novel dbDNA system in order to improve the 
translational potential of iPSCs for a therapeutic benefit. It was therefore critical to 
determine the vectors functional capacity within such clinically transferrable protocols. 
We therefore adopted a xenofree reprogramming method and employed both the 




The dbDNA system was able to produce primary iPSC colonies when incorporated 
into the xenofree reprogramming protocol, as did the oriP-EBNA1 system (Figure 34). 
As mentioned, the system incorporated animal-free products with fibroblasts being 
cultured in Essential 6, before being moved onto the pluripotent Essential 8 medium 
with vitronectin replacing the iMEF feeder layer. The xenofree method of 
reprogramming often results in a reduced reprogramming efficiency. Despite this, the 
dbDNA system (without additional transgenes such as the shp53 sequence) was still 
able to function and produce iPSCs. This was an incredible result, incorporating such 
cells into a xenofree protocol provides proof-of-principle that a big hurdle, which many 
vectors fail to surpass without long-term efforts, can be overcome by the dbDNA 
system. From this, we decided to continue to culture the cells and carry out ICC 
staining for a key pluripotent marker, SOX2.  
Figure 34 - Reprogramming of hDFs using a xeno-free protocol employing both the dbDNA and 
oriP-EBNA1 vectors. 
Images depict primary colonies produced by both dbDNA (top row) and oriP-EBNA1 vectors when 
being incorporated into a xenofree protocol. The images depict a single experiment yielding multiple 
colonies for both vectors. The experiment was carried out concomitantly for both vectors and 




The ICC provided positive staining of cells produced using both the dbDNA and oriP-
EBNA1 system (Figure 35). This suggested that primary colonies produced by both 
vector types were pluripotent by nature. This was an incredibly exciting result and 
demonstrated that the dbDNA system was quite robust in terms of its reprogramming 
potential. This result then drove us to begin to question what other cell types can 
potentially be reprogrammed using this system outside of fibroblast biopsies.  
 
2.1.6. Reprogramming blood and urine-derived cells:  
 
Having demonstrated that the dbDNA system can reprogram dermal fibroblasts using 
both proof-of-principle and xenofree protocols, we wanted to next determine the novel 
vectors ability to reprogram different primary cell types. We applied the dbDNA system 
to attempt to re-constitute pluripotency in both urine-derived and peripheral blood. 
Firstly, urine samples were taken and the process of cellular isolation, outgrowth and 
maintenance was undertaken. 
Figure 35 - ICC staining of key pluripotency marker SOX2 on feeder free dbDNA/oriP-EBNA1 iPSCs 
produced using a xenofree compliant protocol/constituents. 
ICC staining for key pluripotent marker SOX2 on iPSCs produced using a xenofree protocol 






The process of cellular isolation and expansion was fairly time consuming and 
laborious. The initial isolation protocol was lengthy with additional care being taken 
which minimised the increased risk of cellular infection. Once plated into medium, the 
cells required daily feeding, with populations beginning to appear around day 6 before 
becoming confluent 10 days post initial isolation and plating (Figure 36). Once 
confluent, stocks were developed and the remaining cells were incorporated into a 
reprogramming protocol utilising both the dbDNA and oriP-EBNA1 vectors.  
Figure 36 - The isolation and amplification of urine-derived cells from two different donors. 
The phase images represent the process of isolating and culturing cells isolate from urine samples. The 
cells are isolated via centrifugation and continually cultured with daily medium changes before the cells 
begin to develop and grow out. By day 10 the cells should be confluent and ready to passage or 




The reprogramming of urine-derived cells yielded pluripotent colonies for the oriP-
EBNA1 vector and not the dbDNA system (Figure 37). Having attempted the protocol 
several times, it was only successful on a single occasion. This was interesting and 
suggested maybe a technical issue rather than a potential mechanistic failure, 
however, more work is required to elucidate this. Subsequently, both vector types were 
also applied to the reprogramming of adherent peripheral blood mononuclear cells 
(PBMCs). This was a more invasive method of cellular isolation than isolating urine-
derived cells but was considerably less invasive than a biopsy to isolate fibroblasts. 
The PBMCs were isolated from the buffy coat of a fractionated peripheral blood 
sample. The initial isolation of the cells and their subsequent nucleofection were all to 
be carried out immediately following the blood sample being taken. The first phase 
was therefore again incredibly time consuming and labour intensive.  
Figure 37 - AP stain of primary iPSC colonies produced using both the oriP-EBNA1 and dbDNA 
reprogramming vectors in urine-derived cell types. 
Urine-derived cells were subjected to reprogramming using the oriP-EBNA1 and dbDNA systems. The 
images depict the cells 21 days post nucleofection having undergone an AP stain to determine the 




The reprogramming of PBMCs was only successful using the oriP-EBNA1 vector, with 
the dbDNA system producing nothing of a primary colony phenotype (Figure 38). The 
dbDNA system resulted in the formation of an ‘in-between’ phenotype not being a fully-
fledged primary colony but different in phenotype to adherent PBMCs. Several 
titrations were then undertaken, different PBMC cell numbers were applied to the 
protocol alongside different concentrations of the dbDNA vector but with neither 
demonstrating any success. The primary colonies produced using the oriP-EBNA1 
system were taken for pluripotency staining using ICC to determine the presence of 
key pluripotency proteins. 
 
Figure 38 - Reprogramming of PBMCs isolated from peripheral blood using both the dbDNA and oriP-
EBNA1 system. 
Images depict the buffy coat from which the PBMCs are isolated prior to nucleofection and 
reprogramming. The phase images demonstrate the successful primary colony production using the 
oriP-EBNA1 system. The dbDNA system was unsuccessful in primary colony formation, however the 




The oriP-EBNA1 produced iPSCs were clearly pluripotent by nature, demonstrating 
positive ICC staining of key endogenous and transgene specific pluripotency markers 
(Figure 39). Titrations incorporating the dbDNA system within the PBMC 
reprogramming protocol were again undertaken, still with no further success. That 
said, the development of the in-between phenotype by the dbDNA system does 
suggest however that the reprogramming of this cell type isn’t infeasible with this 












Figure 39 - ICC staining for key pluripotency markers on iPSCs produced from reprogramming 
PBMCs using the oriP-EBNA1 vector system. 
Images depict the staining of iPSC colonies produced by the oriP-EBNA1 vector from adherent 
PBMCs. The cells were stained for key endogenous and transgene-present pluripotent markers. Scale 
bar represents 100µm.  
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2.1.7. Microarray analysis of dbDNA/oriP-EBNA1 produced iPSCs.  
 
Following the production of the novel dbDNA iPSCs and the exceptional 
circumstances in which the vector had been able to function, led us to want to begin 
to investigate how the vector of choice was received by each respective host cell. The 
dbDNA system, as previously mentioned, was a clinical grade vector which omits the 
inclusion of any bacterial DNA, the EBNA1 sequence/protein and the shp53 
transgene. I subsequently wanted to investigate did an exclusion of such sequences 
from the dbDNA vector confer any benefit to the transfected host cell? A microarray 
analysis was determined to be suitable for the determination of such differences 
between both cell types on a global scale. An experiment was therefore designed 
which would incorporate iPSCs produced by both the dbDNA and oriP-EBNA1 
systems. The iPSCs were produced concurrently, were at identical passages and 
produced from the same primary fibroblast cultures. Moreover, the primary fibroblasts 
were also included within the experimental design alongside the pluripotent ‘gold 
standard’ ES cells. The experimental design helped us to substantiate the degree by 
which each iPS cell type had progressed away from its parental fibroblast and 
subsequently how closely it then aligned with the pluripotent ES cell type. Moreover, 
it allowed a direct analysis and comparison of the two iPSC lines, elucidating any 
systemic vector-mediated effects. Microarray analysis was carried kindly carried out 
at DKFZ German Cancer research Centre, Heidelberg, Germany. The Illumina HT12 
beadchip system was used to analyse global gene expression in my samples. RNA 
was isolated from each of the biological triplicates used in the experiment before being 
DNase treated. This was a direct hybridization microarray, whereby 750ng of 
biotinylated cRNA isolated from the different experimental conditions was applied to 
the chip and hybridized for 17 hours. The HT12 system was able to determine the 
expression of over 47,000 different probes spanning the whole genome. Once 
completed, the data was processed and normalised by quantile normalisation using R 
studio. Subsequently, all probes and their expression values for each cell type was 
then provided to me.  




R-Studio was initially used to produce a correlogram. A correlogram was a figure that 
would provide the correlation coefficient for each analysed cell type for designated 
probe expression values. Two identical cell types will have a correlation coefficient of 
‘1’ with divergences in probe expression between two cell types promoting a decline 
in this number, with two datasets of complete opposite probe expression profiles 
having a correlation coefficient of ‘-1’. I decided to produce a correlogram between all 
cell types analysed in the microarray across the entire probed transcriptome for each 
cell type.  
 
The analysis suggested a high degree of similarity in the expression profiles of all the 
pluripotent cell types incorporated in the experiment. The highest degree of similarity 
shared between 2 different cell types was between dbDNA iPSCs and ESCs. This was 
closely followed by EBNA iPSCs-ESCs and EBNA iPSCs-dbDNA iPSCs both of which 
demonstrated a coefficient value 0.01 lower than that in relation to that of Doggybone 
and ESCs (Figure 40). That said, the pluripotent cell types all share great similarity in 
Figure 40 - Correlogram depicting the correlation coefficient for each cell type across all gene 
probes included within the microarray analysis. 
A correlogram produced using R-Studio which provides the correlation coefficient of two analyzed 
cell types to determine similarities within their expression profiles. Two identical cell types with have 
a correlation coefficient of ‘1’ with divergence between the expression profiles of two cell types 
driving this numerical value down. The correlogram details the coefficient values for each cell type 




their coefficient values between one and other and were all most significantly divergent 
from that of the parental fibroblasts. ESCs had the most reduced coefficient value in 
comparison to the parental fibroblasts at ‘0.83’ suggesting key differences within 
probed gene expression between these two cell types. dbDNA produced iPSCs had 
the second lowest coefficient value in respect to HDFs at ‘0.86’, yet oriP-EBNA1-
produced iPSCs had a coefficient value of ‘0.90’ in comparison to its parental 
fibroblasts; the highest of all the pluripotent cell types. This suggested a closer 
homology/reduced divergence between these two cell types in comparison to both 
dbDNA iPSCs and ESCs.  
In order to attempt to elucidate the similarity of probed gene expression further, a 
principle component analysis (PCA) was undertaken. The aim of this analysis would 
be to take our complex gene expression dataset and represent it on a 2D graph with 
each cell type being plotted based on its relative variance to each other cell type. 
Therefore, two cell types with very distinct, differential probed gene expression within 
a principle component will be spaced further apart than two cell types that displayed a 
reduced level of variation within the same principle component. A precursor to a PCA 
was the production of a scree plot. A scree plot determined the percentage of complete 
variation captured within each principle component. For our experiment, we wanted to 
capture as close to 100% of the variation as possible to accurately represent the 
differences between each cell type in terms of their probed gene expression. 
Therefore, a scree plot determined the number of principle components that were 
required to be analysed within a PCA to capture and display the highest proportion of 




The scree plot demonstrated that in order to account for all the variation between each 
cell type in the microarray that 3 principle components must be analysed (Figure 41). 
As such, a PCA was carried out across PC1, PC2 & PC3. 
Figure 41 - Scree plot identifying the level of variation captured within each principle component 
for the microarray dataset. 
A scree plot analysis was carried out to determine the level of variation captured within each 
principle component thereby dictating the number of components to analyze. The X-axis displays 
each principle component. The Y-axis, the percentage of variation captured within each principle 




The PCA dataset, representing PCA 1 and PCA 2 encapsulated the majority of 
variation within the microarray. This analysis presented that both dbDNA iPSCs and 
EBNA1 iPSCs were much more divergent in terms of their probe expression than the 
fibroblast dataset, with both being more similar and therefore plotted more closely to 
ESCs (Figure 42). The analysis also indicated that key probe expression differences 
existed between dbDNA and oriP-EBNA1 produced iPSCs; particularly in PC2. A 
second PCA was undertaken between PC1 & PC3 to account for the remaining 
variation.  
Figure 42 - PCA plotting variation captured between PCA1 and PCA2 across the entire microarray 
dataset. 
The PCA will present all the variation between the datasets captured in PC1 and PC2 and present 
them on a 2D graph. The label of each cell type represents the averaged position for that cell type 
based on variation within its own probed gene expression in comparison to the expression values of 
each of the other analyzed cell types too. Therefore, the distance between 2 plots on a single axis 
was proportionate to the variability between the expression profiles of those plots. The further 
apart the plots are, the greater the divergence of probe expression. X-axis represents PC1 and Y-axis 




The variation captured within PC3 conveyed a similar result to that of PC1 and PC2; 
that the probed gene expression in pluripotent cell types was more similar to one-and-
other than that of the fibroblast samples (Figure 43). This was true for the two iPS cell 
types, yet PC3 did seemingly suggest a greater level of variation between the iPSC 
cell types and ESCs than previously captured in the two prior PCs. PC3 seemingly 
details a close similarity between oriP-EBNA1 and dbDNA produced iPSCs in terms 
of probe expression.  
Yet, taken in its entirety the PCA demonstrated that differences exist in the expression 
profiles between all cell types analysed in the microarray. A key interest we wanted to 
explore was differences in probed gene expression specifically between dbDNA and 
oriP-EBNA1 produced iPSCs and what, if any, influence the vector used to produce 
such iPSCs was having in terms of manipulating differential probe expression.  
Figure 43 - PCA plotting variation captured between PCA1 and PCA3 across the entire microarray 
dataset.  
The PCA will present all the variation between the datasets captured in PC1 and PC3 and present them 
on a 2D graph. The label of each cell type represents the averaged position for that cell type based on 
variation within its own probed gene expression in comparison to the expression values of each of the 
other analyzed cell types too. Therefore, the distance between 2 plots on a single axis was 
proportionate to the variability between the expression profiles of those plots. The further apart the 





From here, all the biological repeats from the microarray were averaged for each cell 
type to provide an average probe expression values for each cell type and probe. The 
dbDNA and oriP-EBNA1 probe expression values were then subjected to a student t-
test analysis with a cut off p-value of ≤0.05 to indicate significantly expressed genes 
between the two cell types. This limits the possibility of spurious results to 5%. 
However, all probes with a significant p-value and they’re relative expression values 
were taken forward and subjected to a Benjamini-Hochberg analysis to determine the 
false discovery rate (FDR). The FDR was presented as a q-value. This was an 
analogue of a p-value which had been subjected to multiple hypothesis testing. The 
inclusion of the FDR analysis reduced the possibility of a type 1 error (whereby there 
was an accidental rejection of a true null hypothesis for particular probes) and 
therefore limited the inclusion of false positive results within the dataset. Again, an 
FDR cut off q-value of ≤0.05 was utilised. All probes with a significant q-value (≤0.05) 
were taken forward. A fold change expression was calculated between the dbDNA 
and oriP-EBNA1 differentially expressed probes. Within many analyses, probe values 
with a fold change of ≥1.2 were deemed to be differentially expressed. However, to 
improve the stringency and possibility of detecting real change between the two cell 
types, only probes with a fold change ≥1.5 between dbDNA and oriP-EBNA1 iPSCs 




The analysis detailed that following the multiple hypothesis testing that 8443 probes 
were differentially expressed between oriP-EBNA1 iPSCs and dbDNA iPSCs to a 
significant degree. Following fold change calculations, of those 8443 probes, 1409 
were over-represented in dbDNA produced iPSCs in comparison to oriP-EBNA1 
iPSCs and 1449 were over-represented in oriP-EBNA1 in comparison to the dbDNA 
system (Figure 44). This may seem like a large proportion of probes for each vector. 
However, when considering the margin for variability within the reprogramming 
process, for example, in the ability of each vector to properly induce pluripotency within 
fibroblasts to the same degree alongside the effects any residual vector may be 
potentiating within the same cells, it was clear to see why such variation existed. To 
validate this finding further, a volcano plot was generated using R-studio. A volcano 
plot was a type of scatter plot which could quickly identify changes in large datasets. 
The volcano plot will combine a statistical significance with a magnitude of change. 
Therefore, incorporating our previous statistical principles, script was developed to 
produce a volcano plot.  
Figure 44 - Venn diagram depicting the number of differentially expressed probes between 
dbDNA and oriP-EBNA1 datasets. 
The venn diagram depicts the number of differentially expressed probes between both dbDNA 
and oriP-EBNA1 produced iPSCs. The probe expression values for both cell types were 
subjected to multiple hypothesis testing prior to the fold change analysis – whereby only cells 




The volcano plot result inferred that there was a number of significantly over-
represented probes that were unique to both oriP-EBNA1 and dbDNA iPSCs in 
comparison to one-and-other (Figure 45). The oriP-EBNA1 iPSCs seemingly display 
a greater number of over-represented probes, helping to consolidate the previous 
numbers. The data thus far has clearly evidenced that there was key differences within 
the probed transcriptomics of iPSCs produced using the two different vector types. 
However, what biological processes the differentially expressed probes interact within 
was still unknown.  
The first analysis that we wanted to undertake was to identify and analyse key 
pluripotency markers between all the cell types analysed in the microarray. This was 
carried out using a heatmap produced using R-studio incorporating all cell types 
analysed in the experiment.  
Figure 45 - Volcano plot of the probes over/under-represented in oriP-EBNA1 iPSCs in comparison to 
dbDNA-iPSCs. 
Volcano plot represents a type of dot plot whereby each black dot represents an individual probe. 
With the combination of the statistical significant difference (≤0.05) and the magnitude of change (Fold 
change ≥1.5) we were able to isolate specific probes (dots) that were over-represented in oriP-EBNA1 




The hierarchical clustering tool within the heatmap allows visualization of pluripotency 
probe expression as a whole for each cell type and for the specific pluripotency probes 
incorporated in the analysis. The hierarchical clustering demonstrated on the whole 
that dbDNA produced iPSCs share more in common in terms of pluripotency probe 
expression with ESCs than oriP-EBNA1 produced iPSCs do with either cell type 
(Figure 46). However, the hierarchical clustering did suggest that while the probe 
expression values within dbDNA-produced iPSCs were more similar to that of ESCs, 
that oriP-EBNA1 produced iPSCs were still likewise very similar in their level of probe 
expression. 
Following this, our next aim was to determine if the probes which were over-
represented in oriP-EBNA1 produced iPSCs were occurring independently within this 
cell type and were therefore being influenced by the vector. I carried out a heatmap 
analysis incorporating the over-represented probes from oriP-EBNA1 iPSCs in 
comparison to dbDNA iPSCs. To provide the analysis with greater context, the 
expression values for the same probes from ESCs was also included. This assisted in 
Figure 46 - Heatmap demonstrating the relative expression of key pluripotency markers between 
nhDF, oriP-EBNA1-iPSCs, dbDNA-iPSCs and ESCs. 
Heatmap produced using R-studio depicting several pluripotency-specific probes across all cell types 
incorporated within the microarray. The hierarchical clustering amongst the cells determined which 
cell types probed gene expression pattern was most similar to one and other across such pluripotency 
probe sets and which were more divergent.  
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determining whether the over-represented probes within oriP-EBNA1 produced iPSCs 
were specific to that cell type only, or, if the expression pattern of such EBNA1 iPSCs 
was more similar to that of ESCs therefore indicating a failure of the behalf of the 
dbDNA system to faithfully induce gene expression within its own iPSCs.   
 
 
The heatmap in conjunction with the hierarchical clustering evidences that, on the 
whole, dbDNA iPSCs share a more similar expression profile with that of ESCs in 
relation to oriP-EBNA1 over-represented probes than EBNA1-iPSCs (Figure 47). It 
was clear that, even though some individual genes do share a similar expression 
profile between EBNA1 iPSCs and ESCs, that ESCs generally didn’t share similar 
express levels of most of the probes which were over-represented in oriP-EBNA1 
Figure 47 - Heatmap comparison of probes that are over-represented in oriP-EBNA1 iPSCs in 
comparison with dbDNA iPSCs and ESCs. 
A heatmap produced using R-studio. Image depicts all the over-represented gene probes within oriP-
EBNA1 iPSCs with green being highly expressed, black in-between and red a low level of expression. 
Hierarchical clustering also utilized to determine the similarities between cell types in respect to the 
gene sets.  
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iPSCs. Their expression levels instead were much lower and consistent with that of 
the dbDNA system. This therefore indicated that most of the probes that were over-
represented in oriP-EBNA1 iPSCs, were done so in that cell type only. This suggested 
that the oriP-EBNA1 vector may be the root aetiological cause for the manipulation of 
some of the over-represented probes previously outlined. Following this exciting 
dataset, we wanted to determine what biological processes the oriP-EBNA1 specific 
probes were implicated within.   
 
2.1.8. OriP-EBNA1 over-represented probe analysis: 
 
Suggestions from the above result indicated that probes that were over-represented 
within oriP-EBNA1 iPSCs following a comparison with dbDNA iPSCs, were likewise 
over-represented in comparison to ESCs. The implications from this suggested that 
such probes were over-represented in oriP-EBNA1 produced iPSCs specifically and 
were therefore being manipulated in a vector-specific, pluripotency independent 
manner. To understand what effects the vector may be having on the cells, we aimed 
to determine what specific biological processes such over-represented probes were 
interacting with. Duly, several different software packages were utilised to determine 
transcription factor enrichment terms. The Reactome database was utilised to project 
significant genes onto the human genome, helping to elucidate interacting pathways 
within over-arching biological processes such as cell cycle, metabolism and immune 









The projections made by the Reactome database from the oriP-EBNA1 over-expressed 
probes had significant interactions within several different biological processes. 
Processes in relation to the immune system, cellular responses to extracellular stimuli, 
extracellular matrix organisation and developmental biology were but a few which were 
over-represented (Figure 48). The Reactome system was also able to quantify the 
number of probes which interacted with different biological processes to provide a clear 
understanding of which processes our probes were most commonly aligning in.   
Figure 48 - Projection of oriP-EBNA1 over-represented probes onto the human genome as determined 
by the Reactome database. 
oriP-EBNA1 over-represented probes were incorporated into the Reactome database which projects 
them onto different biological processes with which the probes most specifically align with. Each 
pathway has a focal point in the center with relating pathways being represented as branches 
protruding from this center point. Any pathways determined to be significantly interacting with the 






The quantification of the probes within different biological processes according to 
Reactome demonstrated that immune system processes was the most common 
pathway that the oriP-EBNA1 over-represented probes interacted within (Figure 49). 
A greater level of depth could be extracted from this dataset by investigating how the 
probes were interacting within such overarching pathways. In order to remove any bias 
from this analysis, biological processes with which the oriP-EBNA1 probes interacted 
were determined from 3 separate sources: Reactome, Gene set enrichment analysis 
(GSEA) and Gene ontology (GO). To begin with, the over-represented specific 
biological pathway for oriP-EBNA1 over-represented probes were analysed using 
Reactome.  
 
Figure 49 - Quantification of the number of interacting probes within the main human pathways 
as projected by Reactome. 
The Reactome database will provide the number of probes, an inserted by ourselves into the 




The analysis using Reactome demonstrated a number of pathways associated with 
the immune system which were aligned with a high level of specificity (Figure 50). 
Interferon signalling including both interferon alpha/beta signalling and interferon 
gamma signalling were highlighted, alongside pathways associated with MHC 
expression and Cytokine signalling in the immune system. Overall, the Reactome 
database implicated the EBNA1-iPSC over-represented probes with having a largely 
pro-inflammatory signature.  
Secondly, enrichment analysis was also undertaken using the MSigDB function from 
GSEA. This function provided information on hallmark genes which summarized and 
represented specific, well-defined biological processes generated via overlaps 
between gene sets within the MSigDB system. Subsequently, the analysis can provide 
a p-value for each hallmark process which demonstrates a measure of how significant 
the changes were for each given probe set – the higher the absolute value of the 
Figure 50 - Over-represented pathways determined by the Reactome database - ordered from the 
most significant p-value. 
Specific interacting pathways that the oriP-EBNA1 over-represented gene set interacts with as 
projected by the Reactome database. Reactome provides information on the number of entities or 
probes which interact within this process and likewise the entities p-value/FDR which relates to the 
specificity of the projections too. The processes are ordered from most significant p-value down.  
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statistic, the greater its significance. GSEA also provides k/K values, whereby k = the 
number of genes in the query set and K = the number of genes in the MSigDB 
database. This can therefore provide information on the number of probes interacting 
within a specific pathway. Finally, a q-value was provided which was an FDR analogue 
of the p-value after correction for multiple hypothesis testing and again reduces the 
possibility of including false positive results. 
 
 
The analysis using GSEA demonstrated, again, an interaction with a number of 
inflammatory and immune pathways such as Interferon gamma response, Interferon 
alpha response and inflammatory response (Figure 51). This corroborated and added 
greater validity to the inflammatory signature presented from the Reactome database.  
Figure 51 - Over-represented pathways determined by the GSEA MSigDB database - ordered from 
the most significant p-value. 
Specific interacting pathways that the oriP-EBNA1 over-represented probe set interacted with as 
projected by the MSigDB GSEA software. GSEA provideed information on the number of probes which 
interact within each gene set (k) alongside p-value/FDR which relates to the specificity of the 
projections too. The processes are ordered from most significant p-value down. 
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Moreover, the most significantly projected pathway from the over-represented probe 
set was Epithelial to Mesenchymal transition. This represented unwanted cellular 
differentiation and suggested that a number of probes associated and over-
represented in oriP-EBNA1 iPSCs were in relation to a loss of pluripotent phenotype.  
Finally, the same analysis was undertaken using Gene ontology (GO) - a software of 
a similar ilk to Reactome and GSEA. GO would align the oriP-EBNA1 over-
represented genes within their most specifically projected pathways. This would 
complete the unbiased analysis into key biological processes that oriP-EBNA1 iPSC-
specific probes interacted within. 
 
Again, the analysis demonstrated an alignment with GO terms such as Response to 
cytokines and Regulation of cell differentiation as previously outlined using other gene 
enrichment software (Figure 52). However, GO terms associated with Response to 
oxygen containing compound were also significantly projected, bringing some context 
to previous terms in relation to UV DNA damage response.  
Figure 52 - Over-represented pathways determined by the GO database - ordered from the most 
significant p-value. 
Specific interacting pathways that the oriP-EBNA1 over-represented probe set interacts with as 
projected by the GO software. GO provides information on the number of probes which interact within 
each gene set (k) alongside p-value/FDR which relates to the specificity of the projections too. The 
processes are ordered from most significant p-value down. 
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Taken in its entirety, the initial probe enrichment analysis and biological process 
projection demonstrated that the over-represented probes in oriP-EBNA1-derived 
iPSCs were mostly associated with potentiating a pro-inflammatory cellular 
environment. Processes in relation to unwanted cellular differentiation were also 
commonalities between the analysis and helped to substantiate the spontaneous 
differentiation phenotype described in refractory lines which was negated when using 
the dbDNA system. Moreover, the analysis also demonstrated hints of a DNA damage 
phenotype alongside the presence of oxygen containing compounds in oriP-EBNA1 
iPSCs.  
Following this, several genes were isolated to validate their expression and over-
representation within oriP-EBNA1 iPSCs. Surplus RNA that was taken at the same 
time for the microarray and was utilised to determine the expression of genes 
associated with some of the highlighted pathways within the probe enrichment 
analysis. Gene targets associated with the over-represented biological processes, 
signalling pathways and cellular processes projected by the Reactome database were 
isolated for analysis. An RT-qPCR analysis was undertaken to quantify the levels of 
gene expression within dbDNA and oriP-EBNA1 iPSC samples.  
 
 
Figure 53 - RT-qPCR analysis of EBNA1 over-represented probes using the Reactome database as a 
guide. 
The RT-qPCR represents a single experiment carried out on the remnants of RNA from cells which 
were isolated for the microarray experiment. Data represents n=1 with 3 technical repeats per 
gene. Error bars represent SEM for each gene. 
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The genes isolated for validation followed the same trend as expected with the 
microarray results, being largely over-expressed within oriP-EBNA1 iPSCs (Figure 
53). This permits confidence in the accuracy of the projections determined by the 
enrichment factor software and guided us to dig further into the key transcriptomic 
differences and the potential mechanisms behind them.  
 
2.1.8.1. STAT1 signalling and IFN-γ signalling: 
 
The gene enrichment analysis demonstrated that the genes over-represented within 
the oriP-EBNA1 produced iPSCs were largely associated with immune system 
processes. Moreover, upon analysing more specific, isolated biological processes it 
was clear that interferon signalling was a commonly over-represented within EBNA1-
iPSCs. Using Reactome, we were able to substantiate the clear alignment of the over-
represented EBNA probes to interferon signalling with a high degree of specificity, as 




To further substantiate the alignment of such oriP-EBNA1 over-represented genes 
within interferon related pathways, a heatmap analysis was generated. The analysis 
incorporated genes associated with interferon signalling pathways within both iPSC 
types and ESCs too. This would help to provide further context in relation to interferon-
specific genes and if their expression was specifically over-represented within oriP-
EBNA1 iPSCs or were they likewise shared by ESCs.  
Figure 54 – Reactome projection of oriP-EBNA1 over-represented probes in relation to interferon 
signaling.  
Graphs represent the projection of oriP-EBNA1 over-represented probes in relation to interferon 
signaling. The gprobes aligns with this biological process with a high specificity demonstrated by the p-
value. The higher the absolute value of the statistic, the greater its significance and the greater the 




The heatmap of interferon-related genes demonstrated that they were largely over-
represented in oriP-EBNA1 iPSCs specifically, suggesting that the vector may be 
responsible for the manipulation of such gene sets (Figure 55). The result was 
interesting and guided us to investigate the mechanism behind this further. Previous 
literature had demonstrated that the EBNA1 protein was associated with an increased 
activation of STAT1 which in turn sensitised cells to an increase in IFN-γ expression 
and an activation of Major Histocompatibility Complex (MHC) (Wood et al., 2007). We 
therefore wanted to examine the effect of the oriP-EBNA1 vector and its ability to 
potentiate STAT1 transcription in comparison to the dbDNA vector system. GFP-
expressing oriP-EBNA1 and dbDNA vectors were transiently transfected into 
Figure 55 - Heatmap representing genes associated with interferon expression in oriP-EBNA1 
iPSCs, dbDNA iPSCs and ESCs. 
Heatmap analysis representing interferon-related gene expression within oriP-EBNA1 iPSCs, 
dbDNA iPSCs and ESCs too. The hierarchical clustering of the overall gene expression for this gene 
set demonstrates a close alignment of the expression pattern of both ESC and dbDNA iPSCs with 
oriP-EBNA1 iPSCs having the most divergent expression profile of such gene sets.  
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HEK293T cells and every 24-hours over a 72-hour period the cells transcriptomics 
were analysed for STAT1 expression using RT-qPCR.  
 
The RT-qPCR demonstrated an increased trend in STAT1 transcription following 
transfection with the oriP-EBNA1 plasmid in comparison to the dbDNA system but not 
to a significant degree (Figure 56). Further experiments should be carried out to 
determine the subsequent localisation of STAT1 expression following EBNA1 
transfection to determine any differences in cell response and how this sensitises each 
transfected cell type to an increased propensity for interferon related signalling.  
 
2.1.8.2. Spontaneous differentiation of iPSCs:  
 
A commonality between the unbiased differentially expressed probe analysis carried 
out from the microarray was in relation to epithelial to mesenchymal transition/cellular 
differentiation. The dbDNA system had successfully reprogrammed primary fibroblast 
cultures with which the oriP-EBNA1 system could not produce stabilised iPSC lines 
from. Upon reprogramming such fibroblasts using the oriP-EBNA1 system, the iPSCs 
Figure 56 - RT-qPCR quantifying the relative expression of STAT1 in cells transfected with both 
dbDNA and oriP-EBNA1 GFP expressing vectors. 
The graph represents an n=3 with 3 technical replicates per biological repeat. The data was 
subjected to a Kolmogorov-Smirnov test for normality with the p-value being >0.05 suggesting non-
normal distribution. As such, a Mann-Whitney U-test was carried out per timepoint. *  - p-value = 
<0.05, ** - p-value = <0.01, *** - p-value = <0.001. No significant difference was seen. 
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would undergo spontaneous differentiation independent of any cues whilst the dbDNA 
produced iPSCs would maintain their pluripotent state indefinitely. Having compiled a 
list of markers of early differentiation, a comparison was carried out using expression 
values from the microarray for all the pluripotent cell types in a heatmap analysis.  
 
The analysis indicates an over-representation of genes associated with early 
differentiation in iPSCs produced using the oriP-EBNA1 vector in relation to the 
dbDNA produced iPSCs and ESCs alike (Figure 57). Having evidenced such a pattern 
in the microarray, we then wanted to carry out a phenotypic analysis to determine the 
difference in the level of spontaneous differentiation between the two different iPSC 
types. The analysis was carried out by monitoring the level of spontaneous 
differentiation within the culture flasks for both dbDNA and oriP-EBNA1 produced 
iPSCs. 3 different primary fibroblast cultures were concurrently reprogrammed with 
both the dbDNA and oriP-EBNA1 vectors. The iPSCs produced were stained with AP 
to determine the area of spontaneous differentiation in proportion to the whole colony, 
Figure 57 - Heatmap analyzing the expression of key early markers for differentiation within oriP-
EBNA1 iPSCs, dbDNA iPSCs and ESCs using data obtained from the microarray. 
Heatmap analysis representing markers of early differentiation within oriP-EBNA1 iPSCs, dbDNA 
iPSCs and ESCs. The hierarchical clustering of the overall probe expression for this gene set 
demonstrates a close alignment of the expression pattern of both ESC and dbDNA iPSCs with oriP-
EBNA1 iPSCs having the most divergent expression profile of such probe sets.  
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which was monitored and analysed using imageJ.  The analysis was carried out on 
colonies from as early as p5 up to cells that were p32 in passage number. This was to 
account for any level instability amongst iPSCs at earlier iPSC passages.  
 
The dataset evidenced unequivocally that the oriP-EBNA1 produced iPSC colonies 
displayed greater levels of spontaneous differentiation irrespective of the primary 
fibroblast cells used or the passage of the iPSCs analysed (Figure 58). The analysis 
provided a key quantification of the difference that was being observed routinely within 
the tissue culture environment in relation to the phenotypes of both iPSC cell types. 
The data clearly demonstrated, with a high significance, that the oriP-EBNA1 produced 
Figure 58 – Analysis of spontaneous differentiation in both dbDNA and oriP-EBNA1 produced iPSCs.  
Representative images on how the level of phenotypic differentiation was quantified. Colonies 
underwent AP staining, which stains pluripotent areas and specifically excludes areas of spontaneous 
differentiation. The level of differentiation was then determined in proportion to the total area of the 
colony. This analysis was carried out across 3 different iPSC lines reprogrammed using both the oriP-
EBNA1 and dbDNA systems. These iPSCs were concurrently reprogrammed and cultured 
simultaneously. The graph represents the average level of differentiation observed within iPSCs 
produced by both vector types. 3 different primary fibroblast cultures were analyzed with passages 
ranging from p5 to p32 with a minimum of 150 colonies being analyzed per iPSC line and vector. The 
data was subjected to a Kolmogorov-Smirnov test for normality with the p-value being >0.05 suggesting 
non-normal distribution. As such, a Mann-Whitney U-test was carried out per timepoint. A **** 




iPSCs’ consistently spontaneously differentiate at a higher rate than that of dbDNA 
produced iPSCs’.  
 
2.1.8.3. DNA damage analysis:  
 
Previous literature had demonstrated a clear association between the EBNA1 protein, 
ROS production and a subsequent increased level of DNA damage (Gruhne et al., 
2009). The dataset presented so far has demonstrated how EBNA1 upregulated 
probes were highly aligned with a number of biological processes associated with 
response to oxygen containing compounds and DNA damage response. Taken as a 
whole, there was clear rationale to investigate the potential of the oriP-EBNA1 system 
to induce DNA damage within transfected cells and how that relates in comparison to 
the dbDNA system. The comet assay was a well-established, simple method to detect 
DNA damage at a single cell level. The assay functioned on the premise that, when 
subjected to several buffers and electrophoresed, intact DNA will maintain its integrity 
and progress through the agarose gel as a unified entity. However, upon being 
damaged, this would result in smaller strands of DNA. When subjected to the same 
process, the smaller damaged DNA strands will run behind the intact DNA; creating a 
smear-like effect referred to as ‘Tail DNA’. Tail DNA was proportionate to the level of 
damaged DNA within a single cell – with the remaining Head DNA representing intact 
DNA. Software has also been developed with the capacity to quantify such damaged 
DNA per cell. Therefore, a comet assay was undertaken in order to determine the 
presence of any DNA damage within respective dbDNA and oriP-EBNA1 transfected 
cells. Aware however that incitements of DNA damage and the response to such 
damage may be minimal, we aimed to prime the cells to DNA damage induction by 
spiking the media with hydrogen peroxide to increase the sensitivity of the experiment. 
We therefore decided to titrate the level of hydrogen peroxide required to increase the 
sensitivity of the experiment whilst also to codetermine an appropriate concentration 




It was clear from the experiment that as the concentration of hydrogen peroxide 
increased the level DNA damage induction increased proportionately. This was 
indicated by the increased level of ‘Tail DNA’ as the concentration of hydrogen 
peroxide the cells were treated with increased (Figure 59). To quantify head DNA and 
tail DNA a software called CaspLab was employed. Once thresholds, as detailed by 
the software developers were set, a measurement frame was drawn over cells to be 
analysed. The measurement frame was then be activated which develops a 
measurement profile calculating several parameters (Head DNA, Tail DNA, Tail 
length, Head radius, Tail moment). Head DNA accounts for the level of intact DNA and 
the Tail DNA accounts for DNA which was damaged within single cells. Comet length 
was also calculated which accounts for the length of the cell from the beginning of the 
head to the end of the tail and Tail moment which was a product of tail length and the 
percentage DNA in the tail. These measurements can then be exported for each 
Figure 59 - Respective comet assay images for the titration of different concentrations of hydrogen 
peroxide. 
Representative images of example comets for cells treated with different concentrations of hydrogen 
peroxide are depicted. The concentrations of hydrogen peroxide ranges from 0 to 500µM. Images 
were taken using a fluorescent microscope. Scale bar represents 100µm. 
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photo. This analysis was carried out for a minimum of 100 comets per gel with three 
repeats per concentration of hydrogen peroxide.  
 
 
The results demonstrated a proportionate increase in DNA damage as the 
concentration of hydrogen peroxide increased (Figure 60). This was demonstrated in 
several parameters that were calculated using CaspLab. Head DNA (%) decreased 
as the concentration of hydrogen peroxide increased. As head DNA was proportionate 
to intact DNA there will also be a correlation between the level of head DNA and the 
level of tail DNA which was captured. As Head DNA decreased this will be secondary 
to damaged DNA and therefore an increased level of tail DNA. Tail DNA 
proportionately increased as the concentration of hydrogen peroxide increased 
demonstrating a greater level of DNA damage. Again, comet length was also related 
Figure 60 - Titration of hydrogen peroxide levels added to HEK293T media before being analyzed 
using a comet assay. 
HEK293T cells were subjected to hydrogen peroxide for 30 minutes prior to analysis. CaspLab was 
then employed to quantify comet length, Tail moment, Tail DNA and Head DNA. 1 biological repeat 
with 3 technical repeats being carried out with a minimum of 100 cells per technical repeat being 
analysed. Error bars represent SEM for each biological repeat.  
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to the level of tail DNA. When a cell exhibits more damaged DNA, the tail produced 
should in theory be longer and therefore the cells should display a greater comet 
length. This was corroborated by our results as the comet length likewise 
proportionately increased along with the concentration of hydrogen peroxide and DNA 
damage. Finally, tail moment, proportionate to tail length and DNA within the tail 
likewise increased proportionately with an increase in hydrogen peroxide secondary 
to a higher level of DNA damage. It was clear from our data that a phenotype of DNA 
damage was more apparent in the comet assay as the concentration of hydrogen 
peroxide increased. The results suggested that 50µM initiated small incitements of 
DNA damage that was detectable by the comet assay but produced results that were 
not largely dissimilar to untreated cells. This was therefore deemed an appropriate 
concentration of hydrogen peroxide to prime all cells to be analysed with to increase 
the sensitivity of the assay. A concentration of 200µM of hydrogen peroxide induced 
incitements of DNA damage that were much more extreme in comparison to untreated 
cells and was therefore utilised as a positive control concentration for the assay. From 
this, an experiment comparing and quantifying DNA damage induction in cells 
transfected with the dbDNA and oriP-EBNA1 vectors was carried out. HEK293T cells 
were transiently transfected with 4µg of dbDNA-eGFP (6.12x1035) and 4µg oriP-
EBNA1-eGFP (3.4x1035). The cells were left for 24 hours before the level of GFP-




GFP qualification demonstrated that a good transfection efficiency for both the dbDNA 
or oriP-EBNA1 vectors (Figure 61). The cells were then spiked with 50µM of hydrogen 
peroxide for 30 minutes, with positive controls being spiked with 200µM for the same 
time period. The cells were then subjected to a comet assay and analysed using the 
CaspLab software.   
Figure 61 - eGFP qualification of both the oriP-EBNA1 and dbDNA vector following transfection 
into HEK293T cells. 
HEK293T cells were transfected with dbDNA and oriP-EBNA1 vectors both with an added GFP 
transgene to determine transfection efficiency and success. The GFP qualification demonstrates the 
transfection was successful and that the cells have the oriP-EBNA1 and dbDNA vectors within them. 





Figure 62 - Example representative images of HEK293T cells following transient transfection with 
the oriP-EBNA1 eGFP vector. 
HEK293T cells which have been transfected with the oriP-EBNA1 GFP vector were processed in the 
comet assay with representative images being taken for analysis using CaspLab. An n=3 was taken 





Representative images for both vector types were taken and stored before being 
analysed using the CaspLab software (Figure 62 & Figure 63).  
Figure 63 - Example representative images of HEK293T cells following transient transfection with 
the dbDNA- eGFP vector. 
HEK293T cells which have been transfected with the dbDNA GFP vector were processed in the 
comet assay with representative images being taken for analysis using CaspLab. An n=3 was taken 





The results in demonstrated that oriP-EBNA1 transfected cells displayed a greater 
level of DNA damage in comparison to dbDNA transfected cells to a significant degree 
(Figure 64). oriP-EBNA1 transfected cells demonstrated greater levels of tail DNA and 
tail moment alongside a greater comet length than dbDNA transfected cells. Moreover, 
the level of intact or head DNA was significantly higher in dbDNA transfected cells; 
corroborating that the oriP-EBNA1 vector resulted in a greater induction/reduced 
repair of damaged DNA within transfected cells. To further substantiate this dataset, 
supporting experiments were undertaken.  
Figure 64 – Analysis of HEK293T cells transfected with dbDNA and oriP-EBNA1 vectors using 
CaspLab software. 
Graphs depicting CaspLab generated results examining comet length, tail moment, tail DNA and head 
DNA. Each graph represents an n=3 experiment with 3 technical repeats per biological repeat. A 
minimum of 100 comets was analyzed per technical repeat. Each data type was subjected to a 
Kolmogorov-Smirnov test for normality with the p-values being >0.05 suggesting non-normal 
distribution for all graphs. As such, a Mann-Whitney U-test was carried out between dbDNA and oriP-
EBNA1 transfected cells. *  - p-value = <0.05, ** - p-value = <0.01, *** - p-value = <0.001, **** -p-
value = <0.0001. 
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An analysis incorporating the use of a γ-H2AX antibody was determined to be 
applicable for further experiments to corroborate differences in DNA damage 
incitement between the two vector systems. The γ-H2AX antibody localises to variant 
H2A histones which, upon the incitement of DNA damage, replace conventional H2A 
subsets and become rapidly phosphorylated. As such, a γ-H2AX antibody can easily 
detect and manifest discrete nuclear foci which can be utilised to enumerate the 
volume of DNA double strand breaks (DSB) in a cell. We nucleofected fibroblasts with 
both oriP-EBNA1 and dbDNA GFP-expressing vectors to determine if the transfection 
of either of these vector systems resulted in an increased level of variant/γ-H2AX. The 
use of the GFP vectors would allow for a more specific analysis too, as when carrying 
out ICC the GFP protein was retained allowing us to pinpoint and enumerate γ-H2AX 
in transfected cells specifically. Again, hydrogen peroxide was incorporated to induce 





The immunostain demonstrated foci being present in all conditions of the experiment 
(Figure 65). The foci representing the level of DSB was then quantified for each cell 
type.  
Figure 65 - A γ-H2AX antibody was utilized for ICC being carried out on dbDNA/oriP-EBNA1 eGFP 
transfected cells. 
A γ-H2AX antibody was utilized to stain cells to determine the level of variant H2A within cells in 
proportion to the level of DSB. Both dbDNA and oriP-EBNA1 GFP expressing vectors were 
transfected into fibroblasts before being analyzed 24 hours after transfection. Fluorescent 
microscopy was utilized to determine GFP expressing cells which were then analyzed for γ-H2AX 
foci. A positive control utilizing 2000uM hydrogen peroxide and a negative control was also utilized. 
An n=3 was analyzed with 3 technical repeats per biological replicate. A minimum of 100 





Following quantification, it was clear that there was consistently a greater level of γ-
H2AX foci in oriP-EBNA1 transfected cell types in comparison to dbDNA transfected 
cells (Figure 66). This demonstrated that there was a greater level of DSB present in 
oriP-EBNA1 transfected cells.  
Altogether, the comet assay and γ-H2AX results demonstrated that oriP-EBNA1 
transfected cells display an increased DNA damage phenotype in comparison to 
dbDNA transfected cells. This moreover corroborates some of the phenotypes 
denoted from the microarray analysis alongside what has been noted in previous 
literature too. Potentiating and inciting a reduced level of DNA damage was a real 
benefit to the use of the dbDNA system within reprogramming and iPSC development, 
as genomic integrity is an essential consideration for the downstream application of 
such pluripotent cell types.  
Figure 66 - Quantification of the number of punctae within transfected cells following ICC staining 
using a γ-H2AX antibody.  
Representative images taken following ICC analysis using a γ-H2AX antibody. An n=3 was carried out 
for this experiment with 3 technical repeats per biological replicate. A minimum of 150 transfected 
cells per biological replicate were analysed. The data was subjected to a Kolmogorov-Smirnov test 
for normality with the p-value being >0.05 suggesting non-normal distribution of the dataset. As 
such, a Mann-Whitney U-test was carried out between dbDNA and oriP-EBNA1 transfected cells. *  - 
p-value = <0.05, ** - p-value = <0.01, *** - p-value = <0.001. 
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2.1.9. Over-represented genes within dbDNA-iPSCs:  
 
For a well-rounded interrogation of the microarray dataset, genes which were over-
represented within the dbDNA produced iPSCs were also analysed. As per the oriP-
EBNA1 system, the aim was to investigate what probes was significantly upregulated 
in dbDNA iPSCs in comparison to oriP-EBNA1 produced iPSCs and what biological 
processes such probes interact within. Over-represented dbDNA probes was 
compiled into a heatmap analysis with oriP-EBNA1-iPSCs and ESCs. The aim, as 
before, was to determine if the over-represented probes within the dbDNA system 
were specific to that iPSC-type only or, if the expression profile of this gene set was 
more like that of ESCs. The latter would most likely make it an insufficiency on behalf 




The heatmap analysis suggests that the probes which were differentially expressed 
by dbDNA produced iPSCs were mostly unique to this cell type. Both oriP-EBNA1 
iPSCs and ESCs share a more similar expression pattern in relation to the same 
genes, suggesting a degree of manipulation in a dbDNA dependent and pluripotency 
independent fashion (Figure 67). The probes which were significantly over-
represented within the dbDNA system were then isolated for analysis to determine the 
biological processes within which such over-represented genes interact within. The 
Reactome database was utilised to project significant genes onto the human genome 
to help elucidate their interacting pathways.  
Figure 67 - Heatmap comparison of probes that are over-represented in dbDNA iPSCs in comparison with oriP-
EBNA1 iPSCs and ESCs. 
A heatmap was produced using R-studio. Image depicts all the over-represented gene probes within dbDNA 
iPSCs with green being highly expressed, black in-between and red a low level of expression. Hierarchical 





Reactome projections aligned most of the dbDNA over-represented probes within the 
cell cycle biological processes with a high degree of specificity (Figure 68). Having 
previously detailed that the dbDNA system reprograms fibroblasts back to a pluripotent 
state independent of the shp53 transgene, it was therefore possible that the exclusion 
of this protein may result in cell cycling differences between these two cell types. 
However, in order to gain greater insight, a detailed analysis looking at individual 
pathways was carried out. To remove any bias from the analysis, biological processes 
with which dbDNA over-represented probes interacted within were again determined 
from 3 separate sources: Reactome, Gene set enrichment analysis (GSEA) and Gene 
ontology (GO). 
Figure 68 - Projection of dbDNA over-represented probes onto the human genome as determined by 
the Reactome database. 
dbDNA over-represented probes were incorporated into the Reactome database which projects them 
onto different biological processes with which the genes most specifically align with. Each pathway 
has a focal point in the center with relating pathways being represented as branches protruding from 
this center point. Any pathways determined to be significantly interacting with the upregulated genes 




The specific biological processes as outlined by Reactome demonstrated again that a 
lot of the over-represented genes were interacting within cell cycle processes (Figure 
69). E2F targets could embody several different genes and transcription factors which 
have both progressive and repressive cell cycle functions, but whose functionality was 
intrinsically linked to cell cycling. G2M checkpoint and mitotic spindle again were 
biological processes which were linked to efficient cell cycle functionality. Moreover, 
DNA repair was also highlighted which may again be manipulated secondary to the 
lack of shp53 presence within the dbDNA reprogramming vector. The same analysis 
was subsequently undertaken using GSEA likewise.  
Figure 69 - Over-represented pathways determined by the Reactome database - ordered from the 
most significant p-value. 
Specific interacting pathways that dbDNA over-represented probes interacted with as projected by 
the Reactome database. Reactome provides information on the number of entities which interact 
within this process and likewise the entities p-value/FDR which relates to the specificity of the 





Again, the GSEA software highlighted a number of biological processes associated 
with cell cycling as being specifically associated with the dbDNA over-represented 
probes (Figure 70). Five of the top 10 biological processes identified using GSEA were 
in relation to cell cycle regulation and progression, a common factor identified between 
the first two analysis sets. Finally, the Gene ontology (GO) database was also utilised 
for the same type of analysis.  
Figure 70 - Over-represented pathways determined by the GSEA MSigDB database - ordered from the 
most significant p-value. 
Specific interacting pathways that the dbDNA over-represented probes interacted with as projected by 
the MSigDB GSEA software. GSEA provides information on the number of genes which interact within 
each gene set (k) alongside p-value/FDR which relates to the specificity of the projections too. The 
processes were ordered from most significant p-value down. 
Figure 71 - Over-represented pathways determined by the GO database - ordered from the most 
significant p-value. 
Specific interacting pathways that the oriP-EBNA1 over-represented probes interacted with as projected 
by the GO software. GO provides information on the number of genes which interact within each gene set 
(k) alongside p-value/FDR which relates to the specificity of the projections too. The processes were 
ordered from most significant p-value down. 
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As anticipated, the analysis again yielded results with cell cycle functions being the 
most significantly aligned (Figure 71). 
 
2.1.9.1. Cell cycle analysis:  
 
Following the unbiased probe/gene enrichment and biological process analysis, it was 
clear that differences involving genes associated with cell cycling were a commonality 
amongst the results. The results indicated that differences may exist between cell 
cycle checkpoints between the two iPS cell types (potentially in relation to shp53 
presence) moreover, G2/M transition was also highlighted as a commonality within the 
dataset. Subsequently, a cell cycle analysis between dbDNA and oriP-EBNA1 iPSCs 
was carried out to determine any differences between the two cell types. 
The analysis was carried out using a Propidium Iodide (PI) stain before analysing the 
cells using a flow cytometer. PI was a stain that would intercalate between bases within 
nuclear DNA with little or no preference. Then, dependent on the cycling phase 
exhibited by a cell, this will dictate the amount of stain taken up and subsequently the 
level of fluorescence presented by a cell. In a crude simplification, cells will often go 
through an initial growth phase in G1, before entering the S phase. During the S phase, 
cells will undergo DNA replication before progressing into the G2 phase. Cells within 
the G2 phase will then prepare to divide until ultimately you have cell division or 
mitosis. When incorporated into this explanation, it was clear that cells in the G1 phase 
will have the least amount of DNA and as such a proportionately limited intercalation 
of the PI stain. Cells in the S phase however, will have more DNA than when they are 
in the G1 phase and will continue to fluoresce more brightly until the DNA has doubled 
its content. Therefore, cells in the G2 phase will incorporate twice as much PI as cells 
in G1 phase and therefore fluoresce with a greater intensity. It was therefore possible 
to determine, using this stain, differences between the cell cycle phases exhibited 
between dbDNA and oriP-EBNA1 produced iPSCs. This experiment was carried out 
on dbDNA and oriP-EBNA1 produced iPSCs using PI. Positive stain detection was 




The results produced from the stained iPSCs from both cell types demonstrated that 
different phases were favoured more commonly between the two iPSC-types. The 
representative histogram (‘A)’) demonstrate that dbDNA-produced iPSCs seemingly 
had a greater proportion of its iPSCs within the G0/G1 phases upon analysis in 
comparison to the oriP-EBNA1 (‘B)’) histogram. While, the oriP-EBNA1 iPS cells 
seemingly have more cells in the G2/M phase of cell cycle (Figure 72). However, in 
order to truly elucidate and quantify differences between the two cell types, the number 
of cells within each phase needed to be quantified. The resulting data was then 
Figure 72 - Representative histogram generated from both dbDNA and oriP-EBNA1 produced iPSCs 
following staining with PI any analysis using a flow cytometer. 
Representative histograms generated by the BD FACS Caliber upon subsequent analysis of iPSCs 
following staining with PI. A) represents dbDNA produced iPSCs stained with PI following flow 
cytometry analysis. The 5 different cell cycle phases are demonstrated amongst the 3 peaks beginning 
from ~200 on the FL2-H x-axis. This first peak depicts G0/G1, with the in-between region (between 
200-400 FL2-H) demonstrating the S-Phase before the final peak at ~400 on the x-axis representing 
G2/M. B) represents the same analysis utilizing oriP-EBNA1 produced iPSCs. C) represents extra gating 
undertaken to remove doublets from the analysis, ensuring there was minimal contamination of 
doublets being recognized within the G2/M phase peak.  
132 
 
subsequently applied to ModFit LT 5.0 permitting the quantification of the different cell 
cycle phases demonstrated within each cell type.   
 
 
The analysis using ModFit was able to provide a quantification of the proportion of 
cells within each phase for both oriP-EBNA1 and dbDNA produced iPSCs (Figure 73). 
The analysis was undertaken for 3 different iPSC lines for each vector type produced 
from 3 different fibroblast sources. This was then collated and placed in a bar chart to 
examine the differences between the proportion of cells within each cell cycle phase 
for both iPSC types.  
Figure 73 - Example ModFit analysis of representative histograms for both dbDNA and oriP-EBNA1 
produced iPSCs. 
Following cell cycle analysis, the subsequent histograms can be applied to the ModFit program which 
can then quantify the proportion of a cell population within each different phase for both cell types. 
The analysis was carried out for both dbDNA and oriP-EBNA1 produced iPSCs. An n=3 was analyzed 




The results demonstrated a positive trend which doesn’t reach significance with more 
dbDNA-iPSCs existing within the G0/G1 cell cycle phase and likewise that more oriP-









Figure 74 - Graph representing the average cell cycle of both oriP-EBNA1 and dbDNA iPSCs. 
The quantifications of the populations of cells in different cell cycle phases in both dbDNA and oriP-
EBNA1 produced iPSCs. An n=3 was analyzed originating from 3 different primary fibroblast cultures 
with 3 technical repeats per biological replicate. The data was subjected to a Kolmogorov-Smirnov 
test for normality with the p-value being >0.05 suggesting non-normal distribution of the dataset. As 
such, a Mann-Whitney U-test was carried out between dbDNA and oriP-EBNA1 iPSCs. *  - p-value = 
<0.05, ** - p-value = <0.01, *** - p-value = <0.001. G0/G1 p-value = 0.068, S phase p-value = 0.317 & 




2.1.10. Summary:  
The dbDNA vector was designed by Touchlight Genetics as a transient expression 
system. The vector, in theory, should not integrate within its host cells genomic DNA 
and neither does it have any scaffolding or attachment mechanisms to increase its 
longevity within such cells. The dbDNA system should, in theory, persist within a cell 
and express its transgenic cassette whilst being vulnerable to dilution by cell division 
alongside potential host cell silencing mechanisms.  
Early generation expression plasmids by design should share similarities within their 
functionality to the dbDNA system – with both being transiently designed expression 
vectors. The two systems do differ structurally, with the dbDNA system cutting out the 
presence of any bacterial sequences. The dbDNA system contains the desired 
transgene of interest only, alongside an incredibly short, clinical grade DNA backbone. 
While the plasmid contains the transgene of interest, alongside a plethora of bacterial 
DNA backbone.  
Our results demonstrated that when transiently transfected into a host cell, that the 
dbDNA system persists with a greater longevity. This provided the vector with a longer 
timeframe to express its transgenic cassette which provided us with hope for the 
dbDNA vectors translational potential into the field of iPSC development. A field where 
expression plasmids, under a single transfection, do not function to produce iPSCs; 
instead requiring a minimum of 2 transfections for the induction of pluripotency. 
Following the reduced functionality of the expression plasmid system, it was modified 
to contain the oriP-EBNA1 DNA sequence. This sequence would provide the plasmid 
with a scaffolding function, allowing it to tether to host cell chromosomes. This 
therefore increased the persistence of the plasmid and by virtue, the transgene 
expression period. This led to the success of the system as it is known today, being 
utilised in labs globally and in the few clinical trials which have since received approval. 
The functionality of the plasmid system however was totally dependent on the 
presence of oriP-EBNA1 and its chromosomal tethering capacity. Additional factors 
have also been added to the standard pluripotency cassette over time, with the aim of 
improving the efficiency of system within the induction of pluripotency in somatic cells. 
One common additive was the shp53 transgene, which is a short hairpin protein for 
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the p53 protein. This was determined to improve the efficiency of the reprogramming 
process but duly also increases the tumorigenic potential of the iPSCs it produces. 
All this to say, however, that our data demonstrated that the dbDNA system, which 
incorporated neither the oriP-EBNA1 system, nor the shp53 transgene could still 
function effectively within the reprogramming process much to our surprise and 
excitement. Despite being transient by design, the dbDNA system could function to 
produce iPSCs reliably, having successfully reprogrammed 11 different primary 
fibroblast cultures producing stable iPSCs from them all. The dbDNA vector functioned 
at an equivalent rate to that of the oriP-EBNA1 system within this process too, 
demonstrating a reprogramming efficiency that was not significantly different to that of 
its well-established counter-part. Moreover, the dbDNA vector could also reprogram 
and produce stable iPSC colonies from fibroblasts with which it had been previously 
unachievable with the oriP-EBNA1 system.  
Taken in its entirety we were able to demonstrate that the dbDNA system functions 
effectively, reproducibly and was moreover robust in its functional capacity. The oriP-
EBNA1 vector is utilised globally as aforementioned. For the dbDNA system to 
therefore match the oriP-EBNA1 vector in many functional aspects and even surpass 
it in certain elements was testament to the novel systems clear potential within this 
research area and beyond.    
We have been able to clearly evidence that the dbDNA system was highly functional 
within iPSC development. In this chapter we have also demonstrated that the iPSCs 
produced by this vector system were bona-fide by nature. iPSCs should be able to 
display a dual functionality, incorporating an ability to maintain a pluripotent 
phenotype, but, when required, also being able to differentiate into cells of all three 
germ lineages. We were able to demonstrate such properties using several different 
techniques; ICC and RT-PCR was used to determine the cells pluripotent status and 
likewise ICC was utilised to demonstrate the cells differentiation capacity as well. All 
of which were successful in dbDNA produced iPSCs. 
We attempted to incorporate the dbDNA system into the reprogramming of cell types 
outside of fibroblasts. However, the dbDNA system displayed shortcomings in this 
area, being unable to reprogram neither cells isolated from blood or urine where the 
oriP-EBNA1 system could. The urine reprogramming process was not entirely 
136 
 
reproducible, and the blood reprogramming did yield an ‘in-between’ partially 
reprogrammed phenotype. Duly, these experiments are not the be-all-and-end-all the 
matter and this isn’t to say that the dbDNA system won’t have successes within these 
cell types. The data we produced, provided evidence to suggest that the dbDNA 
system had at least some effect on the adherent PBMCs when reprogramming blood. 
We did attempt several titrations changing the number of cells plated and the 
concentrations of DNA nucleofected but with no further success. The process, 
however, with more work titrating factors such as the transfection process and the 
number of transfections utilised may still be successful yet for the dbDNA system – 
this was by no means the end of the road for this vector within this process. 
The dbDNA system was also applied to a xenofree fibroblast reprogramming protocol. 
This protocol incorporated the use of animal-free constituents and has been described 
to be a stumbling point for different vectors being applied to the field. This is an 
important process as cells that are to be utilised clinically must be reprogrammed using 
this methodology in order to limit the transfer of animal-borne diseases to the cultured 
fibroblasts. The aim of our entire project was to utilise this novel dbDNA vector, which 
can be considered much ‘cleaner’ than its successful counterpart, in order to attempt 
to aid the transition of this cellular technology to the clinic on a more routine basis than 
exists now. The dbDNA system was successful in this process, producing stable 
primary colonies that when cultured, underwent positive pluripotent marker staining 
for SOX2. The success demonstrated by ourselves when applying the dbDNA system 
within this protocol was a great achievement and demonstrated that, pending a 
number of other mandatory thresholds, that the dbDNA system can be applied within 
the production of clinical grade iPSCs.  
Having demonstrated successes in the development of iPSCs using the dbDNA 
system, another core aim of the project was to determine differences in the 
transcription on a global level between the two iPS cell types by using a microarray 
analysis. Differentially expressed genes (DEGs) were incorporated into several 
software which then aligned the DEGs with different biological processes. Using this 
analysis, we were able to demonstrate that DEGs presented by oriP-EBNA1 produced 
iPSCs aligned to largely immune and pro-inflammatory pathways. EBNA1 produced 
iPSCs demonstrated significant alignments to Interferon signalling, iPSC 
differentiation and DNA damage. Further work then clarified a distinct trend of an 
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increased level of STAT1 transcription secondary to transfection of the oriP-EBNA1 
vector. Previous literature had demonstrated that an increased STAT1 transcription 
and nuclear localisation was initiated following EBNA1 protein expression. This 
ultimately increased the cells susceptibility for interferon expression (Wood et al., 
2007). In regards to the transcriptional alignment of oriP-EBNA1 over-represented 
genes to cellular differentiation, we demonstrated that oriP-EBNA1 produced iPSCs 
had an increased differentiation phenotype in culture. The dbDNA produced iPSCs 
demonstrated a more consistent retention of AP stain (which was excluded from areas 
of spontaneous differentiation) than EBNA1 produced iPSCs. This phenotype was 
demonstrated to persist irrespective primary fibroblasts cultures used and across 
several iPSC passages as well. This implied that the differentiation phenotype 
potentially existed secondary to the vector utilised to develop the iPSCs. This was a 
key attribute for the dbDNA system as the maintenance of pluripotency and iPSC 
quality is key to any cells downstream clinical use. Again, secondary to the microarray 
analysis we demonstrated a clear phenotype of an increased incitement of DNA 
damage within oriP-EBNA1 transfected cells in comparison to dbDNA transfected 
cells. The result from the comet assay highlighted that oriP-EBNA1 transfected cells 
exhibited an increased level of DNA damage (Tail DNA, comet length & Tail moment) 
to a significant degree. Likewise, dbDNA transfected cells retained a greater level of 
intact DNA (Head DNA) to a significant degree. To substantiate this, a second 
complimentary analysis in relation to DNA damage was undertaken. ICC was carried 
out utilising a γ-H2AX antibody. The antibody localises and forms foci at areas of 
variant H2A which develop specifically following a double-strand DNA break and DNA 
damage. The foci can then be quantified allowing an insight into the proportion of DNA 
damage being incited within a cell. From this analysis, we demonstrated a significant 
and consistent increase in the number of foci in oriP-EBNA1 transfected cells in 
comparison to dbDNA transfected cells. Overall, we were able to clearly show that the 
oriP-EBNA1 vector resulted in an increased level of DNA damage incitement/reduced 
DNA damage repair in comparison to dbDNA transfected cells which maintained a 
greater level of genomic integrity.  
DEGs isolated from the microarray experiment which were over-represented in dbDNA 
iPSCs were also analysed using several software to determine what biological 
processes the DEGs interacted within. It was clear from the analysis that the genes 
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over-represented within dbDNA-produced iPSCs interacted in biological processes 
mainly associated with the cell cycle. Most of these functionalities were in relation to 
cell cycle checkpoints and cell cycle progression. We therefore carried out a cell cycle 
analysis which incorporated the use of PI, a stain which intercalates within cellular 
DNA to determine different cell cycle phases by using flow cytometry. The results 
exhibited a clear trend and demonstrated an increased level of cells within the G0/G1 
phase in dbDNA iPSCs and, albeit to a lesser degree, G2/M in EBNA1 produced 
iPSCs. Taken on its own it is difficult to discern too much from the cell cycle experiment 
without more corroboratory evidence. That said, alterations to the dbDNA vectors 
transgenic cassette may help to clarify why differences were exhibited in the cell cycle 
assay. The dbDNA vector didn’t incorporate the p53 short-hairpin protein which 
disrupts and minimises p53 protein expression. The p53 protein will function during 
cell cycling to inhibit its progression dependant upon the integrity of cellular DNA. If a 
cell is exhibiting DNA damage, the p53 protein is capable of inhibiting cell cycle 
progression between G1 and S phases and between G2 and M phases. The 
incorporation of the short-hairpin protein which inhibited p53 translation in oriP-EBNA1 
iPSCs and the lack of such shRNA transgene in the dbDNA system may be the 
determining factor for such differences exhibited between the two cell types in terms 
of their cell cycling 
 
2.1.11. Future Work:  
 
Future work should be in relation to elucidating the dbDNA systems potential to 
integrate within the genome and in relation to optimising protocols for the systems use 
in reprogramming primary cell types other than fibroblasts.  
There is a great importance behind determining the potential for the dbDNA system to 
integrate within the genome of the iPSCs it produces. As mentioned, the insertion of 
vector DNA into the host genome can increase the likelihood for insertional 
mutagenesis and therefore diminish the potential to utilise the cells and vector for a 
clinical purpose. In terms of determining the potential for the dbDNA system to 
integrate within the genome, several experiments could be undertaken. With unlimited 
time and resources, the only way to unequivocally determine if the dbDNA system has 
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integrated into iPSC clones is via the use of whole genome sequencing. Whole exome 
sequencing could be employed to determine the presence of integrations within exons, 
but this technique ignores the potential for integrations outside of the coding regions 
of the genome. Hence, whole genome sequencing would be the only test to 
unequivocally exclude the possibility of integrations within the genome of any iPSC 
progeny. A more cost-effective method of potentially determining the presence and 
location of integrations would be to carry out a Linear amplification mediated-PCR or 
LAM-PCR. The method is often carried out to identify regions of viral DNA integrations 
via the identification of viral vector flanking genomic sequences. This system often 
relies on biotin-labelled primers for the viral vectors LTR. The positive DNA sequences 
are then magnetically captured before several PCR amplifications ensue. The process 
will have to be adopted to recognise dbDNA-specific sequences but should still 
function to positively identify any integrations.  
For the reprogramming of other primary cell types outside of fibroblasts, this was 
carried out with little success using the dbDNA system in blood and urine-derived cells. 
Further optimisation can be undertaken applying different nucleofection programmes, 
different transfection mechanisms and multiple transfections for example to increase 
the possibility of deriving iPSC from such primary cells using the dbDNA system.  
Moreover, a karyotyping analysis should also be carried out as part of the standard 
pluripotency assessment to ensure a lack of aneuploidy in the dbDNA produced iPSCs 
as part of a quality control assessment.  
Attempts to clarify any manipulation of STAT1 in an EBNA1-dependent fashion. Work 
to determine the localisation of STAT1 following transfection of both vector types to 
denote any nuclear localisation would help to clarify an increase in activation. Our data 
suggested no significant difference in transcription of STAT1 was exhibited following 
vector transfection, however we did not determine the level of phosphorylated STAT1 
or its localisation following nucleofection both of which would provide great insight into 
any differences exhibited between the vectors. Moreover, how the modulation of 
STAT1 interacts with the differentiation phenotype could also be further elucidated. 
This could be by STAT1 over-expression in a pluripotent cell type, such as ESCs for 
example, and denoting how this affects the cells pluripotent capacity.  
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In relation to the cell cycle analysis, future work should be to identify the mechanism 
behind differences between both cell types and their residence in different cell cycle 
phases. More cells in dbDNA produced iPSCs seemingly resided within the G0/G1 
phase of the cell cycle. There was a potential that this was in relation to an increased 
level of p53 which was present in dbDNA produced iPSCs due to the omission of the 
shp53 transgene from the vector. The p53 protein can function to upregulate p21 
expression to inhibit the passage of cells through the G0/G1 phase and into the S 
phase. Therefore, I believe that extra studies into p21 expression will help to provide 
a clearer image in relation to any differences in cell cycling between the two. Moreover, 
the microarray also indicated that the dbDNA system shows an increased alignment 
with the G2/M progression biological process. Again, the trend in the cell cycle 
experiment suggested that a greater proportion of oriP-EBNA1 produced iPSCs reside 
in the G2/M phase. It is possible that the oriP-EBNA1 produced iPSCs which were 
more resident in the G2/M phase may have been in an arrested phenotype. This in-
turn may ultimately result in an increased level of apoptosis. The microarray suggested 
that the oriP-EBNA1 produced iPSC gene expression specifically aligns with the 
biological process of apoptosis upon analysis using the GSEA software. Therefore, 
further analysis into the level of apoptosis between the two cell types could also be 
carried out. An annexin 5 antibody, which will target apoptotic cells specifically 
followed by a flow cytometry analysis could be undertaken to help substantiate if such 
reasons can help to explain the mechanism behind the differential cell cycling 














The process of reprogramming and iPSC development has been established for well 
over a decade now, following seminal work from the Yamanaka lab in Kyoto, Japan 
(Takahashi et al., 2007). They were able to describe the principles which ultimately 
led to the induction of pluripotency within somatic cells and the induction of a new 
scientific niche which would be studied globally. iPSCs are cell types which function 
based on two rudimental properties – perpetual self-renewal and a capacity to 
differentiate into cells of all three germ lineages. Such properties provide iPSCs with 
a multitude of downstream functional capabilities from organoid development to 
disease modelling, drug discovery and cell replacement therapy (Rao and Malik, 
2012). Despite being discovered over a decade ago, the progression of iPS-cell 
therapies into a clinical setting has been slow. This has been in relation to factors 
associated with safety concerns, a lack of efficiency developing a clinical grade iPSC 
line and issues with the scale-up of production of cells for clinical application.  
Genome integrating lentiviruses and onco-retroviruses present significant safety 
concerns when used therapeutically with insertional mutagenesis being at the forefront 
of such concerns. Initially, in 2007, the first human iPSC line developed was utilising 
an integrating retroviral vector by the Yamanaka lab. This method of iPSC 
development was functionally robust and reliable. In follow up experiments, the 
Yamanaka lab then developed mice progeny from iPSCs derived from the retroviral 
system, which harboured known vector integrations within host cell genomic DNA. 
Around 20% of the mice within the experiment developed tumours secondary to the 
re-activation of MYC-related transgenes (Okita et al., 2007). This was not the first 
instance in which the use of an integrating retroviral system had adverse secondary 
effects. In 2003, correction of X-linked SCID by ex vivo, retrovirally mediated transfer 
of the γc gene in CD34+ cells was undertaken. Patients treated within this cohort 
developed leukaemia and/or sarcoma secondary to vector mediated integrations 
within the CD34+ cells genomic DNA (Hacein-Bey-Abina et al., 2003). Despite the 
latter of the two providing adverse events not being directly related to iPSCs 
specifically, such effects secondary to the use of integrative vectors demonstrated the 
142 
 
need for non-genome integrating systems to aid any potential clinical translation of 
iPSC therapies.  
The research into the development of non-integrating reprogramming vectors yielded 
a multitude of different candidates each with differing levels of success. Research 
grade iPSC lines were produced using a number of non-integrating systems such as 
Sendai virus, mRNA, protein transfection and mini-circle vectors (Haridhasapavalan 
et al., 2019). However, the vector which has received the most widespread use within 
the field leading to it becoming the gold standard of pluripotency induction was the 
oriP-EBNA1 system. The oriP-EBNA1 system was first described in the context of 
iPSC development in 2009, being a system which functioned footprint free leaving 
behind no signs of plasmid or transgene sequence in a host cell with no vector 
mediated integrations (Yu et al., 2009). The oriP-EBNA1 system soon became 
solidified as the gold standard of pluripotency, displaying a functionality that ultimately 
bettered that of its above-mentioned rivals. The plasmid system was able to reprogram 
several different primary cell types (fibroblast, blood, urine) to iPSCs, conveyed a 
relatively competitive reprogramming efficiency and required only a single transfection 
to initiate iPSC development. This makes the plasmid system and its incorporation into 
the reprogramming niche simple, non-laborious and incredibly cheap. A culmination 
of all these factors clearly exhibited the reasons why the oriP-EBNA1 system was 
subsequently more readily adopted than any other reprogramming system.  
The oriP-EBNA1 vector was developed following the failings of previous attempts to 
apply standard plasmid vectors to reprogramming and iPSC development (Okita et al., 
2008; Si-Tayeb et al., 2010).The oriP-EBNA1 system was designed to incorporate a 
standard plasmid DNA backbone with the addition of the oriP & EBNA1 sequences. 
As mentioned, the oriP-EBNA1 sequence conferred a tethering function to standard 
plasmid-based systems. The vector could then be maintained through cell divisions by 
segregating with the host chromosomal DNA during normal mitotic events. This 
therefore prevented the dilution of transient plasmid vectors during mitosis within 
highly proliferating cell systems, such as cells which are undergoing reprogramming 
(Yu et al., 2009; Hodin et al., 2013; Okita et al., 2013; Drozd et al., 2015). The addition 
of such sequences increased the plasmids retention, thereby benefiting both the 
plasmids transgene expression period and its functional capacity for pluripotency 
induction. The development of this vector system had been a key catalyst in the 
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progression of a number of clinical trials. Clinical grade iPSC lines produced from the 
oriP-EBNA1 system have, insofar, been the only cells utilised in all clinical trials 
incorporating iPSC/iPS-based therapies. This clearly demonstrated how vital this 
system was to the translation of iPSCs to the clinic. Yet, despite this, only 6 clinical 
trials incorporating iPSCs have been undertaken globally as opposed to 26 using 
ESCs (Eguizabal et al., 2019). This highlights the nature of the shortfall in terms of 
iPSC translation; with the reprogramming plasmid vector being implicit within this.  
The oriP-EBNA1 system is a plasmid-based vector and so incorporates a bacterial 
DNA backbone and bacterial selection coding sequences. Bacterial DNA has long 
been recognised as potentiating unwanted, pro-inflammatory effects within host cells, 
mediated by interactions with Toll like receptors (TLRs) (O’Neill et al., 2013). Likewise, 
the oriP-EBNA1 plasmid system also incorporated the EBNA1 protein. Derived from 
the potent oncovirus EBV, the EBNA1 protein functions synergistically with the oriP 
sequence to physically scaffold the plasmid to host cell chromosomes; a function 
which has been paramount to the systems success (Yu et al., 2009). However, recent 
literature suggested that the EBNA1 protein specifically has a number of unwanted 
interactions within host cells being responsible for potentiating pro-inflammatory 
responses; evoking the production of reactive oxygen species (ROS) and ultimately 
inciting DNA damage (Wood et al., 2007; Gruhne et al., 2009). The reprogramming 
factors incorporated into a vector can also have huge downstream implications with 
respect to the cell’s translational potential. The oriP-EBNA1 system incorporated an 
shRNA against the p53 protein during reprogramming. The p53 protein, often referred 
to as the guardian of the genome, has several functionalities which support its title. 
Namely, p53 exhibits a rate-limiting function in relation to the cell cycle process. During 
reprogramming, cells which develop a pluripotent phenotype often become 
hyperproliferative (Kapinas et al., 2013). During the cell cycle process there are a 
number of checkpoints at which cells are held to ensure their genomic integrity before 
being allowed to proceed. The p53 protein is responsible for checkpoints in relation to 
allowing cells to progress through to the S phase and the M phase of cell cycling prior 
to mitosis (Chen, 2016). Cells which are deemed to be unfit to progress, potentially 
secondary to DNA damage for example, will often undergo apoptosis mediated again 
by the p53 protein (Zhao and Xu, 2010). It was therefore hypothesised and evidenced 
that by including the shp53 sequence within the reprogramming vector, thereby 
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reducing the level of the p53 protein, that this would improve the reprogramming 
efficiency (Hong et al., 2009). This was evidenced to be true and independently 
corroborated (Hong et al., 2009; Marión et al., 2009; Rasmussen et al., 2014). Yet, the 
greater functional efficiency achieved by incorporating the use of the shRNA for p53 
does come at a cost. An increase in tumorigenicity of the iPSCs developed has been 
reproducibly demonstrated highlighting limitations to the cells downstream potential 
for clinical use (Chin et al., 2009; Marión et al., 2009; Zhao and Xu, 2010; Merkle et 
al., 2017). Taken in its entirety, it’s clear that the development of the oriP-EBNA1 
plasmid system has helped to progress iPSC technology and iPS cell therapies from 
a proof-of-principle technology into a clinically viable treatment modality. However, the 
number of clinical trials incorporating iPSCs is much lower in comparison to its 
pluripotent counterpart, ESCs. The oriP-EBNA1 vector has been suggested to be at 
least partly accountable for such a shortfall due to some of the above-mentioned 
pitfalls of the system being responsible which should not be ignored. 
The Doggybone (dbDNA) system is a clinical grade DNA vector first produced and 
patented by Touchlight Genetics in 2008. The system employs a minimal DNA 
backbone of just two short 28bp telomeric caps which flank a sequence of interest. 
The vector was designed as a transient system which does not incorporate any 
bacterial DNA or the EBNA1 sequence alike. Reprogramming vectors produced using 
the dbDNA system by Touchlight Genetics utilised the same transgenic cassette as 
the oriP-EBNA1 vector but omitted the inclusion of the shRNA to p53. We therefore 
had a system with 3 key differences to the plasmid gold standard:  
1. The dbDNA system negated the inclusion of any bacterial DNA as opposed to 
the oriP-EBNA1 system which contained a bacterial DNA backbone and 
bacterial antibiotic resistance selection cassettes.  
2. The oriP-EBNA1 plasmid included the EBNA1 protein which was absent from 
the dbDNA system.  
3. The dbDNA system did not incorporate the shRNA for p53 within its transgenic 
cassette while the oriP-EBNA1 system did. 
The over-arching aim of my project was therefore to determine the functional 
capabilities of the Doggybone (dbDNA) system within somatic cell reprogramming and 
iPSC production. Following any success in iPSC induction, experiments to elucidate 
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any differences or benefits conferred by using the bacterial, viral and shp53-free 
dbDNA system should also be undertaken.  
 
3.1. Somatic cell reprogramming, pluripotency induction and functional capacity:  
 
The Doggybone (dbDNA) expression system is a monomeric, double-stranded, linear, 
covalently closed DNA construct that can be generated to clinical Good Manufacturing 
Practise (cGMP) standards. The vector was produced enzymatically beginning with a 
plasmid template which was ultimately reduced to a desired transgenic sequence 
inside a covalently closed system – excluding any bacterial DNA (Karbowniczek et al., 
2017). The rationale behind using a vector system of this kind within the remit of 
somatic cell reprogramming was clear when the current vectorology was considered. 
As detailed earlier, there has been a vast array of reprogramming vectors that have 
been applied to iPSC development with differing levels of success (Borgohain et al., 
2019; Haridhasapavalan et al., 2019). These vector types have largely involved the 
adoption and manipulation of virus or bacterial plasmid DNA. The current pluripotent 
gold standard vector that has been adopted globally is the oriP-EBNA1 plasmid 
system (Yu et al., 2009).  
Standard expression plasmid with a CAG promoter to drive strong transgenic 
expression was initially adopted into the reprogramming process a year before the 
oriP-EBNA1 system. Despite being successful in iPSC development, its colony 
forming efficiency was unsustainably low (~0.0001-0.0029%) (Okita et al., 2008; Si-
Tayeb et al., 2010). This vector was therefore modified to contain the oriP-EBNA1 
system, which allowed the plasmid to physically scaffold itself onto host cell 
chromosomal DNA. The functional advantage of a prolonged expression period has 
demonstrated a far improved efficiency in comparison to standard expression plasmid 
and an adoption of this reprogramming method globally (Yu et al., 2009; Okita et al., 
2013; Wang et al., 2013). The dbDNA system shares a greater likeness with standard 
expression plasmid as opposed to the oriP-EBNA1 system. The dbDNA vector, in 
theory, is a non-integrative vector with no additional scaffolding potential. As such, the 
main functional concern when applying dbDNA to iPSC reprogramming in this project 
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was surrounding the transiency of the system and a potential for a reduced 
functionality (Okita et al., 2008; Si-Tayeb et al., 2010; Haridhasapavalan et al., 2019).  
The dbDNA system however was successful when applied to the McKay lab protocol 
for reprogramming and iPSC development – reprogramming a total of 11 different 
primary fibroblast cultures (Hawkins et al., 2016). Our data demonstrated that the 
dbDNA vector was robust and reproducible in the induction of pluripotency within 
fibroblasts. The system functioned with a higher success rate than the oriP-EBNA1 
system and with a non-significantly different reprogramming efficiency. The literature 
suggested that a reprogramming efficiency of <0.01% was a very low reprogramming 
efficiency, with 0.01-0.1% considered as low and >0.1% considered as a high 
reprogramming efficiency (Haridhasapavalan et al., 2019). The oriP-EBNA1 system 
was consistently denoted to express a reprogramming efficiency that was considerably 
lower than its fellow reprogramming counterparts (Yu et al., 2009; Rao and Malik, 
2012; Schlaeger et al., 2015; Borgohain et al., 2019). In a direct comparison, 
reprogramming experiments were carried out within the Daley lab incorporating the 
oriP-EBNA1, Sendi virus and mRNA reprogramming methods. The oriP-EBNA1 
system displayed the lowest average reprogramming efficiency (0.013%) before Sendi 
at 0.77%, with mRNA having the highest reprogramming efficiency at 2.5% (Schlaeger 
et al., 2015). When projected into the efficiency categories outlined by 
Haridhasapavalan, the oriP-EBNA1 system has a low reprogramming efficiency and 
comparatively to other non-integrating vectors it was also considerably lower. This 
could be due to several reasons. Yet, the mRNA system, displayed what seemed to 
be a high reprogramming efficiency, but the protocol associated with this method of 
reprogramming was time-consuming, arduous and difficult to replicate. The mRNA 
system relies on daily transfections of its reprogramming factors and the use of 
chemicals to supress the transfected cells immune response to the system. The 
efficiency of iPSC production using the oriP-EBNA1 system was objectively lower to 
that of mRNA, however, the reprogramming process was much more simplistic and 
less time-consuming, owing only to a single transfection. A delicate balance clearly 
existed in relation to reprogramming efficiency and the workload and reproducibility of 
the protocol. However, despite having a reprogramming efficiency lower than other 
non-integrating vectors, the oriP-EBNA1 system has made the biggest steps, being 
adopted globally and utilised in all approved iPSC clinical trials (Eguizabal et al., 2019). 
147 
 
The reprogramming efficiencies achieved by both the dbDNA and oriP-EBNA1 system 
in our experiments was 0.13% and 0.16% respectively. According to the 
Haridhasapavalan classifications the dbDNA system would be deemed to have a high 
reprogramming efficiency (Haridhasapavalan et al., 2019). However, in relation to 
other non-integrative reprogramming systems, its reprogramming efficiency was on 
the lower end of the scale. That said, it was clear that the efficiency at which a vector 
can reprogram was not the cornerstone of the technologies potential to be translated 
to the clinic – as the vector with one of the lowest relative efficiencies was recognised 
as the gold standard of the field. As previously stated from our dataset, the dbDNA 
system displayed a success rate that was greater (92%) than the oriP-EBNA1 vector 
(84%) in relation to the 12 different primary fibroblast cultures which underwent 
reprogramming using both vectors. In context with other reprogramming vectors the 
oriP-EBNA1 system displayed a high reprograming success rate and reproducibility 
within the reprogramming of fibroblasts. The oriP-EBNA1 plasmid displayed a 93% 
success rate as opposed to a 27% and 94% success rate for mRNA and Sendi 
respectively in experiments outlined by the Daley lab (Schlaeger et al., 2015). In 
relation to the literature and by the experiments carried out by Schlaeger, the dbDNA 
system displays a competitively high success rate when compared to both integrating 
and non-integrating vectors. Despite differences between the vectors structurally, the 
dbDNA and oriP-EBNA1 systems were incorporated into identical protocols to yield 
the results obtained during this project. A novel facet of the literature published by the 
Daley lab was that they carried out a survey across 149 laboratories who were involved 
in iPSC research, 94 of which the author determined to be ‘experienced’ within the 
field. The survey was used established the success rate for the oriP-EBNA1, mRNA 
and Sendi vectors in the reprogramming of fibroblasts. Across 22 labs, the mRNA 
method had a 59% success rate, Sendi across 35 labs had a 97% success rate and 
the oriP-EBNA1 system across 21 different, ‘mixed ability’ laboratories displayed a 
100% success rate (Schlaeger et al., 2015). This demonstrated that, irrespective of 
experience, the reconstitution of pluripotency using the oriP-EBNA1 system was a 
reproducible process. Inferences from this were that the protocol in relation to iPSC 
development using the oriP-EBNA1 system was basic and simplistic enough to be 
carried out in labs globally without error. As mentioned, the dbDNA system 
incorporated the same protocol as the oriP-EBNA1 system. Thereby, in theory, if 
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incorporated into iPSC labs globally the dbDNA system could also work flawlessly 
irrespective of lab user experience. The literature substantiated the idea that the 
dbDNA system not only functionally matched the oriP-EBNA1 system but could also 
be potentially implemented in labs globally without fault.  
Moreover, one of the omitted factors from the dbDNA system was in relation to its lack 
of shRNA for the p53 protein which was present in oriP-EBNA1 iPSCs. The shRNA 
will interfere with p53 translation and protein expression following shp53 expression. 
This results in a reduction/loss of p53 function during the reprogramming process and 
iPSC development. The literature surrounding the function of p53 during 
reprogramming and its resulting effects on its iPSC progeny is conflicting. It was first 
theorized and evidenced in the Yamanaka lab in 2009 that the interactions between 
p53 and p21 resulted in a reduction in reprogramming efficiency. Moreover, the 
publication suggested that using the knock-down of p53 during reprogramming 
experiments could still yield integration-free iPSCs but at a greater reprogramming 
efficiency (Hong et al., 2009). Literature has since been published supporting the 
theory that p53 expression demonstrated a suppressive function in terms of 
reprogramming success and efficiency (Marión et al., 2009; Yi et al., 2012; 
Rasmussen et al., 2014). Experiments outlined in the Claussen lab described that 
reprogramming with the p53 shRNA yields around a 6-fold increase in colony 
production bringing the reprogramming efficiency, using oriP-EBNA1 plasmid, to 
~0.12% (Rasmussen et al., 2014). The results mirror reprogramming efficiencies 
obtained when using the plasmid system with a shp53 transgene as outlined in our 
results - with reprogramming efficiencies persisting at around 0.16%. The work 
published by Claussen also detailed that they see no compromise to the integrity of 
cellular DNA by using flow cytometry in conjunction with a γ-H2AX antibody at regular 
timepoints in fibroblasts following the initiation of reprogramming. However, conflicting 
reports clearly detailed that the loss of p53, despite increasing the reprogramming 
efficiency, compromised the genomic integrity of the iPSC progeny produced when 
reprogramming in this manner. The Blasco lab provided a detailed report, evidencing 
that during the reprogramming of fibroblasts to iPSCs, that the shRNA for p53 
abrogated apoptosis onset, as demonstrated by a flow cytometry analysis using an 
Annexin A5 antibody. Moreover, the publication also outlined that the cells during and 
following successful reprogramming with a shRNA for p53 demonstrated an increased 
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level of DNA damage. ICC using a γ-H2AX antibody and foci quantification, 
accompanied by chromosomal end-to-end fusion analysis was undertaken. Both of 
these types of analysis detected increased levels of DNA/chromosomal damage in 
cells incorporating shRNA in comparison to control cells (Marión et al., 2009). Despite 
some reports suggesting that reprogramming with p53 results in no genetic 
aberrations, it was seemingly more broadly accepted that the process can result in the 
propagation of iPSCs with DNA damage and can limit the cells clinical applicability. 
The premise of our project was in relation to the dbDNA systems ability to produce 
safer iPSCs. It was determined that the shRNA for p53 should therefore be omitted 
from the dbDNA sequence. What was surprising about the results obtained when 
reprogramming using the dbDNA sequence in comparison to the oriP-EBNA1 system 
was that the Doggybone vector was able to reprogram and produce iPSCs at an 
efficiency that was not significantly different to that of the EBNA1 vector. This result 
requires further work to truly elucidate the mechanistic reasoning behind it. However, 
what was clear was that the dbDNA system was able to reprogram and produce iPSCs 
at a greater basal rate than the plasmid-based alternative as studies detailed a large-
scale increase in reprogramming efficiency following the inclusion of the p53 shRNA 
to levels of that exhibited by the dbDNA vector without the shp53 sequence 
(Rasmussen et al., 2014). A hypothesis for this could be that, as demonstrated by 
ourselves, the dbDNA vector incited less DNA damage following cellular transfection 
than the oriP-EBNA1 vector; with EBNA1 being well established in the induction of 
DNA damage (Gruhne et al., 2009). It is therefore within reason to hypothesise the 
grounds behind the increased basal reprogramming efficiency exhibited when using 
the dbDNA system was in relation to evidence that the system initiates less DNA 
damage. In turn the dbDNA system would potentiate a far reduced p53 response and 
subsequent limit on cellular reprogramming than what would be exhibited when 
utilising the oriP-EBNA1 plasmid without the shp53. As mentioned, however, large-
scale experiments would be required to elucidate the real mechanistic reasoning 
behind this result.  
Taken in its entirety, the results obtained by ourselves in conjunction with the literature 
demonstrated that the ability of dbDNA system to function in iPSC development was 
an extraordinary result. The vector, according to ourselves and the literature, 
functioned with a relative equivalence to that of the oriP-EBNA1 system. On a broader 
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scale, the reprogramming efficiency may not be high, relative to other reprogramming 
systems, but neither was that of the oriP-EBNA1 system which has still managed to 
be recognised as the pluripotent gold standard globally. However, the dbDNA system 
structurally contained no shp53 transgene and was designed to be a non-integrative, 
transient system with no scaffolding ability. Therefore, despite these factors, which 
previous literature has described as having fundamental effects on the efficiency of 
iPSC colony formation, the dbDNA system was still able to function at a similar rate to 
that of the oriP-EBNA1 system. This was an incredibly exciting achievement which 
places the dbDNA system in good stead for further development within the 
reprogramming field.  
 
3.2. Increased retention of the dbDNA system and interactions with host cell innate 
immunity:  
 
So far, I have demonstrated that the dbDNA system can reproducibly reprogram 
fibroblasts producing bona fide iPSCs. The vector did so without the need of any 
scaffold attachment proteins to improve its retention, as the oriP-EBNA1 system did. 
Previous literature provided substantiating evidence that a standard expression 
plasmid was not functionally apt within reprogramming, displaying a low success rate 
and efficiency (0.0001-0.0029%) (Okita et al., 2008; Si-Tayeb et al., 2010; 
Haridhasapavalan et al., 2019). To determine and substantiate the novelty of the 
dbDNA vectors functionality within iPSC production, a large-scale re-programming 
experiment was carried out. This experiment employed the dbDNA vector, oriP-
EBNA1, an expression plasmid (without oriP-EBNA1) and a GFP plasmid for a 
negative control. The results from that experiment demonstrated viable, AP positive 
colonies were produced from dbDNA and oriP-EBNA1 nucleofected fibroblasts and no 
AP positive colonies in the expression plasmid or negative control. The results from 
this experiment provided further evidence supporting the novel nature of the ability of 
the dbDNA system to induce pluripotency in fibroblasts. The oriP-EBNA1 null plasmids 
employed in this experiment were polycistronic vectors employing the same factors as 
both the dbDNA and oriP-EBNA1 systems, with each transcript being separated by a 
2A sequence. Previous literature has suggested a need to employ multiple 
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transfections for the successful function of expression plasmid systems in iPSC 
development, owing to the vectors transient nature (Okita et al., 2008). This was true 
also of polycistronic plasmids which were demonstrated to produce iPSCs from human 
dermal fibroblasts again at the expense of more than one transfection timepoint (Si-
Tayeb et al., 2010). Therefore, the lack of AP-positive iPSC development from 
expression plasmids within the McKay lab protocol, which incorporated a single 
transfection was understandable. During reprogramming it had been demonstrated 
that strong transgenic expression was required for a minimum of 12 days in order to 
induce the development of primary iPSC colonies (Brambrink et al., 2008). It was clear 
from our results in conjunction with previous literature, that expression plasmid was 
too transient in nature to fulfil a sustained transgenic expression over this required 
time period following a single transfection; multiple transfections were necessary. 
However, the dbDNA system was clearly capable of expressing its transgenic cassette 
beyond the stipulated 12-day period and could successfully induce iPSC development 
from a single transfection, despite being designed as a transient system.  
The ability of the dbDNA vector to produce iPSCs, concurrent to the expression 
plasmids failure to do so, highlighted the novelty of Doggybones functionality within 
the context of reprogramming. Such data was indicative of a difference within host cell 
recognition of the dbDNA system in comparison to traditional plasmid vectors. The 
dbDNA vector seemingly displayed an increased retention in comparison to the 
plasmid-based system in order to be able to reconstitute pluripotency within somatic 
cells. Results procured by ourselves indicated that the dbDNA system had a more 
prolonged expression timeframe and an increased intensity of expression over its 
plasmid counterpart. Both the dbDNA system and expression plasmid are transient 
vectors by design, therefore the increased longevity of expression within the dbDNA 
system suggested a greater retention of this vector type within cells, or inversely, a 
more prompt dilution/silencing of the expression plasmid. Both vector types shared an 
identical transgenic sequence and subsequently produce the same protein (GFP) too. 
The difference between the two vectors was structural, being in relation to the 
presence/absence of a bacterial DNA backbone. The expression plasmid was the 
template structure used when producing dbDNA from rolling circle amplification (RCA) 
and so was structurally very similar to the Doggybone system. The only difference 
between the two systems was that the bacterial DNA backbone outside of the 
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transgenic sequence in the plasmid was omitted from the Doggybone vector 
(Karbowniczek et al., 2017). It was therefore reasonable to rationalise that the 
difference in retention between the two systems was dependent upon the remaining 
bacterial DNA in the expression plasmid and its interaction within the transfected host 
cell; an interaction that the bacterial DNA-free dbDNA system was able to bypass.  
The enzymatic method of producing the novel dbDNA vector relies on the presence of 
a plasmid starting template but ultimately produces a product that is devoid of plasmid 
backbone DNA, CpG motifs and antibiotic-resistance genes that are required for the 
bacterial propagation of plasmid DNA (Karbowniczek et al., 2017; Allen et al., 2018). 
First hypothesized in 1989, much evidence has been developed to underpin the 
presence of an inherited cellular recognition domain (Pattern Recognition Receptor – 
PRR) capable of detecting pathogenic associated molecular patterns (PAMPs) 
(Dempsey and Bowie, 2015). Moreover, the discovery of Toll like receptors (TLRs) 
provided a further mechanistic foundation for pathogenic detection and ultimately an 
inflammatory cellular response (O’Neill et al., 2013). In 2000, a PRR was implicated in 
the detection of double-stranded (ds) DNA, TLR9. This toll like receptor functions in 
response to the abundance of unmethylated DNA (CpG motifs) present in bacterial 
DNA before inducing cytokine expression whose function ultimately terminates with 
an increased propensity for interferon expression (Hemmi et al., 2000). The incitement 
of such an inflammatory response was likewise associated with an increased level of 
plasmid removal and transgene silencing - whereby the plasmid was still present but 
its expression becomes redundant (Qin et al., 1997; Yew et al., 2000). Work has been 
carried out to determine the ability of the TLR9 system to recognise and potentiate a 
downstream inflammatory response in relation to the dbDNA vector (Allen et al., 2018). 
Experiments detailed by the Savelyeva lab incorporated the use of a HEK293T cell 
line over-expressing the TLR9 bacterial DNA recognition receptor. When the TLR9 
over-expression line interacted with a piece of DNA yielding a positive result the cell 
line produced a secreted alkaline phosphatase (SEAP) which could be quantified. The 
results demonstrated clear experimental evidence that the dbDNA vector bypassed 
recognition by TLR9 receptors when transfected into the overexpression HEK293T 
cells. While plasmid DNA potentiated close to 5-fold increase in SEAP levels – 
indicating activation and processing of the plasmid by the TLR9 receptor. Moreover, 
this effect was quashed following the inhibition of TLR9 function suggesting the 
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plasmid processing was TLR9 specific (Allen et al., 2018). It was reasonable to 
therefore rationalise that the reduced retention and intensity of plasmid expression 
within our experiments was due to the processing of the plasmid bacterial DNA 
backbone via TLR9 systems. This, in turn, would result in an increased potential for 
transgene silencing in combination with plasmid dilution which ultimately reflects a 
reduced functionality. From this initial dataset obtained by ourselves in conjunction 
with the literature, it was clear that the dbDNA system potentiated a much-reduced 
pro-inflammatory cellular environment in comparison to expression plasmid. This 
conveys positive functional benefits to the Doggybone vector in terms of its longevity 
of expression and increased functionality within the reprogramming niche.  
The literature has demonstrated that the oriP-EBNA1 plasmid system is an incredibly 
robust vector in terms of its ability to reprogram fibroblasts alongside a number of cell 
types from different somatic sources (Zhou et al., 2012; Okita et al., 2013). The 
increased efficacy and efficiency of the vector was, without doubt, due to the nature of 
the scaffolding abilities incited by the inclusion of the oriP-EBNA1 system (Yu et al., 
2009). The literature detailed how plasmid systems without any tethering abilities were 
more susceptible to a reduced functionality secondary to increased vector dilution 
and/or transgene silencing. It was ubiquitously recognised within the literature that 
plasmid dsDNA was processed by a host somatic cell via the TLR9 system; initiating 
a proinflammatory response (Yew et al., 2000; Bauer et al., 2001; Allen et al., 2018). 
It is therefore reasonable to postulate that the pro-inflammatory response to the 
plasmid was the mediator of its reduced functionality within somatic cells. However, 
now with the inclusion of the oriP-EBNA1 system within the same plasmid framework, 
this provided the vector with an increased retention and as such an increased 
efficiency in terms of its scope for iPSC development. Yet, it is important not to 
overlook the fact that such vectors will still be potentiating the same inflammatory 
response as before, however, with the new scaffolding system this reduced the 
potential for plasmid dilution. More, the host cell will be subjected to a persistent, 
unwavering pro-inflammatory signature. 
The above data and supporting literature provided the foundations for the hypothesis 
that upon developing iPSCs from both the dbDNA and oriP-EBNA1 systems, that one 
difference between these two cell types could be in relation to the incitement of a pro-
inflammatory microenvironment on a vector specific basis. To begin to clarify any 
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differences in relation to inflammation and beyond, it was determined that a large-
scale experiment was the optimal approach and as such a microarray analysis was 
undertaken. This would provide information on the cell’s probed transcriptomics on a 
more global level as opposed to trying to pinpoint specific genes in a more bias 
manner.  
The microarray analysis yielded global transcriptional changes between oriP-EBNA1 
and dbDNA iPSCs. This was reproducibly demonstrated using R studio to produce a 
correlogram, principle component analysis and volcano plot which demonstrated such 
changes. Further analysis incorporating over-represented probes for dbDNA and oriP-
EBNA1 iPSCs alike into a heatmap was undertaken. This was carried out alongside 
the pluripotent gold standard ESC and it was clear that iPSC over-represented probes 
were being manipulated in a vector specific manner. The data demonstrated that the 
oriP-EBNA1 over-represented probes were significantly downregulated in dbDNA 
iPSCs. The expression of the same probes in ESCs demonstrated a more similar 
expression pattern to that of dbDNA iPSCs than that of oriP-EBNA1 iPSCs; 
determined hierarchical clustering. This suggested that probes that were over-
represented in oriP-EBNA1 iPSCs were largely done so specifically within that cell 
type and not in dbDNA iPSCs or ESCs. It was therefore reasonable to hypothesize 
that such probes were being over-expressed secondary to the internal processing of 
reprogramming vector adopted. The same analysis for dbDNA iPSC over-represented 
probes provided a similar outcome, with several probes being manipulated in a vector 
dependent manner. 
To have iPSCs produced from the same primary fibroblast cultures using different 
vectors providing different global transcriptomic profiles was not uncommon. Work 
published from the Wu lab analysed the global transcriptomics of iPSCs produced 
using 6 different reprogramming vectors (episomal plasmid, mRNA, mRNA + miRNA, 
minicircle vector, lentivirus & Sendi virus) and demonstrated that key global 
differences existed within each vector type in relation to each other and in relation to 
ESCs using a PCA (Churko et al., 2017). Moreover, the PCA also denoted a relatively 
vast level of variation amongst the global genomes within iPSCs produced using the 
oriP-EBNA1 system alone highlighting the vectors inability to accurately recapitulate 
pluripotency within fibroblasts. The Wu lab also quantified such differences using a 
correlogram and demonstrated key transcriptional differences between iPSCs 
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produced using different vectors. It was therefore evident that the vector of choice can 
influence variability amongst iPSCs produced from the same fibroblasts (Churko et al., 
2017). For ourselves what was more illuminating was how the differentially expressed 
genes interacted within different biological processes. This type of analysis provided 
detail and insight as to what specific biological processes our differentially expressed 
probes were interacting with and what their potential effects on the host cells 
intracellular environment were.   
The projection of probes over-represented within different biological processes using 
the Reactome database suggested a clear alignment of oriP-EBNA1 probes within 
‘immune system’ processes; a common theme that continues to be portrayed within 
the unbiased analysis across 3 different gene ontology (GO) web pages. Moreover, 
within such ‘immune system’ processes, an increased propensity for ‘cytokine 
signalling in the immune system’ and ‘interferon-related signalling pathways’ were 
again a commonality highlighted in the online facilities. It was apparent from the 
literature that bacterial DNA present in plasmid vectors was processed through the 
TLR9 receptor, which the dbDNA system managed to bypass (Allen et al., 2018). 
Following TLR9 receptor stimulation by CpG-DNA molecules, TLR9-endosomes traffic 
to lysosome-related organelles before a signalling cascade ultimately triggers the 
induction of type 1 interferon expression (Kawasaki and Kawai, 2014). What was clear 
from our dataset produced from different GO online software, was that a phenotype 
associated with the mechanistic pathway downstream from TLR9 activation was 
displayed. ‘Endosomal and phagosomal pathways’ alongside ‘interferon signalling 
pathways’ were commonalities within our unbiased analysis and demonstrated the 
potentiation of an inflammatory intracellular signature. It has been reproducibly 
evidenced within scientific literature that interferon expression also manipulates the 
upregulation of Major Histocompatability Complex (MHC) related genes (Gaczynska 
et al., 1993; Steimle et al., 1994; Thelemann et al., 2014). This was something also 
detected within our analysis with MHC gene over-expression commonly being 
detected. The initial results from the microarray provided clear evidence that a pro-
inflammatory signature was transcriptionally detectable in oriP-EBNA1 produced 
iPSCs in comparison to dbDNA-produced iPSCs mediated by the presence of 
bacterial DNA in the plasmid system.  
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Residual bacterial DNA present in plasmid vectors such as the oriP-EBNA1 system 
has been demonstrated within the literature to potentiate inflammatory responses 
which mimic those seen within our dataset. The Park lab carried out detailed and 
stringently controlled RNA-sequencing experiment on fibroblasts which had been 
subjected to somatic cell reprogramming using oriP-EBNA1 vectors (Tanaka et al., 
2015). The idea of their experiment was to carry out RNA-Sequencing on fibroblast 
samples 3 days post-transfection of OSKM oriP-EBNA1 vectors. The experiment was 
carried out in parallel with OSKM-negative plasmid vectors (consisting of plasmid 
backbone only) and a negative control of un-transfected parental fibroblasts. The 
results following analysis using Gene Ontology software demonstrated that in 
comparison to parental fibroblasts, the most over-represented genes in both the 
OSKM positive and negative plasmid transfected fibroblasts was in relation to “Type 1 
interferon-mediated signalling pathway”, “Cellular response to type 1 interferon” and 
“response to type 1 interferon” which were all aligned with a high degree of specificity. 
The research article suggested that the triggering of type 1 interferon pathways by 
both the OSKM plasmid system and the empty plasmid system was a general cellular 
response to foreign DNA and not to the OSKM transgenes per se, as substantiated by 
the identical response in the OSKM null plasmid system too (Tanaka et al., 2015). 
Further analysis undertaken by ourselves into interferon signalling highlighted by the 
microarray analysis yielded a heatmap of interferon-related genes almost all of which 
were transcriptionally over-represented in oriP-EBNA1 produced iPSCs only. Our 
dataset provided clear evidence that interferon related gene expression was being 
manipulated and transcriptionally over-represented in oriP-EBNA1 produced iPSCs 
alone. This suggested that the oriP-EBNA1 system was potentiating intracellular 
responses secondary to its structure with which the dbDNA system did not. This had 
been suggested to be purely in relation to the presence of pro-inflammatory bacterial 
DNA present in the plasmid system insofar. However, the bacterial DNA element may 
not be solely responsible for the potentiation of interferon related genes. Experiments 
carried out in the Young lab demonstrated that the EBNA1 protein itself was likewise 
able to elicit an intracellular pro-inflammatory response (Wood et al., 2007). The lab 
was able to generate a carcinoma cell line which over-expressed the EBNA1 protein. 
Such cells were found to result in the activation of STAT1 hyper-transcription which 
resultingly promoted a greater level of STAT1 protein nuclear localisation and 
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activation using ICC. This resulted with the cells demonstrating a greater sensitisation 
to interferon expression and also the induction of MHC gene expression as 
demonstrated via western blotting (Wood et al., 2007). Taken as a whole, the literature 
suggested a synergistic potentiation of gene sets in relation to inflammation and 
interferon expression with both the plasmid DNA and EBNA1 protein expression being 
complicit in the unwanted secondary responses. Responses which were bypassed by 
the dbDNA system, much to its benefit.  
Within our dataset, another commonality in the GO comparisons of over-represented 
probes in oriP-EBNA1 iPSCs was ‘Cellular differentiation’ and ‘Epithelial-to-
Mesenchymal Transition’ which represented a reduced ability for iPSCs to maintain 
their pluripotent capacity. This phenotype was noticed prior to the RNA-sequencing 
experiment where, as mentioned, certain primary fibroblasts reprogrammed with the 
dbDNA system produced stable iPSC lines where the oriP-EBNA1 system failed 
(producing lines which ultimately spontaneously differentiated). Moreover, whilst 
culturing the cells on a routine basis, it became clear that oriP-EBNA1 iPS cells did 
persistently display an increased level of spontaneous differentiation in comparison to 
dbDNA generated iPSCs. To quantify this, iPSCs produced when using both the 
dbDNA and oriP-EBNA1 vectors in concomitant experiments were simultaneously 
analysed using an AP stain which specifically interacted with iPSCs only, excluding 
any areas of differentiation. The result evidenced that across 3 different iPSC lines 
and numerous passages that a differentiation phenotype persisted in oriP-EBNA1 
derived iPSCs and not in dbDNA produced iPSCs.  
Displaying a differentiation potential is a critical function of iPSCs. Maintenance of a 
self-renewal phenotype is important but the therapeutic benefit of this cell type is 
derived from its ability to differentiate into any cell of the three germ lineages 
(Takahashi and Yamanaka, 2016). However, it has been established that cells 
produced by the dbDNA system were not ‘locked’ into pluripotency, as we have 
demonstrated that iPSCs produced by this vector were capable of differentiating and 
forming cells of the mesoderm, endoderm and ectodermal lineages. The lack of 
differentiation displayed during normal culturing conditions was not a symptom of a 
lacking capacity for any differentiation, more it was seemingly an incapability of the 
oriP-EBNA1 system within the iPSCs it produces. Reaffirmation of the increased 
capacity for spontaneous differentiation was demonstrated following a heatmap 
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analysis of early differentiation markers from our microarray analysis. Such probes 
were over-represented in oriP-EBNA1 iPSCs in comparison to dbDNA iPSCs and 
ESCs. Within the literature, it was more recently established that following an 
upregulation of interferon expression, secondary to the recognition of foreign DNA 
through the above-mentioned mechanisms, that iPSCs could not maintain 
pluripotency and ultimately undergo unwanted spontaneous differentiation. The Oever 
research lab demonstrated that, in fact, the initiation of any aspect of the anti-viral 
response was incompatible with pluripotency. The over-expression of interferon-
related genes resulted in the diminished transcriptional expression of KLF4, SOX2 and 
OCT4. Such iPSCs were then incapable of maintaining pluripotency and were instead 
pushed to spontaneously differentiate towards a mesodermal lineage (Eggenberger 
et al., 2019). 
The mechanism substantiated within the literature helped to coalesce the 
transcriptional phenotype demonstrated within our iPSC culture with the microarray 
results we likewise developed. Our results indicated that the potential increased level 
of differentiation observed within oriP-EBNA1 iPSCs was secondary to the processing 
of its volatile foreign DNA. Within the discussion we have demonstrated clearly that 
the bacterial DNA backbone along with EBNA1 protein expression have key roles in 
the potentiation of a pro-inflammatory cellular environment and therefore the 
manipulation of interferon-related genes. Our dataset clearly laid out evidence to 
suggest that the pro-inflammatory phenotype was maintained and persisted within 
iPSCs and has clear, unwanted secondary effects in relation to the increased 
potentiation of a differentiation phenotype. The dbDNA system, free of bacterial DNA 
and the EBNA1 sequence bypasses such secondary unwanted effects in terms of 
inflammation and the primed differentiation phenotype which ensues.   
 
3.3. EBNA1 protein and increased susceptibility for DNA damage:  
 
Following the microarray, GO terms associated with ‘DNA damage responses’ and 
responses to ‘oxygen containing compounds’ were highlighted within our analyses in 
oriP-EBNA1 iPSCs. This was the rationale behind examining the potential for both the 
dbDNA and oriP-EBNA1 system to induce DNA damage within a transfected cell type. 
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A comet assay in HEK293T cells was determined to be appropriate for such analysis. 
As such, oriP-EBNA1-eGFP vectors and dbDNA-eGFP vectors were separately 
transfected into HEK293T cells. GFP expression was qualified after 24 hours before 
the cells were analysed amongst untreated (negative control) cells and cells treated 
with 200µM hydrogen peroxide (positive control) (Uryga et al., 2015). Images were 
collected and analysed using CaspLab software. The results demonstrated an 
increased level of DNA damage within cells transfected with the oriP-EBNA1 vector. 
The amount of Head DNA was lower in comparison to the dbDNA system, alongside 
an increased level of tail DNA which suggested a significantly increased level of 
damage. Moreover, the comet length was higher in oriP-EBNA1 cells and also the tail 
moment. Our results provided experimental evidence to suggest that the oriP-EBNA1 
vector was inducing DNA damage in a way that the dbDNA system seemingly avoided. 
To consolidate this dataset, ICC was carried out incorporating a γ-H2AX antibody. The 
antibody functioned based on the detection of the phosphorylated form of variant 
histone H2AX (γ-H2AX), which occurred specifically at sites of DNA double-strand 
breaks (DSBs) (Redon et al., 2009). The same experimental procedure was carried 
out on fibroblasts transfected with dbDNA/oriP-EBNA1-eGFP. However, as the GFP 
protein was retained by transfected cells following ICC processing, this permitted the 
specific targeting and quantification of γ-H2AX positive foci in transfected cells only. 
This would therefore permit a more precise account of the level of DNA damage being 
inflicted and/or the lack of DNA repair initiated within each vector transfected cell-types 
specifically. The results from this experiment demonstrated that oriP-EBNA1 plasmid 
transfected cells demonstrated a consistently greater level of positive γ-H2AX foci in 
comparison to the dbDNA system. Taken in their entirety, the results of the comet 
assay and γ-H2AX analysis demonstrated that the oriP-EBNA1 vector could incite a 
greater level of DNA damage and/or inhibited the cellular repair mechanisms to a 
significantly greater degree in comparison to the dbDNA system.  
As previously stated, the dbDNA system shared the same transgenic cassette as the 
oriP-EBNA1 plasmid system, but was devoid of the plasmid backbone and oriP-
EBNA1 sequences (Karbowniczek et al., 2017). The mechanism behind the induction 
of an increased level of DNA damage within oriP-EBNA1 transfected cells and not 
within dbDNA transfected cells must be apropos to something within the remaining 
bacterial DNA/oriP-EBNA1 system. Previous literature published from the Masucci lab 
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presented evidence that the EBNA1 protein was implicated within the induction of an 
increased production of reactive oxygen species (ROS) which ultimately manifested 
as an increased level of double-stranded DNA breaks (DSB) (Gruhne et al., 2009). 
The lab produced a tetracycline inducible, constitutively expressing EBNA1-protein 
cell line and so could manipulate its expression within the same cell. Using DCFDA, a 
ROS specific stain, in conjunction with flow cytometry, Gruhne demonstrated that 
EBNA1-expressing cells exhibited a higher level of ROS production. Then, the lab 
group utilised similar experimental procedures employed by ourselves. A comet assay 
was undertaken which demonstrated that cells with a greater level of EBNA1 protein 
production exhibited a much-increased comet length in comparison to control cells; 
indicating a greater level of DNA damage. This was furthermore substantiated by ICC 
analysis incorporating a γ-H2AX antibody. The publication demonstrated positive 
staining within EBNA1 positive cells, but the foci were not however quantified. The 
reversal of such effects in EBNA1 positive cells were demonstrated to be reversed 
following the administration of ROS-scavengers such as the glutathione peroxidase 
mimetic ebselen and citric acid. The mechanistic analysis put forward by the paper’s 
author was in relation to the activation of NADPH oxides via the transcriptional 
activation of the NOX2 gene which was specifically induced by EBNA1 protein 
expression. The activation of NADPH oxidases ultimately led to the induction of DNA 
damage in cells which occurred in an EBNA1-dependant manner (Gruhne et al., 
2009). Our results provided key indications that the oriP-EBNA1 system was inciting 
DNA damage/interfering with cellular repair mechanisms in a vector-specific manner. 
The increased prevalence of genomic instability within iPSCs induced by the 
reprogramming vector could ultimately prohibit the clinical translation of such cells and 
scupper any therapeutic use (Marión et al., 2009; Sullivan et al., 2018). The initiation 
of DNA damage by the oriP-EBNA1 vector, alongside the inhibition of p53 expression 
can increase the prevalence of iPSCs harbouring unwanted genetic mutations and 
modifications. As prior mentioned, this could have damaging effects in terms of an 
increased oncogenic potential of such iPSCs (Gore et al., 2011; Zhang et al., 2013). 
This presented the development of much more stable iPSCs using the dbDNA system, 
free from the volatile EBNA1 sequence and also the shRNA for p53. Many of the 
proposed issues demonstrated by ourselves and within existing literature seemingly 
occur secondary to the oriP-EBNA1 vector structure and the interactions it has within 
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the host cell. Yet, despite this, the oriP-EBNA1 system has become the gold standard 
vector for pluripotency induction. Here, we demonstrated that the dbDNA system can 
match the EBNA1 vector in terms of its functionality and can moreover bypass several 
unwanted secondary responses, such as increased DNA damage, spontaneous 
differentiation and inflammation. The dbDNA vector could therefore become the first 
of a newer, safer generation of reprogramming vectors and could potentially help to 
transition this therapy into the clinic more readily than what was being achieved with 
the oriP-EBNA1 system.  
 
3.4. dbDNA over-expressed genes and cell cycle analysis:  
 
Following the analysis of gene probes that were over-represented in dbDNA iPSCs in 
comparison to oriP-EBNA1 iPSCs it was clear that GO terms in relation to cell cycling 
were common results. From this we decided to carry out a cell cycle analysis between 
dbDNA and oriP-EBNA1 produced iPSCs using a propidium iodide (PI) nuclear stain. 
The results demonstrated a trend existing with dbDNA-produced iPSCs seemingly 
having a greater proportion of cells existing within the G0/G1 phase in comparison to 
the oriP-EBNA1 system. Whilst the oriP-EBNA1 produced iPSCs displayed a greater 
proportion of cells within the G2/M phase. Typically, a highly proliferative pluripotent 
cell type such as iPSCs would have a more abbreviated cell cycling with a reduced 
G0/G1 but normal cycling periods for the remaining phases (Kapinas et al., 2013). The 
dbDNA system, as mentioned, did not employ the use of the shRNA to p53, as the 
oriP-EBNA1 system did. The p53 protein, commonly referred to as the ‘guardian of the 
genome’ has functionalities within cell cycling being responsible for initiating cell cycle 
arrest and DNA repair (Chen, 2016). Upon detecting genetic abnormalities, the p53 
protein, in synergy with p21, was able to halt the cell cycle to prevent such damaged 
cells from progressing through either the G0/G1 or S phase and ultimately propagating 
such damage. Ultimately, if a cell type has incorporated the shp53 system, the cell 
cycling and division of such cells can continue unrestricted and in spite of the presence 
of potential DNA damage. Ultimately, with the dbDNA system permitting the 
expression of the p53 protein, it was reasonable to hypothesise that major differences 
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within cell cycling changes which exist between the two cell types may be a 
consequence of the presence of this factor. 
 
3.6. Reprogramming of different primary cell types:  
 
The dbDNA system was successful in its ability to reprogram fibroblasts using both a 
proof-of-principle and a xenofree protocol. This was an extraordinary achievement for 
the dbDNA system. When reprogramming fibroblasts using protocols employing 
animal-free constituents, both vectors displayed a much-reduced functional efficiency 
in terms of iPSC colony production. This was presumably due to a functional 
advantage conveyed by the inactivated mouse embryonic feeder (iMEF) layer which 
was absent. Inactivated feeder cells have been evidenced to support targeted cell 
growth mediated by the release of growth factors (LIF, FGF2 etc), their ability to 
detoxify culture medium and also to synthesise extracellular matrix proteins (Llames 
et al., 2015). The supportive nature of feeder cells was further substantiated within the 
literature. Experiments were conducted analysing the growth of cells in feeder 
maintained and feeder-free conditions, where the author suggested that, for the above 
mentioned reasons, feeder maintained growth was more beneficial and supported a 
more prolonged, undifferentiated growth of pluripotent cells (Richards et al., 2002). 
Despite functioning at a reduced efficiency in comparison to the feeder produced 
protocol, the dbDNA system was able to produce viable, bona fide iPSCs when 
incorporated into the xenofree protocol.  
A successful protocol for the derivation of iPSCs from both blood and urine-derived 
cells was produced and recorded within our results. A protocol for the derivation, 
culturing and reprogramming of urine-derived cells was successfully established within 
the McKay lab. This was a time-consuming process, but one that offered the prospect 
of isolating cells for reprogramming in the least invasive manner possible. The dbDNA 
system was not successful in the derivation of iPSCs from urine-derived cells. The 
reasoning behind this has yet to be established and was most likely a technical failure. 
With greater research efforts to improve the protocol and to attempt different vector 
transfection methods, the system may still be a success within the derivation of iPSCs. 
That said, a mechanistic failure could still be a possibility that should not be ignored. 
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There was a plethora of potential mechanistic reasons behind the lack of success on 
this occasion with the dbDNA system. The doubling times for urine-derived cells was 
not dissimilar to that of dermal fibroblasts (~24 ± 6 hours and 21 ± 3 hours respectively) 
and so it seemed unlikely that the issue was in relation to an increased dilution of the 
dbDNA system due to its lack of tethering capacity (Bolton and Barranco, 1975; Lang 
et al., 2013). However, upon reprogramming, the urine-derived cells were done so 
according to a feeder-free protocol; with no supporting iMEFs. As prior mentioned, 
when reprogramming fibroblasts, the presence of a supporting iMEF feeder layer was 
a critical element providing the process with a greater reprogramming efficiency with 
both vector types. Inactive MEFs have been previously demonstrated within the 
literature to secrete growth factors that support the maintenance of pluripotency within 
iPSCs and hESCs. When employing a feeder-free protocol, our research group 
adopted the use of the Matrigel matrix. Matrigel is a soluble basement membrane 
being extracted from Engelbreth-Holm-Swarm tumours. The membrane was rich in 
matrix proteins such as laminin, collagen IV, entactin and heparin sulfate proteoglycan 
(Bissell et al., 1982). Such extracellular matrices (ECM) are important to stem cell 
growth and survival by recapitulating in-vivo stem cell niches and specialised 
microenvironments (Higuchi et al., 2011; Lee et al., 2011). Moreover, a finite amount 
of soluble growth factors were present in Matrigel, too. This provided the basis of how 
Matrigel became increasingly successful and a staple of the urine-derived cell 
reprogramming protocol. However, iMEF feeder layers can constitutively express 
growth factors which contribute to the maintenance of pluripotency. Secretion of 
factors such as Activin A, FGF (which in-turn activates PI3K/AKT pathway 
demonstrated increased PSC survival), Wnt signalling, TGFβ and NODAL are all 
demonstrated to inhibit PSC differentiation are all collectively contributors to 
successful iPSC development (Beattie et al., 2005; Saha et al., 2008; Romorini et al., 
2016; Cristo et al., 2017). In a number of studies it has been demonstrated that 
inhibiting TGFβ, NODAL & Activin A resulted in a proportionate increase in 
spontaneous differentiation within culturing hESCs (Saha et al., 2008). Likewise, Wnt 
signalling has been implicated in a reduction of differentiation secondary to its 
increased interactions with β-catenin (Nusse, 2008). The secretion of such factors 
clearly demonstrated an increased ability to maintain PSCs and their pluripotent 
capacity with great longevity. Duly, the perpetual, constitutive release of factors which 
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synergistically functioned to maintain a pluripotent state (Wnt, TGFβ, NODAL & 
Activin) whilst stimulating cellular proliferation (FGF, EGF etc) by iMEFs provided them 
with a supporting role in pluripotency induction and maintenance. This continued 
expression of pluripotent-supporting factors, I believe, was what drove a greater level 
of reprogramming success on feeder layers in comparison to the feeder-free protocol. 
The dbDNA system was designed as a transient system with no scaffolding 
capabilities. Therefore, a dual synergy between the dbDNA vectors transient nature 
and the lacking feeder layer may potentially be the determining factors in relation to 
the lack of success on this occasion using the dbDNA system within urine-derived 
cells. Despite a successful attempt at reprogramming urine-derived cells with the oriP-
EBNA1 system, the vector was un-successful several times during this process – with 
AP positive primary colonies being produced only on a single occasion. This helped 
to substantiate that the failure was not just down to the dbDNA system and that alone, 
that in fact even the most robust of vectors that have the functional advantage of DNA 
scaffolding capabilities also struggled with this process.  
In the context of reprogramming peripheral blood, the dbDNA system was also unable 
to induce pluripotency on this occasion too. This again could be for a number of 
reasons, both technical or mechanistic.  I believe, again, the dbDNA system and its 
reduced success in this instance was attributable to the reduced retention of the vector 
in comparison to the oriP-EBNA1 system. In the protocol for reprogramming peripheral 
blood, iMEFs were adopted which should support the development of iPSCs at a 
greater efficiency for both vector types. However, the protocol also incorporated the 
use of Dynabeads to activate CD3/CD28+ cells and therefore increased T-cell 
proliferation between ‘100 and 1000-fold’. The increased proliferation rate will, most 
likely, result in an increased dilution of the dbDNA system and not the oriP-EBNA1 
system due to the vectors inherent tethering capacity. This ultimately prohibited the 
induction of pluripotency onset within adherent PBMCs using the dbDNA system. The 
dbDNA vector did, however, seemingly result in the formation of some cells of a 
different phenotype from the feeder layer, but that do not resemble iPSCs. This was 
potentially partially reprogrammed cells. There was a possibility that some transfected 
cells were able to persist and progress partly through the initiation phase of 
reprogramming but did not fully transition through it - resulting in only a partially 
reprogrammed cell state (David and Polo, 2014).  
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Taken in its entirety, the dbDNA system on this occasion did not function to reprogram 
and produce iPSCs within cell types other than the previously reported fibroblast 
samples. The failure of the vector to do could be in relation to either technical or 
mechanistic failings on mine or the vectors behalf. However, just because the vector 
did not function to produce iPSCs on this occasion does not mean that it never will. 
The production of iPSCs from fibroblasts using the dbDNA system was an 
extraordinary event that in theory should not have occurred with the relative ease with 
which it did. Therefore, I do believe that with further research efforts that the dbDNA 
system can be successfully incorporated into protocols for the development of iPSCs 
from other cell types such as urine and blood-derived cells. But, if not, then a greater 
mechanistic insight will be gained into the vector to understand its reduced 
functionality in this aspect and how this might be improved. Either way, something will 
be gained from future experiments undertaken within this remit.  
3.7. Future work: 
 
In my opinion the future line of work should follow trying to meet relevant criteria in 
order to truly establish the first clinical grade dbDNA iPSC line. The established criteria 
involves a host of experiments determining mycoplasma presence, endotoxin, 
bacteriology/virology testing, SNP testing, Karyotyping, tests for residual vector 
alongside pluripotency & differentiation tests (Sullivan et al., 2018). Moreover, 
comprehensive terminal differentiation studies should likewise be undertaken using 
dbDNA iPSCs to form neurons, cardiac cells, hepatocytes etc to demonstrate the 
ability of these iPSCs to form specific and potentially therapeutic cell types. An 
integration analysis should also in my opinion be carried out to determine the presence 
of vector DNA within the iPSC genomic DNA. A whole genome sequencing or exome 
sequencing experiment would unequivocally rule out the potential of the dbDNA 
system to integrate into the iPSC genomic DNA and so would be a future experiment 
to consider. Moreover, as an internal quality control and to also determine the effects 
that the shp53 transgene has on oriP-EBNA1 iPSCs in comparison to the dbDNA 
system, a ddPCR looking at p53 associated mutations in oriP-EBNA1 and dbDNA 
iPSC lines would be of interest. This would help to elucidate any underlying mutations 
within the dbDNA produced iPSCs and at what rate they occur or are incited at in 






The dataset produced by myself during this PhD demonstrated a proof-of-principle that 
the dbDNA system can be successfully applied to the process of iPSC production from 
human dermal fibroblasts; the most common source of cells for reprogramming. The 
iPSCs produced by the dbDNA system adopted a perpetual self-renewal phenotype 
as well as being prompted to differentiate forming cells of all three germ lineages. The 
iPSCs produced by the dbDNA system have been evidenced to be, without doubt, 
bona fide iPSCs. The dbDNA system also has the capacity to produce iPSCs when 
applied to a xenofree reprogramming protocol. In the context of reprogramming, the 
dbDNA system demonstrated a functionality that was competitive in relation to the 
oriP-EBNA1 system, and as the literature states, other non-integrating reprogramming 
systems too. The extraordinary nature of this result in relation to the Doggybone 
system however, was that the dbDNA system functioned independent of scaffolding 
capabilities or additional transgenes which have been evidence to improve 
reprogramming efficiencies. Following global transcriptome analysis, the dbDNA 
produced iPSCs exhibited a reduced pro-inflammatory environment, alongside greater 
maintenance of its pluripotent nature and its genomic integrity in comparison to the 
oriP-EBNA1 system. Taken together, the dbDNA system presents as a vector which 
has the capacity to produce safer and more stable iPSCs in comparison to its plasmid 
counterpart; a counterpart which has become well-established as the gold standard of 
iPSC development. Therefore, if we have been able to describe a functional 
reprogramming system which remedies many secondary issues associated with the 
EBNA1 plasmid system, there is no reason why, with further investment, the dbDNA 
system cannot itself become the next pluripotency gold standard. I feel that this, in 
conjunction with my outlined future work could result in the beginning of a new era of 
iPSC development, using clinical grade dbDNA vectors as opposed to ones rooted 
firmly in the manipulation of bacteria and viruses. The production of a cGMP dbDNA-
iPSC line could kickstart the incorporation of dbDNA iPSCs into potential future clinical 
trials which will exponentially increase as the field of stem cell biology also continues 




4.0. Materials and Methods 
4.1. Cell Culture: 
 
Reagent Company Catalogue No 
DMEM Sigma D6546 
mTeSRTM 1 Stemcell Technologies 05851/05852 
DMEM/F12 Gibco, Life Technologies 31331093 
XVIVO10 Lonza 04-743Q 
REBMTM Renal Epithelial Cell 
Growth Basal Medium 
Lonza CC-3191 
OptiMEM   
Dulbecco’s Phosphate buffered 
saline 
Sigma D8662 
MEM Non-essential amino acids Life Technologies 1140050 
Plasmocin Invivogen Ant-mpp 
Foetal Bovine serum Gibco, Life Technologies 10270-106 
L-Glutamine Sigma G7513 
Penicillin/Streptomycin Sigma P0781 
Dulbecco’s Phosphate buffered 
saline 
Sigma D8662 
Human Dermal Fibroblast 
NucleofectorTM Kit 
Lonza VPD-1001 
Knockout serum replacement Gibco, Life Technologies 10828-028 
β-mercaptoethanol Life Technologies 31350-010 
Mitomycin C Sigma Aldrich M4287 
TrypLE express enzyme Gibco, Life Technologies 12605028 
FGF2 R&D Systems 233-FB-025 
Laminin Millipore CC095 
Gelatin from porcine skin Sigma G1890 
Rock Inhibitor (Y-27632) Sigma Y0503-1mg 
Dimethyl sulfoxide Sigma BP231-100 
Matrigel BD Bioscience 734-0270 
Rock inhibitor (Y-27632) Sigma Y0503-1mg 
Polyethylenimine Sigma 03880 
UltraPure™ 0.5M EDTA, pH 8.0 ThermoFisher Scientific 15575020 
Ficoll® Paque Plus Sigma GE17-1440-02 
rIL-2 Peprotech 200-02 
Gibco™ Dynabeads™ Human T-
Activator CD3/CD28 
ThermoFisher Scientific 111.61D 
REGMTM Renal Epithelial Cell 
Growth Medium SingleQuotsTM Kit  
Lonza CC-4127 
PDGF-AB Peprotech 100-00AB 
hEGF Peprotech E9644-.2MG 
SIGMAFASTTM BCIP®/NBT Sigma B5655-25TAB 
Essential 6TM medium ThermoFisher Scientific A1516401 
Essential 8TM medium ThermoFisher Scientific A1517001 
Vitronectin StemCell Technologies 07180 
Table 2: Cell culture reagents. 
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HEK293T cells were acquired from Dr Steve Howe – institute of child health, UCL. 
Control neonatal dermal fibroblasts (nhDF) were purchased from Fisher Scientific 
(C0045C) and PromoCell (CAT NO). CLN3 and CLN6 hDFs were obtained from 
Prof. Sara Mole from the Laboratory for Molecular Cell Biology at UCL as part of the 
BATcure Horizon2020 consortium. Furthermore, Shef3 Human Embryonic stem cells 
(hESCs) were procured from the UK stem cell bank (SCSC10-48). Finally, MEF 
feeder cells were purchased from Cambridge Bioscience (CBA-310).  
 
4.2. Cell culture methodologies:  
 
4.2.1. The culturing and inactivation of Mouse embryonic fibroblasts (MEFs):  
 
MEFs were cultured in complete DMEM (DMEM (4500mg/L glucose), 10% FBS (v/v), 
L-Glutamine (4mM), Penicillin/Streptomycin (1x)) supplemented with 1x (v/v) non-
essential amino acids. The cell medium was replaced every other day and upon 
reaching confluency (90-95%) the cells were passaged in a 1:4 ratio using 150μL/cm2 
of TrypLE. The cells were centrifugated at 258 G for 5 minutes before being re-
suspended in an adequate volume of culturing media and re-plated.  
Following amplification to passage 4 (P4), the MEFs were mitotically inactivated. The 
cells were incubated in complete DMEM with Mitomycin C (0.1μg/uL) at 37°C for 3 
hours. Post-incubation, the MEFs underwent a minimum of 3 wash steps in 10mL of 
Dulbeccos Phosphate Buffered Saline (DPBS) before again being enzymatically 
detached using TrypLE. Once the cells had dis-associated from the flask surface, they 
were stored at -80°C in FBS supplemented with 10% (v/v) Dimethyl Sulfoxide (DMSO) 
at a density of ~5 x 106 cells/mL. Once required, MEFs were defrosted and seeded at 








4.2.2. Culturing and passaging of Pluripotent stem cells (PSCs):  
 
Human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) – 
both of which are considered PSCs - were cultured on MEF feeder layers (iMEFs) in 
hESC media. The medium was refreshed every other day. PSC colonies were 
passaged regularly - every 4-10 days – determined mostly by colony morphology. 
Upon passaging, fresh hESC media was placed onto the cells. PSC colonies were 
then manually excised from the flask into the fresh media. The colonies were then 
further dissociated by being passed through a pipette before being placed onto a fresh 
iMEF feeder layer.  
4.2.3. Human Dermal Fibroblast (HDF) culturing and maintenance:  
 
HDFs were cultured in complete DMEM with regular media changes every other day. 
The cells were routinely passaged, being dissociated using TrypLE before 
centrifugation at 258G for 5 minutes. The cells were then seeded at a density of ~3 x 
104 cm2.  
4.2.3. Somatic cell reprogramming & production of iPSCs: 
4.2.3.1. Reprogramming of Human dermal fibroblasts (hDFs): 
 
Episomal plasmid-based reprogramming factors (SOX2, OCT4, KLF4, l-Myc, shp53) 
were prepared to concentrations outlined in Table 4. Additional EBNA1 expression 
plasmid was also included to facilitate an improved reprogramming efficiency. 
Doggybone vectors were prepared as outlined in Table 4. The dbDNA system did 










Table 4: Reprogramming plasmids and the concentrations at which each vector is utilised. 
Construct DNA amount (μg) Catalogue number 
pCXLE-hSK 2.0 Addgene ID: 27078 
pCXLE-hUL 2.0 Addgene ID: 27080 
pCXLE-hOCTshp53 2.0 Addgene ID: 27077 
pCXLE-EBNA1 2.0 Addgene ID: 37624 
DbDNA-hSK 2.33 n/a 
DbDNA-hUL 2.33 n/a 
DbDNA-OCT4 2.33 n/a 
 
Nucleofection solution, consisting of 90μL NHDF NucleofectorTM solution + 20μL of 
Supplement 1 (LONZA: VPD-1001) was firstly prepared. 8μg of episomal DNA/dbDNA 
was then deposited into the solution. ~4.5 x 105 HDFs were trypsinised and centrifuged 
at 258G before being re-suspended in the Nucleofector/DNA mixture and transferred 
into a glass cuvette. The cells were then nucleofected (P-022 programme: Human 
dermal fibroblasts – high viability). The fibroblasts were then seeded onto a single 6-
well in complete DMEM – this would be considered day 0.  
On day 1, the medium was refreshed before then being replaced every 2 days. Upon 
reaching confluency (>90%), the nucleofected HDFs could then be passaged and 
seeded into a T75cm2 flask. On day 8, the re-programming HDFs were dissociated 
using TrypLE before 6x104 cells were re-plated onto a T25cm2 flask containing a 
feeder layer in 5mL complete DMEM. On day 9, the cell medium was exchanged from 
complete DMEM to hESC media which was likewise replaced every 2 days until colony 
formation and clonal excision.  
171 
 
4.2.3.2. Reprogramming of fibroblasts using a xenofree protocol:  
 
Human dermal fibroblasts were cultured using Essential 6 media prior to the 
introduction of reprogramming plasmids via Amaxa nucleofection. The reprogramming 
protocol initiated and carried out was identical to that described in 4.2.3.1 using HDFs. 
However, the iMEF feeder layer the reprogramming fibroblasts were introduced onto 
7 days post nucleofection was replaced by vitronectin coated wells. Vitronectin was 
thawed at room temperature before being diluted in DPBS to 10µg/mL (v/v). Wells of 
a 6-well plate were then coated with vitronectin for a minimum of 1 hour prior to use. 
Secondly, the traditional hESC medium which the reprogramming cells are normally 
cultured in on Day 8 onwards for the reprogramming protocol is replaced by Essential 
8. Once primary colonies are ready to be excised, they are re-plated again using 
vitronectin and Essential 8 medium.  
 
4.2.3.3. Reprogramming of Peripheral blood: 
 
Peripheral blood was isolated into an appropriate anti-coagulant containing 
vacutainer. The sample was then immediately processed being diluted at a minimum 
of 1:1 (v/v) with DPBS supplemented with 0.5M EDTA. With care not to disturb the 
interface between the two liquids, 6mL of diluted blood was gently layered atop 3mL 
of Ficoll. Isopycnic centrifugation (400G for 35 minutes at 18°C) was then undertaken. 
This was to fractionate the blood and ficoll based on their relative densities. The buffy 
coat layer (in-between the plasma and ficoll layers) was then carefully extracted before 
being washed in DPBS twice. 3-5x106 cells were then resuspended into 110μL of 
Nucleofection solution with 4μg of episomal DNA/dbDNA. The cells were then 
nucleofected using the V 0-24 programme on the Amaxa 2b nucleofector. The product 
was then seeded onto an iMEF layered 6-well in xVIVO10 medium. This was 
furthermore supplemented with 30 U/mL rIL-2 and 5uL Dynabeads® for human T-cell 
activation. 2 days post nucleofection, hESC media was then added without aspirating 
the previous xVIVO10 medium. 4 days post nucleofection, all the medium was then 




4.2.3.4. Urine reprogramming: 
 
Pre-sample collection & collection process:  
1 hour prior to sample collection, a participant was advised to drink plenty of water to 
increase the propensity of cellular shedding and collection. Once ready, the participant 
was advised to clean the urethral area using an anti-septic wipe prior to any sample 
collection. The first stream of urine was not collected, the rest was collected in a 
sterilised beaker.  
Post collection/Cellular isolation: 
The next steps of the process were carried out in a sterile environment. The sample 
was transferred from the beaker into 50mL Falcon tubes. The samples were 
centrifuged at 200g for 10 minutes. During this, 12-well plates should be gelatinised 
and placed in an incubator at 37°C for ~20 minutes. Once centrifuged, the sample 
supernatant was discarded from each tube and 1mL of primary medium (DMEM/high 
glucose and Ham’s F12 nutrient mix (1:1), FBS (10% (v/v)), Penicillin/Streptomycin 
(1x), 1 x REGMTM Renal Epithelial Cell Growth Medium SingleQuotsTM Kit (CC-4127)) 
was added. The primary medium and any cells were transferred to the gelatinised 12 
well-plate where an additional 1mL of primary medium was added to each well. The 
cells were then incubated at 37°C overnight.  
Cell Expansion:  
24 hours post isolation, 1mL of primary medium was added to each well without 
removing any of the previous media. This was repeated for the next 3 days. 96 hours 
after the initial plating of cells, 3 of the 4mL of primary medium was removed. Two 
different proliferation media were then produced. RE proliferation media (REBMTM 
Renal Epithelial Cell Growth Basal Medium (CC-3191), 1 x REGMTM Renal Epithelial 
Cell Growth Medium SingleQuotsTM Kit) and MC proliferation media (DMEM w/high 
glucose, 10% FBS (v/v), 1% GlutaMAX (v/v), 1% NEAA (v/v), Penicillin/Streptomycin 
(1x), bFGF (5ng/mL),  PDGF (5ng/mL), EGF (5ng/mL)) were produced. Then, 1mL 
RE/MC proliferation media was added to each well. From this point onward, half of the 
media was replaced with RE/MC proliferation media daily. Upon reaching confluency, 




Upon reprogramming, between 5 x 105 – 1 x 106 cells are required. A total of 6μg of 
plasmid/dbDNA (Table 5) was nucleofected using the Amaxa 2b Nucleofector with the 
programme T-020. The cells were subsequently plated onto Matrigel coated wells in 
MTESR medium. The medium was refreshed daily until colony formation. 
Table 5: Vector concentrations utilised in the reprogramming of urine derived cells. 
Construct DNA amount (μg) 
hSK (SOX2 + KLF4) 1.75 
OCT/shp53 1.75 





4.2.4. Colony counting & reprogramming efficiency:  
 
The efficiency of reprogramming was calculated to determine the ability of each vector 
type to induce the production of iPSCs. This was calculated as a percentage of the 
number of colonies produced by each vector type relative to the total number of 
fibroblasts re-plated onto the iMEF feeder layer on day 8 of the protocol. 
On day 21, alkaline phosphatase (AP) staining was carried out to determine the 
presence of fully reprogrammed iPSCs. This would stain the legitimate iPSC colonies; 
whose expression of AP is much higher than the feeder layer and most other cell types. 
These colonies could then be counted to determine an efficiency. 
4.2.5. HEK293T maintenance and transient transfection:  
 
HEK293T cells were seeded at 2-5 x 104/cm2 in complete DMEM medium. The 
medium was replaced with fresh media every 2 days. Once a confluency of 80-90% 
was reached, the cells were passaged using TrypLE.  
For a transient transfection, HEK293T cells were cultured to a confluency of ≥90%. 
Equal volumes (Table 6) of Polyethylenimine (PEI) and DNA were aliquoted into 
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separate tubes containing OptiMEM. The tubes containing PEI and DNA were then 
combined and mixed before a 20-minute incubation step at RT. During this incubation, 
300μL of OptiMEM was also added to the well of HEK293T cells to be transfected. 
Afterwards, the PEI-DNA complexes were added to the cells before a 2-3-hour 
incubation at 37°C followed. Afterwards, any un-transfected or remaining PEI/DNA 
complexes were removed from the HEK293T cells before the addition of 2mL of 
complete DMEM.  
Table 6: Preparations of PEI and DNA for the transfection of a vector into cells. 
PEI preparation: 






















4.3. Molecular Biology: 
 
Reagent Company Catalogue No 
RIPA buffer Thermo Scientific 89900 




TEMED Sigma T9281 
Tween 20 Sigma 19379 




Marvel original dried 
skimmed milk 
Supermarket  
Protease inhibitor cocktail Sigma Aldrich P8340 







APS Sigma 215589-100G 
Blot absorbent filter paper Biorad 1703932 
Methanol Fisher scientific  
Glycine Sigma G8898-500G 
Tris base Fisher scientific BP152-1 
Sodium dodecyl sulphate   
Proteinase K  Fisher scientific 10172903 
Qiaprep spin miniprep kit Qiagen 27106 
RNeasy mini kit Qiagen 74104 
RQ1 RNase-free DNase kit Promega M6101 




RNasin plus inhibitor Promega N2611 
Random primers Promega C1181 
KAPA SYBR FAST 
universal 2x qPCR master 
mix 
KAPA Biosystems KK4601 
GelRed nucleic acid stain VWR International 730-2958 
Agarose (NMA) Sigma A5093 
O’Generuler ladder mix Fisher Scientific 1188393 
Isopropanol  Sigma 190764 
4% Paraformaldehyde   
Triton 100x Sigma T8532 
Bovine serum albumin Sigma 05479 




UltraPure™ 0.5M EDTA, pH 
8.0 
Thermo-Fisher 15575020 
Table 3: Molecular biology reagents. 
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Q5® High-Fidelity DNA 
Polymerase 
New England BioLabs M0491L 
ISOLATE II Genomic DNA 
Kit 
Bioline BIO-52066 
UltraPure™ Low Melting 
Point Agarose 
Thermo-Fisher 16520050 
Sodium Chloride Merck S3014 
Sodium Hydroxide Merck 795429-500G 
Dimethyl sulfoxide Merck BP231-100 
Anhydrous sodium acetate Merck W302406 
SYBR™ Gold Nucleic Acid 
Gel Stain (10,000X 
Concentrate in DMSO) 
Thermo-Fisher S11494 





Hybridization and Detection 
Kit 
Thermo-Fisher 17097 
Nylon membranes Thermo-Fisher LC2003 
EcoRI New England BioLabs R0101S 
Ficoll® 400 Merck F2637-5G 





4.3.1. Protein quantification & Western Blotting analysis:  
 
4.3.1.1. Protein quantification 
 
Cells were lysed for protein isolation utilising RIPA buffer augmented with 1:1000μL 
protease inhibitor cocktail. The lysates were then stored at -80°C until required.  
Each lysate underwent quantification using the Bradford assay. Bradford reagent was 
diluted at a ratio of 1:5 (v/v) with water. 195μL diluted Bradford reagent was then added 
in triplicate to wells of a 96-well plate. 5μL Protein standards were added to wells 
containing diluted Bradford with concentrations ranging from 0.5μg - 8μg per 5μL. 
Experimental lysates were diluted 1:10 (v/v), thereby minimizing the effects of RIPA 
on the Bradford reagent. 5μL of each diluted lysate was then added in triplicate. The 
wells were mixed prior to spectrophotometric quantification at 630nm.  
 
4.3.1.2. SDS-PAGE gel production: 
 
Following protein quantification using the Bradford assay, the constituents of a bis-
acrylamide separating gel were added to a 50mL Falcon tube. The contents were then 
carefully decanted into a glass cast. Isopropanol was then carefully added to the top. 
This was to ensure a uniform interface between the separating gel and stacking gel 
whilst also preventing any oxygen-dependant interference with gel polymerisation. 
Upon solidification of the separating gel, the isopropanol was removed. A stacking gel 
was then subsequently made before being poured on top of the separating gel and a 










Table 7: Recipe to produce the stacking and separation gels for western blotting.  
Separation gel: 
Reagent Volume 
Solution A (1.5M Tris pH8.8 / 0.4% (w/v) 
SDS) 
2.5mL 






Solution B (0.5M Tris-HCl pH6.8 / 0.4% 
(w/v) SDS) 
2.5mL 
30% Bis/acrylamide 5mL 
Water 2.5mL 
TEMED 10μL 
APS (10%) 30μL 
 
4.3.1.3. Electrophoresis & Protein transfer: 
 
The SDS-PAGE gels were submerged in running buffer (Tris base (25mM), 0.1% SDS 
(w/v), Glycine (190mM), 1L ddH2O) within the tank before 15-30μg of each protein 
sample was loaded into wells alongside a single well containing 5μL Kaleidoscope 
protein ladder. The gel was then electrophoresed for 105 minutes at 90v. After 
sufficient migration, the separated protein lysate was then transferred from the SDS-
PAGE gel onto a PVDF membrane. The gel containing the separated protein was 
placed atop the PVDF membrane. Both were then sandwiched between blotting paper 
which had been soaked in blotting buffer (Tris Base (25mM), 20% Methanol (v/v), 
Glycine (190mM), 1L ddH2O). The sandwiched membrane was furthermore placed 
into the semi-dry blotter and transferred at 15v for a minimum of 60 minutes - 





4.3.1.4. Primary antibody addition: 
 
Following protein transfer, the membrane was carefully removed using sterilized 
tweezers before being blocked in DPBS supplemented with 5% (w/v) milk and 0.1% 
(v/v) Tween20 for a minimum of 60 minutes. After blocking, primary antibodies were 
diluted in blocking buffer before being placed atop the membrane. This was then 
incubated on a rocker at 4°C overnight.  
Table 8: Antibodies used for western blotting.  
 
 
4.3.1.5. Secondary antibody detection: 
 
Following incubation with a primary antibody, the membrane was washed with PBS 
with 0.1% (v/v) tween20 for 5 minutes (per wash). A HRP-conjugated secondary 
antibody was then added to blocking buffer at a 1 in 2000 dilution. This was added to 
the membrane on a rocker at room temperature for a minimum of 60 minutes. The 
membrane was washed again prior to the addition of a chemiluminescent HRP 
substrate detection reagent. This was incubated on the membrane for 1 minute. The 
blot was then visualized on a transilluminator.   
  
Antibody Dilution Catalogue No 
OCT3/4 1:400 Abcam (Ab18976) 
SOX2 1:2000 Biotechne (AF2018) 
LIN28 1:1000 R&D (AF3757) 
β-actin 1:10,000 Sigma Aldrich (A2228) 
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4.3.2. Immunocytochemistry (ICC):  
 
Culture medium was firstly removed from cells to be analysed. The cells were then 
washed with DPBS (x3). PBS supplemented with 4% paraformaldehyde (PFA) (v/v) 
was used to fix the cells at room temperature for 20 minutes. The cells were washed 
following fixation, with DPBS (x3). The wells to be stained were then permeabilised if 
the protein of interest was not membranous. Permeabilization was carried out utilising 
0.3% Triton X (v/v) in PBS for 10 minutes at room temperature. Further DPBS washes 
(x3) were carried out before the cells were blocked for a minimum of 30 minutes. 
Blocking buffer was produced using PBS supplemented with 2% bovine serum 
albumin (BSA) (w/v) + 0.1% (v/v) Tween20. Primary antibodies were then diluted to 
appropriate concentrations (table) in blocking buffer and were added to the cells before 
an incubation at 4°C overnight. The cells were thereafter washed before the secondary 
antibody was diluted (1:500) in blocking buffer and left on the cells for 1 hour at room 
temperature in the dark. Following further wash steps, DAPI was added in PBS for 1 
minute before being removed and the cells visualised on a fluorescent microscope.  
Table 9:  Antibodies used for ICC analysis.  
 
  
Antibody Dilution Catalogue No 
OCT4 1:100 Abcam (Ab18976)  
SOX2 1:200 Biotechne (AF2018) 
Tra-1-60 1:200 Abcam (Ab16288) 
Tra-1-81 1:200 Abcam (Ab16289) 
βIII-tubulin 1:200 R&D systems (MAB1195) 
α-Smooth muscle actin 
(SMA) 
1:100 Abcam (ab5694) 
SOX17 1:60 R&D systems (AF1924) 
H2AX 1:1000 Abcam (ab11174) 
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4.3.3. Reporter gene expression kinetics via FACS analysis:  
 
Cells were firstly trypsinised and counted using a haemocytometer. Then, 
approximately 4.5 x 105 cells were centrifuged at 258 G for 5 minutes. GFP-expressing 
plasmid DNA/dbDNA (8μg) was then nucleofected - as per the previously mentioned 
protocol. Following nucleofection, the cells were then added to 1mL of complete 
DMEM before being distributed evenly for different timepoints. Upon fluorescence 
quantification, the cells were trypsinised and pelleted as before (258G, 5 minutes). 
This was re-suspended in 1mL of DPBS before being transferred into a Falcon® 5mL 
round bottom polystyrene test tube. 
Upon analysis, a negative control of un-transfected HDFs was firstly utilised to gate 
and quantify any cellular autofluorescence using FITC-A expression (P1). 
Subsequently, FITC expression beyond the autofluorescence of the control HDFs 
(P1), was likewise gated as GFP expressing cells (P2). The percentage of cells outside 
of the P1 gate and within the P2 gate were continually monitored over a 21-day period 
and quantified as a percentage of 10,000 cells.  
 
4.3.4 RNA assays 
 
4.3.4.1. RNA extraction from human cell lines:  
 
Total RNA extraction was carried out utilising the Qiagen RNeasy Minikit. The cells to 
be lysed were collected or re-suspended in the lysis buffer (RLT). Then, for cells that 
may be difficult to lyse, homogenisation steps were taken to maximise the potential 
RNA yield. A plastic pestle was used as well as passing the sample through a fine 
needle. During extraction, the RNA undergoes a DNase treatment on-column using 
RQ1 DNase. The Minikit adopts the use of a silica membrane, which binds RNA from 
cell lysates. The high purity RNA was then eluted from the column using 30μL of 
RNase free water. The concentration of RNA isolated was then determined using a 
spectrophotometer (Nanodrop, U.K). The RNA samples were subsequently stored at 
-80°C.  
Prior to use, the quality of RNA was determined by gel electrophoresis. 1μg of RNA 
was loaded onto a 1.5% gel prepared using 1x TAE (Tris Base (40mM), glacial acetic 
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acid (40mM), EDTA (1mM)). The gel was submerged in 1x TAE and electrophoresed. 
If both the 18s and 28s ribosomal bands were clearly observed, it was concluded that 
the RNA was intact and suitable for any further analysis.  
 
4.3.4.2. cDNA generation from RNA:  
 
A 1μg RNA starting product was mixed with 0.5μg DNA hexamers of randomized 
sequences for first strand Complimentary DNA (cDNA) synthesis. The RNA/Random 
primer mixture was then heated at 70°C for 5 minutes – melting template (RNA) 
secondary structure formation. The sample was then stored immediately on ice to 
prevent any secondary structure re-formation. The sample was then briefly centrifuged 
to coalesce the solution to a pool at the bottom of the tube. To the annealed 
template/primer mixture, the subsequent components were added, in order, to 
commence reverse transcription. Firstly, 5μL M-MLV reaction buffer (5x), 1.25μL dATP 
(10mM), 1.25μL dGTP (10mM), 1.25μL dCTP (10mM), 1.25μL dTTP (10mM), 0.6μL 
(25 units) Recombinant RNasin® Ribonuclease Inhibitor, 1μL (200 units) M-MLV RT, 
ddH2O up to 25μL. The sample was then gently mixed before being incubated for 1 
hour at 37°C. The reaction was then terminated by heating at 70°C for 10 minutes. 
cDNA samples were then stored at -20°C until use.  
 
4.3.4.3. Quantitative Polymerase Chain Reaction:  
 
Transcript analysis was performed by qPCR using the KAPA SYBR® FAST qPCR kit 
in a 96 well-plate format. Each well contained a 10μL total reaction, of this, 5μL of 
SYBR, 200nM of both forward and reverse primers (0.4μL), 3.6μL ddH2O and 1μL 
cDNA was used. A no template control and a no RT control were also incorporated, 
with ddH2O replacing the missing component. The qPCR was then carried out on a 
StepOnePlus (Thermo, U.K). Initial denaturation was carried out at 95°C for 5 minutes, 
followed by 40 cycles of 95°C for 30 seconds, 60°C for 30 seconds and 72°C for 30 
seconds. Primers were often designed with an annealing temperature of 60°C for 
continuity and to span an exon to prevent amplification of genomic DNA. Relative 
expression of the analysed genes was normalised to the PABPC4 housekeeping gene 
and calculated via the ∆∆Ct method. 
183 
 
4.3.4.4. iPSC pluripotent RT-PCR characterization:  
 
Endogenous expression of key pluripotency factors was determined through Reverse 
transcriptase-PCR (RT-PCR) amplification. RNA isolation and subsequent cDNA 
generation was carried out as prior mentioned. cDNA was then utilised as the starting 
product for the reaction. PCR was then carried out using Q5 high fidelity DNA 
polymerase. Each reaction contained: 5μL Q5 reaction buffer (5X), 0.5μL dNTPs 
(10mM), 2.5μL forward & reverse primer mixture (10μM), 0.25μL Q5 DNA polymerase, 
1μL cDNA (40ng), ddH2O up to 25μL. The samples were briefly mixed before 
beginning the reaction on the Agilent Sure Cycler 8800 thermocycler. The reaction 
began with an initial denaturation step of 98°C for 5 minutes. The samples were then 
subjected to 35 cycles of 98°C for 30 seconds, 55°C for 30 seconds and 72°C for 1 
minute. A final extension step of 72°C was carried out for 7 minutes prior to incubation 
at 4°C. The samples were then analysed by being run on a 1.5% agarose gel produced 
using TAE and supplemented with gel red (10,000X). The gel was submerged in TAE 
before the PCR samples were loaded and electrophoresed. The gel was subsequently 
imaged using a transilluminator.   
Table 10: Primers and their forward and reverse sequences used for the pluripotency RT-PCR.  
Target Forward primer Reverse primer 
Endogenous OCT4 GCGATCAAGCAGCGACT TTCACCTTCCCTCCAACC 
Endogenous SOX2 CATGTCCCAGCACTACCAGA GGGTTTTCTCCATGCTGTTT 
Endogenous LIN28 TGTCCAAATGCAAGTGAG GCAGGTTGTAGGGTGATTCC 
Nanog TTTGTGGGCCTGAAGAAAACT AGGGCTGTCCTGAATAAGCAG 
E-Cadherin TGCCCAGAAAATGAAAAAG GTGTATGTGGCAATGCGTTC 








4.3.5. DNA-based PCR assays:  
 
4.3.5.1. Vector integration:  
 
Genomic DNA was isolated using the ISOLATE II genomic DNA kit. Once prepped, 
the sample was then used as a starting product to determine potential integrations by 
reprogramming vectors in clonal iPSC lines. A typical reaction using the Q5 high 
fidelity DNA polymerase system is outlined in Table 11.  
Table 11: recipe for a typical PCR reaction using Q5 DNA polymerase.  
Reagent Volume (μL) 
Q5 high fidelity DNA polymerase  0.5 
Q5 5x Reaction buffer  5 
10mM dNTPs 0.5 
10μM Forward primer 1.25 




PCR parameters would vary between primer sets. Firstly, a 95°C denaturation step 
was typically utilised. The primer annealing temperature varied between reactions a 
gradient PCR was employed to determine the optimum annealing temperature, often 
between 50-60°C. Finally, an extension temperature of 72°C was used. Q5 DNA 
polymerase functions at an extension rate of 1kb every 30 seconds.  
 
4.3.6. Comet Assay: 
 
4.3.6.1. Slide and buffer preparation:  
 
At least 24 hours prior to the start of any comet assay, slides were pre-coated in a 1% 
(w/v) normal-melting agarose (NMA). This was produced using TAE and kept in warm 
water to ensure the agarose did not re-solidify. 175µL of agarose was then dotted onto 
a single slide in duplicate, before coverslips were placed on top. The slides were left 
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to dry at room temperature for 30 minutes. Once complete, the coverslips were then 
removed, and the slides allowed to dry overnight at room temperature.  
4.3.6.2. Sample loading, lysis & electrophoresis:  
 
Firstly, a 0.7% (w/v) low-melting agarose (LMA) mixture was produced in TAE, boiled 
and kept in a warm water bath to maintain its liquid state. Any medium was removed 
from cells to be analysed before being washed in PBS and re-suspended at a 
concentration of 1 x 106/mL. 60µL of cells (~6 x 104 cells) was then added to 190µL of 
PBS in an Eppendorf tube. 1mL of LMA was added to the cells before being mixed 
using a vortex. Immediately after, 75µL of the cell suspension was then placed atop 
each gel on the pre-made slides (in duplicate) and covered with a 22x22mm glass 
coverslip. These slides were then placed at 4°C for 5 minutes to set.  
Once set, the coverslips were removed from the samples. 190mL of ice cold ready to 
use lysis buffer (2.5M NaCl, 100mM EDTA, 0.3M NaOH. 5.5% DMSO, 1.1% Triton 
100X pH 10) was then decanted into a black slide trough. The slides were left overnight 
at 4°C.  
The following day, the slides were removed and washed for 5 minutes at room 
temperature in dH2O. Ice cold electrophoresis buffer (3M anhydrous sodium acetate, 
10M Tris, pH 9) was then decanted into an electrophoresis tank at 4°C. The slides 
were subsequently transferred to the electrophoresis tank and left for 20 minutes to 
equilibrate. A charge of 25v, 300mA was applied for 25 minutes to the slides. Following 
this, the slides underwent 2 washes in ready to use neutralisation buffer (0.4M Tris 
Base pH 7.5, diluted to 30%) before being transferred into a dark box to dry overnight.  
4.3.6.3. DNA staining and visualisation:  
 
The following day, the slides were firstly rehydrated in dH2O for 30 minutes. SYBR 
gold was then diluted to 1x (1:10,000) in dH2O. Once rehydrated, the slides were left 
to dry for 5 minutes before 100µL of diluted SYBR gold was added to each slide and 
covered with a 24x60mm coverslip. The slides were then left to stain in the dark for 30 
minutes. Once complete, the coverslips were removed, and the slides washed in dH2O 
before being dried again for 1 hour. The slides were then ready to image at 10/20x 
using a fluorescence microscope.  
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4.3.6.4. Comet analysis:  
 
Analysis of the images was carried out using CaspLab (1.2.3beta2). A minimum of 
100 comets were analysed per gel with each technical repeat having 2 gels per slide. 
3 biological repeats were analysed per vector.  
 
4.3.7. Flow cytometric analysis of cell cycle with propidium iodide: analysis: 
 
Cells were analysed using a Becton Dickinson (BD) FACScalibur flow cytometer (BD 
bioscience). The software, BD CellQuest Pro™ was utilised to generate a histogram 
plot. Before analysis, the single cell population was gated using the forward scatter 
(FS) and side scatter (SS) plot. The propidium iodide histogram was generated by 
plotting FL-2 versus cell count. Data shown represents 1x 104 cells from the total gated 
population. 
Propidium iodide is a stoichiometric fluorescent intercalating agent that binds DNA in 
proportion to the amount that is present in the cell. Cells that are in G2 phase and 
about to undergo cell division contain twice the amount of DNA as cells that are in a 
quiescent or resting state (G0-G1) so should have an increased fluorescent intensity, 
detected quantitatively by flow cytometry. Doggybone and oriP-EBNA1 produced 
iPSCs were expanded before being isolated and mechanically into single cells via 
pipetting. The cells underwent centrifugation at 300g for 2 minutes. The cells were 
then re-suspended in DPBS before 2ml of ice-cold 70% ethanol was added dropwise 
while vortexing to prevent clumping. The cells were left to fix for 30 min at 4°C. After 
fixation, the culture was centrifuged and washed once with PBS. Again, the 
supernatant was discarded and 100µl of a 100µg/ml stock solution of RNase A was 
added to the pellet. 400µl of a 50µg/ml stock of propidium iodide was added and the 







4.3.8. Microarray & unbiased analysis:  
 
4.3.8.1. Analysis of raw data:  
 
Microarray analysis was carried kindly carried out at DKFZ German Cancer research 
Centre, Heidelberg, Germany. The Illumina HT12 beadchip system was used to 
analyse global gene expression in the samples. RNA was isolated from each of the 
biological triplicates used in the experiment before being DNase treated. This was a 
direct hybridization microarray, whereby 750ng of biotinylated cRNA isolated from the 
different experimental conditions was applied to the chip and hybridized for 17 hours 
at 58°C. QC analysis was also undertaken by our collaborators in Germany who 
carried out a quantile normalization using R studio and the normalize.quantiles 
function from the Bioconductor package preprocessCore. Following QC analysis, 
probes from dbDNA & oriP-EBNA1 iPSCs were as such subjected to a student’s t-test 
analysis with a cut off p-value of ≤0.05. From this, the results were then subjected to 
a Benjamini-Hochberg analysis to determine the False discovery rate (FDR). This was 
to reduce the possibility of a type 1 error and thereby limit the inclusion of false positive 
results within the dataset. Again, an FDR cut off ≤0.05 was utilised. Subsequently, fold 
change expression was calculated between the dbDNA and oriP-EBNA1 samples - 
probes with a fold change difference of ≥1.5 were taken forward. 
Using these significant probes, several different software was used to determine 
transcription factor enrichment terms. The Reactome database was utilised to project 
significant probes onto the human genome to help elucidate interacting pathways in 
relation to cell cycle, metabolism, immune function etc. Moreover, enrichment analysis 
was likewise undertaken using the MSigDB function from Gene Set Enrichment 
Analysis (GSEA). This function can then provide information on hallmark genes which 
summarize and represent specific well-defined biological processes generated via 
overlaps between gene sets within the MSigDB system. Subsequently, the analysis 
can provide a p-value for each hallmark process which demonstrates a measure of 
how significant the changes were for each given gene set – the higher the absolute 
value of the statistic, the greater its significance. GSEA also provides k/K values, 
whereby k = the number of genes in the query set and K = the number of genes in the 
MSigDB database. This can therefore provide information on the direction of change 
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for the biological processes for each significant probe. Finally, a q-value is provided 
which is an FDR analogue of the p-value after correction for multiple hypothesis testing 
and again reduces the possibility of including false positive results.  
 
4.3.8.2. Graphics produced using R studio: 
 
Probe expression values were visualised using images generated from different 
analyses using R studio. The coding software was used to firstly take the top 1000 
highly expressed genes between all data sets and their expression trend compared 
using a scatterplot. This was further substantiated by the generation of a correlogram 
for the whole genome of each cell type. A Pearson Product-moment Correlation 
Coefficient value was generated for each dataset, putting an exact numerical value on 
the trends between the gene expression of each cell type. Moreover, a Principle 
component analysis (PCA) was also carried out. This analysis results in the expression 
of whole transcriptomic datasets for each cell type on a 2D graphic. The distance 
between the co-ordinates of each plot was therefore proportionate to the respective 
variability of each cell types transcriptomic profile. Moreover, a volcano plot was also 
generated permitting the visualisation of DEGs (differentially expressed genes) on a 
whole transcriptome level. Finally, heatmaps were also generated to permit and 




























Western blots:  
 
































R Script:  
Microarray data processing:  
Quantile normalisation was carried out with R using the function normalize.quantities 
from the Bioconductor package “preprocessCore”.  
Heatmap script:  
> heatmap.2(ebna_matrix, Rowv = NA, col = redgreen(75), scale = "row", mar
gins = c(5,10), trace = "none", dendrogram = "column") 
> col<-colorRampPalette(redgreen(75)) 
> heatmap.2(ebna_matrix, Rowv = NA, col = col, scale = "row", margins = c(
5,10), trace = "none", dendrogram = "column") 
 
Scree plot and PCA R script: 
pca <- prcomp(t(Chup), scale=TRUE)  
  
## plot pc1 and pc2 
plot(pca$x[,1], pca$x[,2]) 
  
## make a scree plot 
pca.var <- pca$sdev^2 
pca.var.per <- round(pca.var/sum(pca.var)*100, 1) 
  
barplot(pca.var.per, main="Scree Plot", xlab="Principal Component", 
ylab="Percent Variation") 
 
pca.data <- data.frame(Sample=rownames(pca$x), 
  X=pca$x[,1], 
  Y=pca$x[,2]) 
pca.data 
  
ggplot(data=pca.data, aes(x=X, y=Y, label=Sample)) + 
  geom_text() + 
  xlab(paste("PC1 - ", pca.var.per[1], "%", sep="")) + 
  ylab(paste("PC2 - ", pca.var.per[2], "%", sep="")) + 
  theme_bw() + 
  ggtitle("My PCA Graph") 
 
Volcano plot script:  
with(topT, plot(lfc, -log10(padj), pch=20, main="Volcano plot - dbDNA - or
iP-EBNA1", cex=1.0, xlab=bquote(~Log[2]~fold~change), ylab=bquote(~-log[10
]~P~value))) 
> abline(v=0, col="black", lty=3, lwd=1.0) 
> abline(v=-1.0, col="black", lty=4, lwd=2.0) 
> abline(v=1.0, col="black", lty=4, lwd=2.0) 
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> abline(h=-log10(max(p_Val[padj<0.05], na.rm=TRUE)), col="black", lty=4, 
lwd=2.0) 
> points(res[2:674,18], -log10(res[2:674,13]), pch=21, bg="green") 




Correlogram was produced using the GGally package in R (e.g: corrgram(x, order = , 
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